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LIST OF ABBREVIATIONS 
ABC ATP-binding cassette NIS Sodium/iodide symporter 
ABCB1 ATP-binding cassette, sub-family B, member 1 NSAIDs Non-steroidal anti-inflammatory drugs 
ABCC1 ATP-binding cassette, sub-family C, member 1 NTI Non-thyroidal illness 
AKT1 v-Akt murine thymoma viral oncogene homolog 1 OS Overall survival time 
AKT2 v-Akt murine thymoma viral oncogene homolog 2 P-gp Permeability glycoprotein 
ALARA As Low As Reasonably Achievable PAX8-
PPARG 
Paired-box 8 – peroxisome proliferator-
activated receptor-γ APES 3-Aminopropyltriethoxysilane 
BRAF v-Raf murine sarcoma viral oncogene homolog B PDGFRα Platelet derived growth factor receptor alpha 
bTSH Bovine thyrotropin PDGFRβ Platelet derived growth factor receptor beta 
c-Kit Stem cell factor receptor PDPK1 3-phosphoinositide dependent protein kinase-1 
CALCA Calcitonin-related polypeptide alpha PI3K Phosphoinositol-3-kinase 
cAMP Cyclic adenosine 3’,5’-cyclic monophosphate PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha Cox Cyclooxygenase 
Cox-1 Cyclooxygenase-1 PIK3CB Phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit beta Cox-2 Cyclooxygenase-2 
CSF1R Colony stimulating factor 1 receptor PTEN Phosphatase and tensin homologue 
CT Computed tomography qPCR Quantitative RT-PCR 
DFS Disease-free survival RAIU Radioactive iodine uptake 
dFTC Differentiated follicular cell thyroid carcinoma RAS Rat sarcoma 
EGFR Epidermal growth factor receptor RET Rearranged during transfection 
FF-PE Formalin-fixed paraffin-embedded rhTSH Recombinant human thyrotropin 
FLT-3 Fms-like tyrosine kinase 3 RPS5 Ribosomal protein S5 
FTC Follicular cell thyroid carcinoma RTK Receptor tyrosine kinase 
GDP Guanosine diphosphate T3 Triiodothyronine 
GTP Guanosine triphosphate T4 Thyroxine 
GTPase Guanosine triphosphatase TCC Transitional cell carcinoma 
H-RAS Harvey rat sarcoma viral oncogene homolog Tg Thyroglobulin 
HE Hematoxylin and eosin THW Thyroid hormone withdrawal 
HPRT Hypoxanthine phosphoribosyltranferase 1 TKI Tyrosine kinase inhibitor 
123
I
 
Radioiodine-123 TM Time to distant metastases 
131
I Radioiodine-131 TSH Thyrotropin 
IHC Immunohistochemistry TR Time to loco-regional recurrence 
K-RAS Kirsten rat sarcoma viral oncogene homolog TT4 Total thyroxine 
MAPK Mitogen-activated protein kinase VEGF Vascular endothelial growth factor 
MNG Multinodular goiter VEGFR-1 Vascular endothelial growth factor receptor-1 
MST Median survival time VEGFR-2 Vascular endothelial growth factor receptor-2 
MTC Medullary thyroid carcinoma WBS Whole-body scintigraphy 
N-RAS Neuroblastoma RAS viral (v-ras) oncogene homolog   
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 Thyroid cancer represents 1.2-3.8% of all neoplasms in the dog.
1
 The Beagle, 
Golden Retriever and Boxer are predisposed breeds, there is no gender predilection and 
dogs over 7 years old are more commonly affected.
2
 
In people, thyroid cancer accounts for 2% of all diagnosed cancers and is the 
most common form of endocrine neoplasia.
3
 Thyroid cancer is nearly 3 times more 
frequent in women than men and although it can occur at any age, it is more common 
in middle aged women and men over the age of 60.
3
 
Ninety percent of canine thyroid tumors detected clinically are carcinomas and 
can be classified as either follicular cell thyroid carcinomas (FTCs), which arise from 
thyroid follicular cells, or medullary thyroid carcinomas (MTCs), which arise from the 
parafollicular cells (C-cells) and have a neuroendocrine origin.
2
 In a study including 38 
dogs with thyroid carcinoma, FTC accounted for 64% of carcinomas while MTC had a 
prevalence of 36%.
4
 The morphological, cytochemical and immunohistochemical 
features of canine MTC resemble human MTC.
5
 
According to the World Health Organization (WHO), canine FTC can be 
classified as well-differentiated (follicular, compact, follicular-compact, papillary), 
poorly differentiated, undifferentiated or carcinosarcoma, while human FTC can be 
classified as well-differentiated (papillary, follicular), poorly differentiated or 
undifferentiated.
6,7
 Follicular, compact and follicular-compact carcinomas represent 
86% of canine FTCs and are remarkably similar in terms of histology and biological 
behavior to human follicular thyroid carcinoma.
8,9
 The most frequent form of thyroid 
carcinoma in humans is papillary thyroid carcinoma with a prevalence of 80%, 
followed by follicular (14%), medullary (4%) and undifferentiated (2%) carcinoma.
10
 
Unlike in humans, papillary thyroid carcinoma is rare in dogs.
9
  
The research expounded in this manuscript will focus on the pathogenesis and 
treatment of canine thyroid tumors. In the general introduction, we review the current 
knowledge of the aspects of thyroid cancer investigated in this PhD: genetic events, 
prognostic markers and treatment optimization. A detailed review of all other aspects 
of thyroid neoplasia is beyond the scope of this introduction.  
In the past decade, the major advances made in understanding the molecular 
pathogenesis of human thyroid cancer have helped to develop new diagnostic, 
Chapter 1 
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prognostic and treatment tools, providing an interesting perspective for veterinary 
medicine.
11
 Given the similarity between human and canine thyroid carcinoma, the 
current knowledge of the pathogenesis and treatment of human thyroid cancer will also 
be discussed. 
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1  PATHOGENESIS 
1.1  Genetic events leading to thyroid cancer 
There is a variety of genetic alterations described in human thyroid cancer, 
including gene mutation, gene amplification, gene translocation, aberrant gene 
methylation and abnormal number of chromosomes (aneuploidy).
12
  
In human follicular thyroid carcinomas, the most important genetic events are 
PAX8-PPARG (paired-box 8 – peroxisome proliferator-activated receptor-γ) gene 
rearrangement, with a prevalence of 60%, and point mutations in the RAS genes, with a 
prevalence of 20-52%.
13,14
 The RAS genes (N, K, and H) encode membrane-bound 
intracellular proteins involved in cellular signal transduction. These proteins act as 
on/off switches, relaying extracellular signals to the cytoplasmic signaling cascades of 
the mitogen-activated protein kinase (MAPK) and phosphoinositol-3-kinase(PI3K)/Akt 
pathways, which control cellular proliferation and differentiation (Fig. 1).
15
 In many 
human cancers, point mutations in exon 1 (codons 12 and 13) or exon 2 (codons 59 and 
61) fix RAS proteins in a permanently activated form, promoting uncontrolled cellular 
division and malignant transformation.
16
 Although RAS is a classical dual activator of 
both pathways, RAS mutations seem to preferentially stimulate the PI3K/Akt pathway 
in thyroid gland tumorigenesis.
14
  
RAS mutations are generally uncommon in canine tumors.
17
 However up to 
25% of canine non-small cell lung tumors and 80% of canine pancreatic tumors have 
been reported to harbor K-RAS mutations, and 25% of dogs with acute myeloid or 
lymphoid leukemia harbor N-RAS mutations.
15,18,19
 RAS mutations have not been 
investigated in canine thyroid cancer. 
Point mutations in the tumor suppressor gene phosphatase and tensin 
homologue (PTEN) and in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PIK3CA) gene are also reported in human follicular carcinomas with a 
prevalence of 6% and 13%, respectively.
12
 Because PTEN has an inhibitory effect on 
the PI3K/Akt pathway, inactivating mutations or deletions in PTEN lead to PI3K/Akt 
pathway activation and promote tumorigenesis.
20
 Activating point mutations in the 
PIK3CA gene lead to a constitutively activated protein which also activates PI3K/Akt 
Chapter 1 
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pathway. Mutations in PTEN and PIK3CA have not been evaluated in canine thyroid 
cancer. 
 
 
Fig. 1: The main signaling pathways involved in thyroid gland carcinogenesis are the MAPK and 
PI3K/Akt pathways. These pathways are involved in propagation of signals from various cell 
membrane receptor tyrosine kinases into the nucleus, and they regulate multiple cell processes 
including proliferation, differentiation and survival. Activation of the MAPK pathway by 
oncogenic stimuli such as mutated BRAF or the chimeric fusion proteins rearranged during 
transfection (RET)/PTC is a common tumor initiating event in human papillary carcinoma. 
Mutations involving the effectors of the PI3K/Akt pathway such as the PIK3CA, AKT1 and 
PTEN are found more frequently in follicular carcinomas and in less differentiated types of 
thyroid cancer. Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Endocrinology]21, copyright (2011)  
Abbreviations: BRAF, serine/threonine protein kinase B-RAF; MEK, mitogen-activated protein 
kinase (MAPK)/ERK kinase; ERK, extracellular signal-regulated kinase; PI3K, 
phosphatidylinositol-3-kinase; AKT, protein kinase B; PTEN, phosphatase and tensin homolog; 
mTOR, mammalian target of rapamycin; 
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The most important genetic alterations in human papillary thyroid carcinoma 
are RET/PTC gene translocation, present in 36% of cases, and activating point 
mutations of the v-raf murine sarcoma viral oncogene homolog B (BRAF), which have 
a prevalence of 45%.
22,23
 The most prominent example of such mutations is the 
transverse point mutation T1799A (exon 15) which leads to expression of a 
constitutively activated mutant protein (BRAF-V600E) that activates MAPK signaling 
pathway.
24
 The prevalence of BRAF mutations in canine thyroid tumors is unknown.  
In humans, a thyroid follicular cell tumorigenesis model has been proposed 
associating genetic alterations to pathway activation and tumor type. The MAPK 
pathway is mainly associated with papillary carcinoma while the PI3K/Akt pathway is 
the major signaling pathway involved in follicular carcinoma. Activation of both 
pathways becomes more frequent as the grade of thyroid tumors increases (Fig. 2).  
 
 
Fig. 2. Model of the progression of thyroid follicular cell tumorigenesis driven by the MAPK and 
PI3K/Akt pathways. Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Cancer]12, copyright (2013)  
Abbreviations: ATC, anaplastic (undifferentiated) thyroid carcinoma; FTA, follicular thyroid 
adenoma; FTC, follicular thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; 
PTC, papillary thyroid carcinoma;  
 
Chapter 1 
12 
In dogs, constitutive activation of the PI3K/Akt pathway has been recently 
demonstrated in cell lines of canine lymphoma, hemangiosarcoma, mammary 
carcinoma, glioma and mast cell tumors.
25
  These findings suggest the major 
importance of this signaling pathway in the pathogenesis of canine cancer.  
Mutations in the tumor suppressor gene p53 are rare in human differentiated 
FTC (dFTC) (papillary and follicular) occurring mainly in poorly differentiated and 
undifferentiated carcinomas.
26
 In dogs, a study where part of the coding region of p53 
was analyzed revealed a somatic mutation of p53 in 1 of 23 canine FTCs.
27
  
The principal molecular mechanism underlying human MTC is aberrant 
activation of the receptor tyrosine kinase (RTK) rearranged during transfection 
(RET).
28
 Germ line RET mutations are responsible for the hereditary form of MTC (eg, 
multiple endocrine neoplasia types 2A and 2B) while somatic RET mutations are 
present in approximately 50% of patients with sporadic MTC.
29
 RET signaling leads to 
activation of the PI3K/Akt and MAPK pathways and has key roles in cell growth, 
differentiation, and survival.
30
 RAS mutations have also been reported in up to 68% of 
RET-negative MTC.
31
 In a recent study, exomic sequencing revealed that 90% of 
human MTCs had mutually exclusive mutations in RET, H-RAS or K-RAS. In the only 
case report of canine familial MTC, no mutation was found after complete sequencing 
of RET.
32
 To present date, the genetic events underlying canine sporadic MTC have not 
been investigated. 
Oncogenic gene amplification or copy-number gain is an additional prominent 
genetic mechanism causing thyroid gland tumorigenesis in humans.
12
 This is 
particularly the case for genes involved in the PI3K/Akt pathway. Prominent examples 
(and respective prevalence in human follicular thyroid carcinoma) include EGFR 
(32.2%), VEGFR-1 (44.1%), VEGFR-2 (3.8%), PIK3CA (23.8%), PIK3CB (45.5%), 
AKT1 (8.1%), AKT2 (22.4%) and PDPK1 (24.1%).
14
 An important and expected 
consequence of gene amplification or pathway activation is increased mRNA and 
protein expression and consequent aberrant activation of downstream signaling.
14
 The 
mRNA expression of RTKs and effectors involved in PI3K/Akt signaling may provide 
valuable information regarding gene amplification and pathway activation and has not 
yet been investigated in canine thyroid tumors.  
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Several reports have suggested that the PI3K/Akt signaling pathway regulates 
the expression of cyclooxygenase-2 (Cox-2).
33,34
 It has been demonstrated that Cox-2 
functions downstream of Akt, and that elevated Akt activity is crucial for Cox-2 
overexpression in apoptotic-resistant cells.
33
 Cox-2 mRNA expression could therefore 
also be used to infer on the activity of the PI3K/Akt pathway. 
Abnormal number of chromosomes (aneuploidy) is another genetic event 
described in human and canine thyroid cancer. Approximately 60% of human follicular 
thyroid carcinomas are aneuploid which is comparable to what is observed in dogs.
35,36
 
However, while in dogs more than 80% of aneuploid thyroid tumors are hypodiploid, 
in humans hypodiploidy is only rarely found.
35,36
 Furthermore, ploidy abnormalities 
(DNA-index variation) are less extensive in the dog compared to those in humans, 
which could indicate either a fundamental difference in carcinogenesis or that the 
human genome needs stronger destabilization to promote tumor development.
36,37
  
The differentiation between canine MTC and FTC of compact type may be 
difficult based on microscopic observation alone.
4
 Immunohistochemistry (IHC) for 
thyroglobulin, calcitonin or markers of neuroendocrine tissue aids the diagnosis.
5
 
mRNA expression of the gene encoding calcitonin (calcitonin-related polypeptide 
alpha - CALCA) has not yet been evaluated in dogs with thyroid tumors and may also 
help differentiating FTC from MTC. 
1.2  Prognostic markers 
The median survival time (MST) for dogs with thyroid carcinoma left 
untreated is only 3 months.
38
 However, prognosis can be good with appropriate 
treatment.
39
 The reported MST for dogs with freely moveable thyroid tumors treated 
with thyroidectomy is > 36-50 months, in the absence of metastatic disease.
40,41
 Dogs 
with unresectable invasive tumors can be treated with radioiodine-131 (
131
I) therapy or 
external beam radiation. When no distant metastases are present, 
131
I therapy is 
associated with a MST of 28-30 months and external beam radiation is associated with 
a 3-year progression-free survival of 72%.
38,42,43
 The role of chemotherapy in the 
treatment of canine thyroid carcinoma has not been fully elucidated.
44
 In dogs with 
unresectable thyroid carcinoma, partial responses have been described to doxorubicin 
Chapter 1 
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and cisplatin in 44-54% of patients, yielding MSTs of 3-8 months.
45,46
 The studies 
published to present date on adjuvant chemotherapy following thyroidectomy have 
serious limitations but do not suggest it provides a survival benefit.
47,48
 
Prognostic markers help assessing the biological behavior of cancer 
identifying tumors with high potential for local recurrence and metastases. In humans, 
well established prognostic factors of thyroid carcinoma include age, gender, tumor 
size, stage, histologic type, histologic grade, vascular invasion and extrathyroidal tumor 
extension.
49,50
 Low-risk patients undergo a follow-up strategy that is considerably 
different from that of high-risk patients.
3
  
In dogs, thyroid tumor volume > 20 cm3, bilateral thyroid neoplasia and 
cervical vascular invasion have all been associated with high metastatic rates.
8,9,42
 
However, these associations were often based on necropsy studies or studies in dogs 
with unresectable thyroid tumors. In fact, few studies have investigated prognostic 
predictors for dogs with operable thyroid tumors. Breed, sex, tumor size, histologic 
subtype and tumor vascular density did not appear to affect prognosis after surgical 
resection, while bilateral disease and histological grade of malignancy were 
prognosticators.
8,40,41,47,51 
Prognostic markers for dogs with thyroid tumors undergoing 
thyroidectomy are lacking. 
The majority of dogs with thyroid neoplasia are euthyroid.
52,53
 It has been 
suggested that although thyroid carcinoma tissue has a decreased capacity to synthesize 
thyroid hormones, the contralateral thyroid lobe may function in a compensatory 
state.
54
 Around 30-40% of dogs with thyroid tumors have decreased circulating total 
thyroxine (TT4) concentrations due to euthyroid sick syndrome or hypothyroidism, and 
22-31% of patients are hyperthyroid.
8,38,52,53
 It can be hypothesized that functional 
tumors (in dogs with hyperthyroidism or with preserved scintigraphic uptake) are more 
differentiated and, therefore, carry a better prognosis. Although a prospective 
evaluation of 23 dogs with thyroid tumors undergoing thyroidectomy did not indicate 
an effect of thyroid function or tumor scintigraphic uptake on prognosis, further studies 
are warranted.
41
 
In humans, MTC is more aggressive than dFTC.
10
 In most veterinary studies, 
the prevalence of MTC is likely underestimated as these tumors may be difficult to 
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distinguish from compact dFTC by microscopic observation alone. IHC for calcitonin 
or for markers of neuroendocrine tissue is required for their identification.
4
 In a study 
with relatively low number of dogs, MTC represented 36% of all canine thyroid tumors 
and was suggested to be more amenable to complete surgical resection and have lower 
metastatic potential than FTC.
4
 However, it is still not clear whether canine dFTC and 
MTC differ with respect to prognosis following thyroidectomy.  
E-cadherin is a transmembrane adhesion glycoprotein of epithelial tissues and 
plays a role in neoplastic cell behavior as a suppressor of invasion and metastasis.
55
 In 
human thyroid carcinomas, loss of E-cadherin expression is an independent prognostic 
indicator associated with a higher degree of dedifferentiation and higher metastatic 
potential.
55
 In dogs with mammary carcinoma, loss of E-cadherin expression was also 
found to be related to prognosis.
56
 The prognostic significance of E-cadherin 
expression in canine thyroid carcinoma has not been investigated.  
Ki-67 is a cellular proliferation marker expressed in the cell nuclei during all 
active phases of the cell cycle (G1, S, G2 and mitosis) but not in G0.
57
 In human dFTC, 
high Ki-67 labeling index is associated with higher metastatic rates at diagnosis and 
shorter disease-free survival (DFS).
58,59
 Although the use of Ki-67 as a marker for 
prognosis was shown to have limitations in certain canine tumors, its value is well 
established in mast cell tumors.
57,60
 The prognostic relevance of Ki-67 expression has 
not yet been examined in canine thyroid tumors. 
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2  TREATMENT OPTIMIZATION 
In dogs, thyroidectomy is the preferred treatment modality for thyroid tumors 
that are freely moveable at palpation, yielding a MST beyond 3 years if no metastases 
are present.
40,48
 However, 38% of dogs present with pulmonary metastases at the time 
of diagnosis and approximately half of dogs undergoing thyroidectomy experience 
recurrence or metastatic disease within 2 years of surgery.
4,8
  
To present date, research on adjuvant treatment of canine thyroid carcinoma 
remains scarce and no single treatment modality has been shown to be effective in the 
treatment of metastatic disease, which occurs mainly to the lungs and regional lymph 
nodes (mandibular, retropharyngeal and cranial cervical).
44
 The few studies evaluating 
post-operative chemotherapy have serious limitations but did not suggest an 
improvement in outcome.
47,48
 Therefore, it is important to investigate new treatment 
modalities for the large number of dogs with metastatic disease.  
Up to 45% of canine thyroid tumors are unresectable due to local invasiveness 
and these patients can still have a good prognosis with external beam radiation or 
131
I 
therapy. However, these treatment modalities are expensive and are not widely 
available.
4,42,43
 Furthermore, 
131
I is only expected to be effective in a subset of thyroid 
tumors with adequate 
131
I uptake. Recently, tyrosine kinase inhibitors (TKIs) and 
continuous low-dose (metronomic) chemotherapy have shown promising results for 
palliative treatment of dogs with unresectable thyroid tumors.
61,62
 Given the high 
percentage of thyroid tumors that are unresectable in dogs, it is vital to continue 
searching for new ways to improve the treatment of these patients.  
The progress made in understanding the pathogenesis of human thyroid cancer 
has led to increased interest in the development of targeted therapies, including 
angiogenesis suppression, restoration of wild-type p53, Cox-2 inhibition, P-
glycoprotein (P-gp) modulation, and inhibition of aberrant intracellular signaling of the 
MAPK and PI3K/Akt pathways. Additionally, thyrotropin (TSH) suppression and the 
use of recombinant human TSH (rhTSH) to optimize 
131
I therapy have also allowed a 
significant improvement of the treatment of human thyroid cancer and have not yet 
been adequately investigated in dogs. 
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2.1  Therapeutic targets 
Vascular endothelial growth factor (VEGF) is a potent stimulator of 
endothelial cell growth and can stimulate both physiological and pathological 
angiogenesis.
63
 VEGF mediates its biological effects by binding to 2 main RTKs, 
vascular endothelial growth factor receptor-1 (VEGFR-1) and vascular endothelial 
growth factor receptor-2 (VEGFR-2), expressed mainly on endothelial cells. VEGFR-2 
is responsible for signaling while VEGFR-1 is thought to play a regulatory role by 
decreasing the availability of VEGF to VEGFR-2.
64,65
 VEGF is the main stimulator of 
angiogenesis in the thyroid gland and overexpression VEGF, VEGFR-1 and VEGFR-2 
has been demonstrated in human thyroid cancer.
66,67
 When VEGF secreted by cancer 
cells binds to VEGFR-2 on the surface of endothelial cells and thyrocytes, it promotes 
signaling through the MAPK and PI3K/Akt pathways stimulating cellular proliferation, 
migration and survival. This activation of angiogenesis is fundamental for tumor 
growth and development of metastasis.
68,69
 In people, VEGFR-2 inhibition with TKIs is 
the most effective new therapeutic strategy developed to date in the treatment of 
advanced thyroid cancer.
70
 VEGF, angiogenesis and VEGF-induced pathway activation 
may play an important role in the progression of canine thyroid cancer and constitute 
an important therapeutic target.  
Toceranib phosphate (Palladia®; Pfizer Animal Health, Madison, NJ, USA) is 
a TKI which targets VEGFR-2, platelet-derived growth factor receptor alpha and beta 
(PDGFRα/β), stem cell factor receptor (c-Kit), Fms-like tyrosine kinase 3 (FLT-3) and 
colony-stimulating factor 1 receptor (CSF1R), and has been reported to yield a clinical 
benefit rate of 80% in 15 dogs with FTC (partial remission n=4; stable disease n=8).
71
 
In a recent study evaluating the major RTKs targeted by toceranib phosphate in 15 
canine FTCs, expression of VEGFR-2 was demonstrated in a subset of tumors although 
no phosphorylation was observed.
71
 This suggests that VEGFR-2 is not in an aberrant 
state of continuous activation and that the clinical response of canine FTCs to toceranib 
phosphate may be related to inhibition of RTKs on the vascular endothelium and 
stroma rather than on tumor cells. Overexpression of VEGF by canine thyroid tumors 
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may be driving activation of stromal RTKs and has not been investigated in canine 
thyroid cancer. 
Tumor suppressor gene p53 encodes a nuclear phosphoprotein that mediates 
cell cycle regulation and induces apoptosis in response to DNA damage.
72
 Mutations 
that result in loss of normal p53 function lead to loss of cell cycle control and increased 
risk of malignancy. In humans, p53 mutations have been described in 40-62% of 
undifferentiated thyroid carcinomas and 5-10% of other thyroid carcinomas.
26
 Research 
in human thyroid cancer shows that restoration of wild-type p53 expression by gene 
therapy is associated with inhibition of tumor cell growth and enhanced sensitivity to 
chemotherapy and radiation.
72
 As previously stated, investigations of the p53 gene 
coding region identified a somatic mutation in 1 of 23 canine FTCs.
27
 Thus, p53 tumor 
suppressor gene may be a potential molecular target of modest weight in canine thyroid 
cancer. 
Cyclooxygenases (Cox) are the major cellular targets of non-steroidal anti-
inflammatory drugs (NSAIDs). There are 2 Cox isoforms, cyclooxygenase-1 (Cox-1) 
and Cox-2, and both are involved in prostaglandin biosynthesis. While Cox-1 is 
expressed constitutively in many tissues, Cox-2 is inducible by growth factors, 
inflammation and several oncogenes.
73
 
Cyclooxygenases, particularly Cox-2, may play a critical role in tumor 
development and progression. In particular, epithelial neoplasms are prone to express 
large amounts of the inducible form of Cox-2. In dogs, Cox-2 overexpression has been 
described, for example, in transitional cell carcinoma (TCC) of the urinary bladder and 
in prostatic carcinoma.
74
 Several studies have shown that Cox-2 or Cox-1/Cox-2 
inhibitors have antitumor and chemopreventive effects, presumably through induction 
of apoptosis, reduction of angiogenic growth factors and suppression of regulatory T-
cells.
75,76
 Cox-2 is an appealing therapeutic target and its expression has not yet been 
investigated in canine thyroid tumors. 
One study in 44 dogs with surgically excised thyroid carcinoma failed to 
demonstrate a clinical benefit of adjuvant chemotherapy.
47
 Moreover, the reported 
survival times for dogs with unresectable thyroid tumors treated with chemotherapy are 
disappointing.
45
 One of the major mechanisms for resistance to chemotherapy is high 
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expression of ATP-binding cassette (ABC) transporter proteins such as P-gp and multi-
drug resistance-related protein 1 (ABCC1).
77
 These ATP-dependent membrane efflux 
pumps decrease the intracellular concentration of chemotherapeutic agents, thereby 
limiting cytotoxicity at their target site. Expression of P-gp could be one of the 
mechanisms responsible for the resistance of canine thyroid cancer to chemotherapy. 
Recent research shows that TKIs and Cox-2 inhibitors can reverse multi-drug 
resistance by decreasing the expression and function of P-gp.
78,79
 P-gp expression has 
been identified in several canine tumors and may constitute an attractive molecular 
target.
80
 
2.2  TSH-suppressive therapy 
The standard treatment for human dFTC is total or near-total thyroidectomy, 
followed by destruction of all remaining thyroid cells with 
131
I therapy (thyroid 
remnant ablation) and long-term TSH-suppressive therapy with levothyroxine.
3
 
Levothyroxine supplementation is not only given to treat iatrogenic hypothyroidism but 
also to suppress endogenous TSH, which constitutes a potential stimulus for tumor 
growth. In humans and dogs, FTC cells contain TSH receptors and endogenous TSH 
may stimulate neoplastic cell growth and tumor progression.
51,81
 In people with dFTC, 
TSH-suppressive therapy with levothyroxine significantly reduces recurrence rates and 
cancer-specific mortality.
82
 The American and European Thyroid Associations 
currently recommend adapting the target level of TSH suppression to the patient’s risk 
for tumor recurrence and mortality.
83
  
In a recent retrospective study of 15 dogs with bilateral thyroid neoplasia 
undergoing thyroidectomy, the dogs receiving levothyroxine replacement therapy after 
surgery had a significantly longer survival time.
48
 These results are encouraging but 
further studies are needed to corroborate these findings in a larger number of dogs. 
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2.3  Optimization of 
131
I therapy 
TSH is a glycoprotein secreted by thyrotrophs in the adenohypophysis. It is 
composed of α and β subunits. The α subunit has 2 oligosaccharide chains and is 
common to other glycoprotein hormones; the β subunit has 1 oligosaccharide chain and 
is hormone-specific.
84
 Although the exact amino acid sequence of the β subunit varies 
among species, there is biological cross-reactivity, such that the TSH of 1 species will 
stimulate the thyroid follicular cells of another species.
85,86
 The sequences of the α and 
β subunits of canine TSH are 96 and 94% homologous to feline TSH and 60 and 91% 
homologous to human TSH.
87
  
TSH binds to a membrane TSH G protein-coupled receptor on the surface of 
thyroid follicular cells and constitutes the most important stimulus for proliferation, 
differentiation and metabolic activity in these cells. This binding activates adenyl 
cyclase, causing an increase in the intracytoplasmic concentrations of adenosine 3’,5’-
cyclic monophosphate (cAMP), with subsequent phosphorylation of protein kinases.
88
 
This interaction triggers a cascade of reactions, leading to increased iodide uptake and 
synthesis and secretion of triiodothyronine (T3), thyroxine (T4) and thyroglobulin (Tg). 
3-6 hours after TSH binds, endocytosis of colloid increases and pre-formed thyroid 
hormone is released into the bloodstream; hormone concentrations reach a maximum 
after 24 hours.
89
 When TSH stimulation persists, increased expression and functionality 
of the Na/I symporter (NIS) leads to increased uptake and organification of iodine, 
which peaks after 72 hours (Fig. 3).
89-91
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Fig. 3. Effects of TSH on the thyroid follicular cell. Reprinted by permission from Hellenic 
Endocrine Society: [Hormones]92, copyright (2002) 
1. TSH, consisting of α and β subunits, binds to and activates the TSH receptor (TSHR). 
2. Stimulation of the cAMP pathway results in enhanced iodide uptake, growth, 
differentiation and hormone synthesis. 
3. Iodide is actively transported into thyroid follicular cells by the sodium-iodide symporter 
(NIS) at the basolateral membrane. At the apical membrane, pendrin mediates iodide 
efflux into the follicular lumen. 
4. Organification – thyroid peroxidase (TPO) oxidizes iodide and subsequently iodinates 
tyrosil residues of thyroglobulin (Tg) in the presence of hydrogen peroxide. The 
iodotyrosines, mono- and diiodothyrosil, are coupled to T4 and T3; this reaction is also 
catalyzed by TPO (coupling). 
5. Tg is internalized into the follicular cell, hydrolyzed in lysosomes and the thyronines T3 
and T4 are released into the blood stream. 
Abbreviations: TSH, thyrotropin; TSHR, thyrotropin receptor; cAMP, adenosine 3’,5’-cyclic 
monophosphate; NIS, sodium/iodide symporter; TPO, thyroid peroxidase; Tg, thyroglobulin; T4, 
thyroxine; T3, triiodithyronine.  
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Follow-up of human dFTC is based on cervical ultrasonography, measurement 
of plasma Tg concentrations and 
131
I whole-body scintigraphy (WBS).
82,83,93,94
 As 
previously stated, TSH-suppressive therapy with levothyroxine is an important 
component of the standard treatment of human dFTC.
3
 However, high concentrations 
of TSH are temporarily required during follow-up for appropriate 
131
I uptake by normal 
and neoplastic thyroid cells and, consequently, a sensitive WBS. High TSH levels also 
increase the sensitivity of Tg determination as a marker for tumor persistence and 
recurrence. To achieve high concentrations of endogenous TSH (>30 mIU/mL), 
levothyroxine supplementation must be discontinued for 4 to 6 weeks.
3
 However, 
thyroid hormone withdrawal (THW) typically results in severe hypothyroidism which 
has serious impact on the patients’ quality of life.95,96 Alternatively, levothyroxine 
supplementation may be continued. In this case, exogenous TSH administration would 
be used before WBS and plasma Tg determination. Initially, bovine TSH (bTSH) and 
extractive human TSH (obtained from cadaver pituitary glands) were used for this 
purpose.
97
  
In the early 1990s, the use of bTSH in humans had been largely abandoned 
because of allergic reactions and the use of extractive TSH was discarded due to its 
limited availability and potential for transmission of Jacob-Creutzfeldt disease.
98-103
 
The need created by these difficulties led to the development of rhTSH. The genes 
encoding the  and  subunits of TSH were identified and cloned in the 1980s.104 This 
success was followed by the expression of an intact human TSH heterodimer in 
Chinese hamster ovary cells.
105,106
 The amino acid sequence of rhTSH is identical to 
that of endogenous human TSH, although there is less glycosylation and more sialic 
acid.
107
 
The efficacy of the treatment of human dFTC is increased by 
131
I ablation of 
thyroid remnants after thyroidectomy which destroys all remaining thyroid gland tissue 
that may contain tumor cells.
3
 Not only does this allow a better treatment, but 
additionally measurement of plasma Tg concentration during follow-up becomes a 
highly specific marker for recurrent or persistent disease.
108
 Preparation of patients for 
thyroid remnant ablation after thyroidectomy traditionally involved THW which 
resulted in clinical hypothyroidism and impaired quality of life. Several studies 
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demonstrated that rhTSH could stimulate 
131
I uptake by the thyroid remnants after 
thyroidectomy, facilitating complete ablation.
109-111
 Preparation of thyroid remnant 
ablation with rhTSH is associated with a higher quality of life, lower radiation 
exposure to the blood and lower radiotoxicity whereas ablation rate and tumor 
recurrence are comparable to THW.
112-114
 
 rhTSH can also be used as an adjuvant to 
131
I treatment of metastatic and 
persistent dFTC. If patients with metastatic dFTC cannot achieve adequate plasma TSH 
concentrations after THW or experience serious depression associated with iatrogenic 
hypothyroidism, rhTSH may be used compassionately to increase 
131
I uptake by tumor 
tissue.
115,116
 
 Recombinant human TSH also is valuable in the treatment of multinodular 
goiter (MNG). Toxic MNG is characterized by multiple nodular enlargements in the 
thyroid gland and hyperthyroidism, resembling feline hyperthyroidism.
 131
I is the 
treatment of choice and recent studies have shown that pretreatment with rhTSH allows 
increased thyroidal uptake of 
131
I, reduction of the therapeutic dose of 
131
I and 
decreased radiation delivery to extrathyroidal tissues.
117-123
 
 Until recently, research on the use of rhTSH in dogs has focused on the 
diagnosis of hypothyroidism. Initial studies in healthy Beagles showed rhTSH has a 
biological effect on the canine thyroid gland and that the IV route allows a maximal 
increase in TT4 concentrations 4 and 6 h after injection.
124,125
 Different studies have 
investigated the optimal dosage of rhTSH for TSH stimulation. Most studies have 
shown there is a dose dependent effect of rhTSH on post-stimulation TT4 concentration 
which seems to be independent of body weight.
125,126
 The most recent study comparing 
2 dosages of rhTSH (75 μg/dog and 150 μg/dog) in healthy and suspected hypothyroid 
dogs concluded that use of 150 μg/dog provides higher discriminatory power to 
differentiate hypothyroidism from nonthyroidal illness (NTI).
126
 
In dogs, 
131
I can be an excellent treatment option for unresectable FTC when 
external beam radiation is not available.
38,43
 Two retrospective studies showed that 
dogs with unresectable thyroid tumors treated with 
131
I therapy experience a MST of 
approximately 2.5 years.
38,43
 High therapeutic doses of 
131
I (555-1850 MBq) are 
required and this usually implies a prolonged hospitalization period and high doses of 
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radiation eliminated to the environment through the excreta. Use and exposure to 
radiation should be kept ‘‘As Low As Reasonably Achievable’’ (ALARA principle) to 
minimize risks for patient and human health.
127
 Exposure of nonthyroidal tissues to 
high doses of radiation may cause treatment complications such as fatal 
myelosuppression, reported at 
131
I dosages higher than 160 MBq/kg.
43,128
 Although ¾ 
of canine thyroid tumors trap sufficient 
131
I to be visualized by scintigraphy, major 
limitations of 
131
I therapy include its selected effectiveness in differentiated follicular 
cell tumors with adequate 
131
I uptake and the potential need of multiple treatments for 
tumor control.
53
  
The obvious benefits of the use of rhTSH to optimize the treatment of human 
thyroid cancer with 
131
I provide an interesting perspective for the optimization of 
131
I 
therapy of canine FTC. On the one hand, by increasing the uptake of
 131
I by the thyroid 
tumor, rhTSH may improve 
131
I treatment efficacy and decrease the need for multiple 
treatments. On the other hand, rhTSH may allow a decrease of the therapeutic dosage 
of 
131
I, thereby improving radioprotection, limiting radiotoxicity and complying with 
the ALARA principle. Furthermore, 
131
I dose reduction could potentially reduce the 
required hospitalization period and costs.  
TSH receptors have been demonstrated in canine neoplastic thyroid cells; both 
in primary tumors and metastases.
81
 Furthermore, earlier reports have already 
suggested the potential of exogenous TSH to increase thyroid radioactive iodine uptake 
(RAIU) in dogs.
53,129,130
 However, in these studies the effect of TSH stimulation on 
thyroid 
131
I uptake was described in a small number of healthy and hypophysectomised 
dogs and no statistical analysis was performed. Our group recently evaluated the effect 
of rhTSH on thyroid RAIU in hyperthyroid cats and a small but statistically significant 
increase in thyroid RAIU was observed.
131
 The effect of rhTSH on the uptake of 
131
I in 
dogs with thyroid tumors has not been investigated.  
The use of 
131
I for diagnostic imaging in clinical research has several 
limitations. Its half-life (8 days) makes it impractical for repeated RAIU determinations 
within a reasonable period. Furthermore, the emission of limited tissue penetrating beta 
particles during the decay of 
131
I causes a higher localized radiation dose and due to the 
presumed radiotoxicity may have a deleterious effect on the uptake of the actual 
131
I 
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therapeutic dosage, a controversial phenomenon named thyroid stunning.
132
 Unlike 
131
I, 
123
I has a much shorter half-life (13 h), decays by emitting gamma rays and has been 
shown to be equal or even superior to 
131
I as a scanning agent.
133
 Hence, in this 
research 
123
I was chosen as an imaging agent, despite its high cost. 
2.4  Safety of rhTSH 
Before evaluating any human drug in veterinary medicine it is paramount to 
verify its safety. The use of rhTSH in dogs with thyroid cancer raises 2 major concerns: 
hypersensitivity reactions and effect on the volume of the primary tumor and tumor 
metastases. 
Differences in amino acid sequences make the β subunit of TSH immunogenic 
in a non-homologue species. This leads to the risk of antibody induction and 
hypersensitivity reactions when rhTSH is administered repeatedly. A review of the 
veterinary literature indicates that at least 547 dogs and 93 cats already have received 
rhTSH.
134
 Furthermore, 87 of the 547 dogs and 7 of the 93 cats underwent repeated 
rhTSH administration. To date, no anaphylactic reactions have been recorded and the 
only adverse effect was transient pain after IM injection.
125
 Since 2006, approximately 
30 dogs have undergone TSH stimulation with rhTSH every year at our clinic and this 
test also is frequently used in other clinics around the world. To our knowledge, no 
serious adverse reactions have been reported. The adverse reactions previously 
observed with bTSH (ie, anaphylactoid reactions) most likely were a result of the 
unpurified chemical grade of bTSH rather than its amino acid sequence.
135
 It is 
therefore not surprising that the use of a purified pharmaceutical grade rhTSH does not 
yield similar adverse reactions. 
In humans, rhTSH increases the volume of the thyroid gland in healthy 
subjects
136,137
 and causes expansion of primary thyroid tumors and thyroid tumor 
metastases.
138,139
 Therefore, rhTSH should be used carefully in patients with large 
thyroid tumors or central nervous system, spinal, lung or bone metastases because 
tumor expansion may compress adjacent structures and lead to complications.
140
 This 
effect is thought to be related to intravascular and interstitial fluid accumulation rather 
than regular growth of the thyroid tissue.
136
 Evidence of peritumoural edema, 
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hemorrhage and response to glucocorticoid administration also support this 
hypothesis.
138,139
 No information is available on the effect of rhTSH on thyroid gland 
volume in dogs and it seems prudent that this is investigated before rhTSH is used in 
dogs with thyroid tumors. 
 Research on pathogenesis and optimization of treatment of canine thyroid 
cancer is still very limited. Many dogs with thyroid tumors already have metastases at 
the time of diagnosis and almost half of dogs treated with thyroidectomy develop 
recurrent or metastatic disease within 2 years of surgery. Given the disappointing 
results of chemotherapy, it is imperative to investigate new ways to improve treatment. 
The discovery of the main genetic events leading to human thyroid cancer and research 
on therapeutic targets has led to the development of novel treatment strategies for 
patients that are refractory to conventional therapy. Furthermore, stratification of 
patient risk with prognostic markers, TSH-suppressive therapy and enhancement of 
131
I 
uptake with rhTSH have allowed a significant optimization of the treatment of humans 
with dFTC. The molecular pathogenesis and expression of potential therapeutic targets 
is largely unknown in canine thyroid cancer. Furthermore, prognostic markers, TSH 
suppression and optimization of 
131
I therapy with rhTSH have not yet been adequately 
investigated. 
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 In the last 10 years, major advances have been made in unveiling the 
molecular pathogenesis of human thyroid cancer and this has allowed the development 
of new diagnostic, prognostic and treatment tools. A deeper knowledge of the 
pathogenesis of canine cancer has already allowed the development of targeted therapy 
(eg, cox-2 inhibitors in canine TCC; TKIs in canine mast cell tumors) and significant 
improvements in patient outcome. In humans, the use prognostic markers to adapt 
treatment to the patients’ risk, the benefit of TSH suppression, and the use of rhTSH to 
optimize 
131
I therapy provide an interesting perspective for optimization of treatment of 
canine thyroid cancer. The general aim of this research was to provide new insights 
into the pathogenesis and treatment of canine thyroid tumors. 
 The specific aims of our research on pathogenesis were: 
1) To investigate mutational hotspots in RAS (N, K, H), PIK3CA PTEN, BRAF and 
RET genes, and to study the mRNA expression of VEGFR-1, VEGFR-2, EGFR, 
PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2 and CALCA in canine 
FTC and MTC. 
2) To identify clinical, pathological and immunohistochemical (calcitonin, Ki-67 and 
E-cadherin) prognostic factors in dogs with thyroid tumors. 
The specific aims of our research on treatment optimization were: 
3) To evaluate the immunohistochemical expression of VEGF, p53, Cox-2 and P-gp in 
canine thyroid tumors and to assess their potential as therapeutic targets.  
4) To evaluate the effect of levothyroxine therapy and TSH suppression on survival of 
dogs with thyroid tumors undergoing different treatment modalities.  
5) To evaluate the short-term effect of rhTSH on thyroid volume and echogenicity, 
measured by ultrasonography in healthy Beagles. 
6) To evaluate the effect of rhTSH, administered 24 h or 48 h before 123I, on thyroid 
RAIU in healthy Beagles. 
7) To evaluate the effect of rhTSH, administered 24 h before 123I, on tumor RAIU in 
dogs with thyroid tumors. 
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ABSTRACT 
Background: Information on the genetic events leading to canine thyroid 
cancer is lacking. 
Hypothesis/Objectives: To investigate mutational hotspots in candidate genes 
and mRNA expression of PI3K/Akt pathway related genes in canine thyroid 
carcinomas 
Animals: 59 dogs with thyroid carcinoma and 10 healthy controls. 
Methods: Mutation analysis was performed for known hotspots of RAS (N, K, 
H), PIK3CA, BRAF, RET and for the entire coding region of PTEN. Quantitative RT-
PCR was performed for VEGFR-1, VEGFR-2, EGFR, PIK3CA, PIK3CB, PDPK1, 
PTEN, AKT1, AKT2, COX-2 and CALCA. 
Results: 43 dogs (73%) had follicular cell thyroid carcinomas (FTC) and 16 
dogs (27%) had medullary thyroid carcinomas (MTC). Mutation analysis of K-RAS 
revealed 2 activating missense mutations, which have also been described in human 
thyroid cancer. A G12R substitution was present in 1 FTC and an E63K substitution 
was present in 1 MTC. No functional mutations were found in the sequenced regions of 
H-RAS, N-RAS, PIK3CA, BRAF, RET and PTEN.  
The mRNA expressions of VEGFR-1 (P<0.001), VEGFR-2 (P=0.002), 
PDPK1 (P<0.001), AKT1 (P=0.009), and AKT2 (P<0.001) were increased in FTCs, 
and those of EGFR (P<0.001), VEGFR-1 (P=0.036), and PIK3CA (P=0.019) were 
increased in MTCs when compared to normal thyroid glands. 
Conclusions and clinical importance: The mutations most frequently 
associated with human thyroid neoplasia are rare in canine thyroid cancer. An 
increased expression of several genes associated with PI3K/Akt signaling pathway was 
identified, indicating the involvement of this pathway in the pathogenesis of canine 
thyroid carcinomas, and warranting further research on gene amplification. 
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INTRODUCTION 
Thyroid cancer represents 10-15% of all head and neck neoplasms in the dog.
1
 
Ninety percent of canine thyroid tumors detected clinically are malignant and can be 
classified as either follicular cell thyroid carcinomas (FTCs), which arise from thyroid 
follicular cells, or medullary thyroid carcinomas (MTCs), which arise from the 
parafollicular C cells.
2
  
Information on the genetic pathogenesis of canine thyroid cancer is scarce. In 
agreement with human studies showing that mutations in the tumor suppressor gene 
P53 are uncommon in differentiated thyroid cancer, a somatic mutation in P53 has 
been identified in one of 23 canine FTCs.
26,27
 It has also been shown that approximately 
60% of canine thyroid tumors are DNA-aneuploid which is comparable to what is 
observed in humans.
35,36
 However, in dogs more than 80% of aneuploid thyroid tumors 
are hypodiploid, while in humans hypodiploidy is rare.
35,36
 
In humans, follicular cell-derived thyroid carcinomas represent a wide 
spectrum of lesions, ranging from differentiated (follicular and papillary) to poorly 
differentiated and undifferentiated (anaplastic) carcinomas. Canine differentiated FTC 
(follicular, compact, follicular-compact, papillary) is remarkably similar in terms of 
histology and biological behavior to follicular thyroid carcinoma in humans.
8
 Likewise, 
the morphological, cytochemical and immunohistochemical features of canine MTC 
also resemble human MTC.
5
 
One of the most important genetic events described in human follicular 
thyroid carcinoma are point mutations in one of the three RAS genes, with a prevalence 
of 20-52%.
13,14
 The RAS genes (N, K, and H-RAS) encode membrane-bound 
intracellular proteins involved in cellular signal transduction. These proteins act as 
on/off switches, relaying extracellular signals to the cytoplasmic signaling cascades of 
the mitogen-activated protein kinase (MAPK) pathway and phosphoinositol-3-
kinase(PI3K)/Akt pathway, which control cellular proliferation, differentiation and 
survival (Fig. 1).
15
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Fig. 1. Simplified schematic illustration of PI3K/Akt and MAPK 
signaling pathways in thyroid cancer. These pathways are 
involved in propagation of signals from various cell membrane 
receptor tyrosine kinases into the nucleus, and they regulate 
multiple cell processes including proliferation, differentiation and 
survival. Adapted by permission from Macmillan Publishers Ltd: 
[Nature Reviews Endocrinology]21, copyright (2011) 
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In many human cancers, point mutations in exon 1 (codons 12 and 13) or exon 
2 (codons 59 and 61) fix RAS proteins in a permanently activated form, promoting 
uncontrolled cellular division and malignant transformation.
16
 Although RAS is a 
classical dual activator of both PI3K/Akt and MAPK signaling, RAS mutations seem to 
preferentially activate the PI3K/Akt pathway in thyroid gland tumorigenesis.
14
 RAS 
mutations overall are uncommon in canine tumors, however up to 25% of canine non-
small cell lung tumors and 80% of canine pancreatic tumors have been reported to 
harbor K-RAS mutations, and 25% of dogs with acute myeloid or lymphoid leukemia 
harbor N-RAS mutations.
15,17-19
 RAS mutations have not yet been investigated in canine 
thyroid tumors. 
Point mutations in the tumor suppressor gene phosphatase and tensin 
homologue (PTEN) and in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PIK3CA) gene are also reported in human follicular thyroid carcinoma 
with a prevalence of 6% and 13%, respectively.
12
 Because PTEN has an inhibitory 
effect on the PI3K/Akt pathway, inactivating mutations or deletions in PTEN lead to 
PIK3/Akt pathway activation and promote tumorigenesis.
20
 Activating point mutations 
in the PIK3CA gene lead to a constitutively activated protein which also activates 
PI3K/Akt pathway. Mutations in PTEN or PIK3CA have not been evaluated in canine 
thyroid cancer. 
The most important genetic alterations in human papillary thyroid carcinoma 
are activating point mutations of v-raf murine sarcoma viral oncogene homolog B 
(BRAF), which have a prevalence of 45%.
22,23
 The most prominent example is the 
transverse point mutation T1799A in exon 15 which leads to expression of a 
constitutively activated mutant protein (BRAF-V600E) that activates the MAPK 
signaling pathway.
24
 Mutations in BRAF have not been investigated in canine thyroid 
tumors. 
The principal molecular mechanism underlying human MTC is aberrant 
activation of the receptor tyrosine kinase (RTK) rearranged during transfection (RET) 
which signals through the PI3K/Akt and MAPK pathways.
28,141
 Germ line RET 
mutations are responsible for the hereditary forms of human MTC, such as multiple 
endocrine neoplasia type 2, while somatic RET mutations are present in approximately 
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50% of patients with sporadic MTC.
29
 Additionally, RAS mutations have been reported 
in up to 68% of human MTCs without RET mutation.
31
 In the only case report of 
canine familial MTC, no mutation was found after complete genomic sequencing of 
RET.
32
 The genetic events underlying canine sporadic MTC have not yet been 
investigated. 
Oncogenic gene amplification or copy-number gain are additional prominent 
genetic mechanisms causing thyroid gland tumorigenesis in humans.
12
 This is 
particularly the case for genes involved in the PI3K/Akt pathway. Prominent examples 
of such genes (and respective prevalence in human follicular carcinoma) include 
epidermal growth factor receptor (EGFR;32.2%), vascular endothelial growth factor 
receptor-1 (VEGFR-1; 44.1%), vascular endothelial growth factor receptor-2 (VEGFR-
2; 3.8%), PIK3CA (23.8%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit beta (PIK3CB; 45.5%), v-akt murine thymoma viral oncogene homolog 
1 (AKT1; 8.1%), v-akt murine thymoma viral oncogene homolog 2 (AKT2; 22.4%) and 
3-phosphoinositide dependent protein kinase-1 (PDPK1; 24.1%).
14
 EGFR, VEGFR-1 
and VEGFR-2 are important regulators of both MAPK and PI3K/Akt signaling 
pathways, however copy number gains in these RTK genes are particularly associated 
with PI3K/Akt pathway activation in human thyroid cancer.
14,142-144
 An important and 
expected consequence of gene-amplification or pathway activation is increased mRNA 
and protein expression and consequent aberrant activation of downstream signaling.
14
 
The mRNA expression of RTKs and effectors involved in PI3K/Akt signaling may 
provide valuable information regarding gene amplification and pathway activation and 
has not yet been investigated in canine thyroid tumors.  
Several reports have suggested that the PI3K/Akt signaling pathway regulates 
the expression of cyclooxygenase-2 (Cox-2). 
33,34
 It has been demonstrated that Cox-2 
functions downstream of Akt, and that elevated Akt activity is crucial for COX-2 
overexpression in apoptotic-resistant cells.
33
 COX-2 mRNA expression could therefore 
also be used to infer on the activity of the PI3K/Akt pathway. 
The differentiation between canine MTC and FTC of compact type may be 
difficult based on microscopic observation alone.
4
 Immunohistochemistry (IHC) for 
thyroglobulin, calcitonin or markers of neuroendocrine tissue aids the diagnosis.
5
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mRNA expression of calcitonin gene (calcitonin-related polypeptide alpha or CALCA) 
has not yet been evaluated in dogs with thyroid tumors and may also help 
differentiating FTCs from MTCs. 
The goals of our study were to investigate mutational hotspots in RAS (N, K 
and H), PIK3CA PTEN, BRAF and RET, and to study the mRNA expression of 
VEGFR-1, VEGFR-2, EGFR, PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2 
and CALCA in canine FTC and MTC. 
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MATERIALS AND METHODS 
Case selection  
The medical record databases of the Companion Animal Clinics of Ghent and 
Utrecht Universities were searched for dogs diagnosed with thyroid carcinoma from 
1986 to 2013. Patients from which frozen (-80ºC) tumor samples were not available 
were excluded.  
Thyroid specimens 
In total 59 thyroid tumors (43 FTC and 16 MTC) and 10 normal thyroid 
glands (whole tissue explants) were analyzed. Tumor samples were collected from the 
Department of Pathology, Bacteriology and Poultry Diseases of Ghent University and 
the Department of Pathobiology of Utrecht University. Samples were collected 
immediately after surgical or necropsy removal, slit and either formalin-fixed paraffin-
embedded (FF-PE) or snap-frozen in liquid nitrogen and conserved at -80ºC until total 
RNA extraction. 
Histopathology 
All HE slides were reviewed by a board-certified pathologist (RD). All tumors 
were classified according to World Health Organization classification of canine thyroid 
tumors.
7
 The distinction between adenoma and carcinoma was based on the histologic 
evidence of either capsular invasion, vascular invasion or metastases. Classification of 
medullary thyroid tumors was also based on positive immunohistochemistry for 
calcitonin, as previously described.
5
  
Immunohistochemistry  
Five-μm sections from each FF-PE block were prepared on 3-
aminopropyltriethoxysilane (APES)-coated slides. After dewaxing and rehydration, 
antigen retrieval was performed by immersion in citrate-buffered (0.01 M, pH 6) 
distilled water and microwaving in a pressure cooker for 15 min at 850 W and 15 min 
at 300 W. Slides were then allowed to cool for 20 min. Endogenous peroxidase was 
blocked with hydrogen peroxide 0.03% for 5 minutes followed by rinsing with water 
and phosphate-buffered saline (PBS pH 7.4). For calcitonin immunohistochemistry, 
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sections were incubated overnight with the primary antibody (rabbit polyclonal 
antibody A0576
a
 diluted 1:400) in a humidity chamber at 4ºC. Preliminary evaluation 
of the optimal concentration of the primary antibody was performed with serial 
antibody dilutions using normal canine thyroid gland as positive control. Incubation 
with a polymer-based secondary antibody (EnVision
TMa
) was performed at room 
temperature for 30 min. After each incubation step, sections were rinsed with PBS. 3,3’ 
diaminobenzidine
a
 in substrate buffer solution served as chromogen and was allowed to 
react for 5 min. The sections were then counterstained with hematoxylin, rinsed in tap 
water, dehydrated and mounted with cover slips. Immunohistochemistry was 
performed in 2 batches. 
All sections were examined by the same observer (MC) who was blinded to 
the clinical information and outcome of each patient. Thyroid tumors positive for 
calcitonin were classified as MTCs and thyroid tumors negative for calcitonin were 
classified as FTCs.
5
 To verify our classification, the subset of tumors positive for 
calcitonin was also stained for thyroglobulin (rabbit polyclonal antibody A0251
a
 
diluted 1:800) in an automated immunostainer (Dako, S/N S38-7410-01). Calcitonin 
and thyroglobulin immunolabeling were not quantified. In both stains, the tumors were 
considered positive when the cytoplasm of neoplastic cells exhibited a fine granular 
staining pattern with cell-to-cell variation. Normal thyroid gland was used as control in 
each batch. 
RNA isolation and reverse transcription 
Frozen tissue samples were disrupted and homogenized using a rotor-stator 
homogenizer and total RNA was isolated using an RNeasy mini kit
b
 according to the 
manufacturer’s instructions. A DNAse step was performed to avoid genomic DNA 
contamination. Purified RNA was quantified on a NanoDrop ND-1000 
Spectrophotometer
c
 and, in 12 samples (first 10 patients of inclusion period and two 
normal thyroid glands sequenced), its integrity was assessed on a Bioanalyzer Micro 
RNA Chip.
d
 Total RNA was reverse transcribed into cDNA using the iScript cDNA 
synthesis kit
e
 according to the manufacturer’s instructions. 
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Primer design 
All PCR amplification primers (Table 1) were designed with Perl-primer 
v1.1.21 according to the parameters of the Bio-Rad iCycler manual and were ordered 
from Eurogentec.
f
 All PCR primers were also used as sequence primers. When the 
region of interest could not be amplified in 1 stretch, overlapping primer pairs were 
used (Table 2). For quantitative RT-PCR (qPCR), temperature gradients were 
performed to determine the optimal annealing temperature of each primer pair and 
primer specificity was confirmed by melting curve analysis and sequence analysis of 
the PCR products (Table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
42 
Table 1. PCR primers for amplification of canine RAS (K, N, H), BRAF, PIK3CA, RET and PTEN. All 
positions are based on the mRNA sequence published on NCBI. 
PCR primers Sequence (5’-3’) Location Exons Ta (ºC) 
Product 
length (bp) 
K-RAS Fw18 ATAAACTTGTGGTAGTTGGAGC 18/39 1 – 3 62ºC 463 
K-RAS Rv480 GTATAGAAGGCATCGTCAACAC 459/480    
N-RAS Fw12 GGTCTCCAACCTTTCTCC 12/29 1 – 5 55ºC 660 
N-RAS Rv672 AGTGTCTTGTTACATCACCA 653/672    
H-RAS Fw54 CCATGACGGAGTATAAGCTG 54/73 1 – 2 55ºC 253 
H-RAS Rv306 ATGGCAAATACACAGAGAAAG 286/306    
BRAF Fw1555 CGACAGACTGCACAGGGCATGG 1555/1573 13 – 16 55ºC 372 
BRAF Rv1926 CCGTACCTTACTGAGATCTGGAG 1904/1926    
PIK3CA Fw1504 TGCTGAACCCTATTGGTG 1504/1521 8 – 12 55ºC 450 
PIK3CA Rv1953 TACAGTCCAGAAGCTCCA 1936/1953    
PIK3CA Fw2872 TGGGAATTGGAGATCGTC 2872/2889 19 – 21 55ºC 554 
PIK3CA Rv3425 CAGTCTTTGCCTGTTGAC 3408/3425    
RET Fw1600 AAGTGCGAGTGGAGACAG 1600/1617 9 – 15 62ºC 1055 
RET Rv2654 GAAATCTTCATCTTCCGCCC 2635/2654    
PTEN Fw76 TCCTCCTTCCTCTCCAG 76/92 1 – 6 55ºC 748 
PTEN Rv823 TGAACTTGTCTTCCCGTC 806/823    
PTEN Fw719 CAATGTTCAGTGGCGGA 719/735 6 – 8 55ºC 742 
PTEN Rv1460 CGAGATTGGTCAGGAAGAG 1442/1460    
Accession numbers: K-RAS: XM_003433561.2, N-RAS: NM_001287065.1, H-RAS: NM_001287069.1, 
BRAF: XM_532749, PIK3CA: XM_545208.4, RET: NM_001197099.1, PTEN: NM_001003192.1;  
Abbreviations : K-RAS, Kirsten rat sarcoma viral oncogene homolog; N-RAS, neuroblastoma RAS viral (v-
ras) oncogene homolog; H-RAS, Harvey rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma 
viral oncogene homolog B; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha; 
RET, ret proto-oncogene; PTEN, phosphatase and tensin homolog; Fw, forward; Rv, reverse; Ta, optimal 
annealing temperature; bp: base pairs 
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Table 2. Sequencing primers for canine RAS (K, N, H), BRAF, PIK3CA, 
RET and PTEN. All positions are based on the mRNA sequence 
published on NCBI.  
PCR primers Sequence (5’-3’) Location 
K-RAS Rv355 ATTTCCTACTAGGACCATAGGT 334/355 
N-RAS Fw217 AAACAGGTGGTTATAGACGG 217/236 
N-RAS Rv524 GTTTCAATGAATGGAATCCC 505/524 
H-RAS Fw167 GACTCCTATCGGAAGCAAG 167/185 
H-RAS Rv230 CTGTGTCCAGGATGTCCAG 212/230 
PIK3CA Fw1549 CTCCATGCTTAGAGTTGGAG 1549/1568 
PIK3CA Rv1815 CACAATAGTGTCTGTGGCTC 1796/1815 
PIK3CA Fw3029 GATTAGTAAAGGAGCCCAGG 3029/3048 
PIK3CA Rv3336 CATGCTGCTTAATGGTGTGG 3317/3336 
RET Fw1906 GTGCTCTTCTCCTTCATCGT 1906/1925 
RET Fw2221 AAAGGCAAAGCAGGATACAC 2221/2240 
RET Rv1958 GTGGGCATTCTTGTGGTAGC 1977/1958 
RET Rv2278 GGGAAGCATTCTCTTTCAGC 2259/2278 
PTEN Fw475 CACTGTAAAGCTGGAAAGGG 475/494 
PTEN Rv249 CCTGTATACGCCTTCAAGTC 230/249 
PTEN Rv595 TGTCTCTGGTCCTTACTTCC 576/595 
PTEN Fw1158 TGTAGAGGAGCCATCAAACC 1158/1177 
PTEN Rv1285 CAAAGGGTTCATTCTCTGGG 1266/1285 
Accession numbers: K-RAS: XM_003433561.2, N-RAS: NM_001287065.1, 
H-RAS: NM_001287069.1, PIK3CA: XM_545208.4, RET: 
NM_001197099.1, PTEN: NM_001003192.1;  
Abbreviations : K-RAS, Kirsten rat sarcoma viral oncogene homolog; N-
RAS, neuroblastoma RAS viral (v-ras) oncogene homolog; H-RAS, Harvey rat 
sarcoma viral oncogene homolog ; PIK3CA, phosphatidylinositol-4,5-
biphosphate 3-kinase, catalytic subunit alpha; RET, ret proto-oncogene; 
PTEN, phosphatase and tensin homolog; Fw, forward; Rv, reverse. 
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Table 3. Quantitative RT-PCR primers for canine VEGFR-1, VEGFR-2, EGFR, PIK3CA, 
PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2, CALCA, RPS5 and HPRT. All positions are 
based on the mRNA sequence published on NCBI. 
qPCR primers Sequence (5’-3’) Location Ta (ºC) 
Product 
length (bp) 
VEGFR-1 Fw189 GGCTCAGGCAAACCACAC 189/206 63 190 
VEGFR-1 Rv378 CCGGCAGGGGATGACGAT 361/378   
VEGFR-2 Fw3606 GGAAGAGGAAGTGTGTGACCCC 3606/3627 64 181 
VEGFR-2 Rv3786 GACCATACCACTGTCCGTCTGG 3765/3786   
EGFR Fw2078 CTGGAGCATTCGGCA 2078/2092 53 108 
EGFR Rv2185 TGGCTTTGGGAGACG 2171/2185   
PIK3CA Fw1269 CCTTGTTCTAATCCCAGGTG 1269/1288 58.5 134 
PIK3CA Rv1402 GGACAGTGTTCCTCTTTAGC 1383/1402   
PIK3CB Fw2978 CCTTCAACAAAGATGCCC 2978/2995 62.5 142 
PIK3CB Rv3119 CTATGTCTATCACCAATCCCA 3099/3119   
PDPK1 Fw667 AGGTCTGAACTCTTACACGC 667/684 55.5 199 
PDPK1 Rv865 AGGGCATCATTCACAGGG 846/865   
PTEN Fw1209 AGATGTTAGTGACAATGAACCT 1209/1230 62 102 
PTEN Rv1310 GTGATTTGTGTGTGCTGATC 1291/1310   
AKT1 Fw717 CACCGTGTGACCATGAATGAG 717/737 64 83 
AKT1 Rv799 TTCTCCTTGACCAGGATCACC 779/799   
AKT2 Fw71 GGACCTTCCACGTAGACTC 71/89 60.5 195 
AKT2 Rv265 CATTCATGGTCACCTTGGC 247/265   
COX-2 Fw971 TTCCAGACGAGCAGGCTAAT 971/990 60 112 
COX-2 Rv1082 GCAGCTCTGGGTCAAACTTC 1063/1082   
CALCA Fw157 ATCATGGGCTTGTGGAAGTC 157/176 58.5 98 
CALCA Rv254 AGAGCGGACCTGAATGGT 237/254   
RPS5 Fw405 TCACTGGTGAGAACCCCCT 405/423 62.5 141 
RPS5 Rv545 CCTGATTCACACGGCGTAG 527/545   
HPRT Fw484 AGCTTGCTGGTGAAAAGGAC 484/503 58 104 
HPRT Rv587 TTATAGTCAAGGGCATATCC 568/587   
Accession numbers: VEGFR-1: AF262963.1, VEGFR-2: NM_001048024.1, EGFR: 
XM_533073.4, PIK3CA: XM_545208.4, PIK3CB: XM_534280.4, PDPK1: XM_005621677.1, 
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PTEN: NM_001003192.1, AKT1: XM_548000.4, AKT2: NM_001012340.1, COX-2: 
NM_001003354.1, CALCA: NM_001003266.1, RPS5: XM_533568.4, HPRT: AY_283372; 
Abbreviations : VEGFR-1, vascular endothelial growth factor receptor 1; VEGFR-2, vascular 
endothelial growth factor receptor 2; EGFR, epidermal growth factor receptor; PIK3CA, 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PIK3CB, 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta; PDPK1, 3-
phosphoinositide dependent protein kinase-1; PTEN, phosphatase and tensin homolog; AKT1, v-
akt murine thymoma viral oncogene homolog 1; AKT2, v-akt murine thymoma viral oncogene 
homolog 2; COX-2, cyclooxygenase-2; CALCA, calcitonin-related polypeptide alpha; 
RPS5, ribosomal protein S5; HPRT, hypoxanthine phosphoribosyltransferase; Fw, forward; Rv, 
reverse; Ta, optimal annealing temperature; bp: base pairs; 
PCR amplification 
PCR amplification was performed using the Phusion Hot Start Flex DNA 
Polymerase
g
 on a C-1000 Touch thermal cycler (BioRad
d
). PCR products were 
evaluated by agarose gel electrophoresis to confirm expected product length.  
Sequencing 
Sequencing was performed for human mutation hotspots of N-, K- and H-RAS 
(exons 1 and 2)
145
, BRAF (exon 15)
146
, PIK3CA (exons 9 and 20)
147
, RET (exons 8, 10, 
11, 13-16)
32
 and for the entire coding region of PTEN (hotspot exons 5-8)
148
 on all 59 
tumor samples and two normal thyroid glands. 
PCR products were amplified for sequencing using the BigDye Terminator 
version 3.1 Cycle Sequencing Kit
h
 and filtrated using Sephadex G-50 Superfine
i
. 
Sequencing was performed using the ABI3130XL Genetic Analyzer
j
 according to the 
manufacturer’s instructions. The obtained sequences were compared to the consensus 
mRNA sequence using DNAstar Lasergene core suite 11
k
. All mutations affecting the 
amino acid sequence were confirmed by repeating RNA extraction, reverse 
transcription and sequencing.  
Quantitative RT-PCR 
After reverse transcription, qPCR analyses were performed on cDNA to 
determine and compare the levels of expression of VEGFR-1, VEGFR-2, EGFR, 
PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2 and CALCA in thyroid tumors 
and normal thyroid glands. To correct for differences in sample input, the expression 
levels were normalized to the expression of the reference genes ribosomal protein S5 
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(RPS5) and hypoxanthine phosphoribosyltranferase (HPRT), already proven to be 
stable in other canine tissues.
149
 Furthermore, the stability (M-value) of the reference 
genes was verified. 
Quantitative RT-PCR was performed on a CFX384 real-time PCR detection 
system (Bio-Rad). Each qPCR reaction mixture consisted of 4 μL cDNA (diluted 50x), 
0.4 μL of both the forward and the reverse primers, 5 μL iQ SYBR Green Supermixe 
and 0.2 μL MilliQ, adding up to a final reaction volume of 10 μL. The thermal cycles 
were performed as previously described.
150
 A fourfold reference standard dilution 
series using 10× diluted cDNA was included in every plate to assess reaction 
efficiency, and negative controls to assess the specificity of the reaction and check for 
contamination. Data were analyzed with CFX manager version 3.0
e
. Relative mRNA 
expression levels were calculated by relative quantitation and the fold-expression 
changes were determined by means of the 2
-ΔΔCT 
method. The maximum allowed cycle 
threshold (CT) value for calculations was 45.  
Statistical analysis  
Relative expression levels of VEGFR-1, VEGFR-2, EGFR, PIK3CA, PIK3CB, 
PDPK1, PTEN, AKT1, AKT2, COX-2 and CALCA were compared between thyroid 
tumors (FTCs and MTCs) and normal thyroid glands with an independent-sample 
Kruskal-Wallis test
l
. Significance level was set at 5%. The Dunn’s test was used for 
multiple comparisons (adjusted P values shown in the results section). The same 
procedure was done to compare the relative expression of reference genes between 
tumor samples and normal thyroid glands.  
According to the mRNA expression of target genes, patients were grouped by 
means of unsupervised hierarchical clustering
m
.
 
Unsupervised clustering was 
implemented by Pearson correlation for genes, and by Spearman correlation for 
samples.  
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 RESULTS 
All 59 thyroid tumors were classified as carcinomas. Forty-three dogs (73%) 
had FTC and 16 dogs (27%) had MTC. Histologic subtypes of FTC included follicular 
(n=8, 13%), follicular-compact (n=11, 19%), compact (n=18, 30%), papillary (n=1, 
2%), follicular-papillary (n=1, 2%), and carcinosarcoma (n=4, 7%). 
Mutation analysis 
Mutation analysis of K-RAS revealed 2 amino acid changing (missense) point 
mutations in 2 different tumors and a splice variant present in all thyroid samples, 
including the normal thyroid glands. A G12R substitution (GGT>CGT) was present in 
one FTC of compact type and an E63K substitution (GAG>AAG) was observed in one 
MTC (Fig. 2). In the K-RAS splice variant, exon 2 was missing. 
 
 
 
Fig. 2. Mutations found in codon 12 of K-RAS; 
A: G12R substitution in a canine FTC; B: E63K substitution in a canine MTC. 
Abbreviations: WT, wild type 
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Mutation analysis of N-RAS showed 1 silent mutation in codon 138 
(GGG>GGA) in 2 FTCs of compact type, occurring in heterozygous form.  
Mutation analysis of H-RAS showed 1 silent mutation in codon 47 
(GAC>GAT) in 21 FTCs and 5 MTCs occurring in both homozygous and 
heterozygous form. 
Mutation analysis of BRAF did not reveal any point mutations. However, a 
splice variant in which exons 13 and 14 were missing was present in all samples, 
including normal thyroid glands. 
Mutation analysis of PIK3CA did not show any abnormalities in the sequenced 
region. 
Mutation analysis of the entire coding region of PTEN showed 1 silent 
mutation in codon 325 (CTC>CTT) in 5 FTCs and 3 MTCs, occurring in both 
homozygous and heterozygous form. 
mRNA expression of PI3K/Akt pathway related genes 
Relative mRNA expression was evaluated in 41 FTCs, 15 MTCs and 10 
normal thyroid glands (Fig. 3).  Relative expression levels of reference genes were not 
significantly different between thyroid tumors and normal thyroid glands. 
The relative expression levels of VEGFR-1 (P<0.001), VEGFR-2 (P=0.002), 
PDPK1 (P<0.001), AKT1 (P=0.009), and AKT2 (P<0.001) were significantly higher in 
FTC than in normal thyroid glands. The relative expression levels of EGFR (P<0.001), 
VEGFR-1 (P=0.036), PIK3CA (P=0.019), and CALCA (P<0.001) were significantly 
higher in MTC than in normal thyroid glands. Relative expression levels of PTEN, 
PIK3CB and COX-2 were not significantly different between thyroid tumors and 
normal thyroid glands. The relative expression levels of CALCA did not overlap 
between FTCs (range 0 – 3.6) and MTCs (range 3.9 – 156.1).  
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Fig. 3. Dot plots representing the relative mRNA expression levels of VEGFR-1, VEGFR-2, 
EGFR, PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2 and CALCA in canine normal 
thyroid gland (n=10), FTC (n=41) and MTC (n=15). Significant differences between tumors and 
normal thyroid gland tissue are indicated with asterisks. 
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Abbreviations: EGFR, epidermal growth factor receptor; VEGFR-1, vascular endothelial growth 
factor receptor 1; VEGFR-2, vascular endothelial growth factor receptor 2; PDPK1, 3-
phosphoinositide dependent protein kinase-1; AKT1, v-akt murine thymoma viral oncogene 
homolog 1; AKT2, v-akt murine thymoma viral oncogene homolog 2; PTEN, phosphatase and 
tensin homolog; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, subunit alpha; 
PIK3CB, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta; COX-2, 
cyclooxygenase-2; CALCA, calcitonin-related polypeptide alpha;  
* P<0.05 ; ** P<0.01 ; *** P<0.001. 
Unsupervised hierarchical clustering of the samples showed an almost perfect 
branching of normal thyroid gland, FTC and MTC when all genes were included in the 
analysis (Fig. 4). After omitting the relative expression of CALCA, clustering based on 
the remaining genes showed a more elaborate branching with normal thyroid gland 
enrichment in one branch, MTC enrichment in subsequent branching, and a final 
branch enriched in FTC. 
 Unsupervised hierarchical clustering of the genes showed separate branching 
for CALCA, COX-2, EGFR and PTEN, while VEGFR-1 and VEGF-2 were grouped 
together and closely positioned to all effectors of the PI3K/Akt pathway (PIK3CA, 
PIK3CB, PDPK1, AKT1 and AKT2). 
 
 
 
 
 
 
 
 
 
  
 
Fig. 4. Heat maps illustrating the results of the unsupervised hierarchical clustering in canine normal thyroid gland (n=10), follicular cell thyroid carcinoma 
(n=41) and medullary thyroid carcinoma (n=15). A: All genes included in the analysis. B: Relative expression of CALCA omitted from the analysis. 
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 DISCUSSION 
Information on the genetic events leading to canine thyroid cancer is scarce. In 
our study, we investigated mutational hotspots and relative expression of candidate 
genes commonly involved in tumorigenesis of the human thyroid gland, in 59 canine 
thyroid carcinomas. Missense mutations in K-RAS were found in 1 FTC and 1 MTC. 
Furthermore, the expression of several genes involved in the PI3K/Akt signaling 
pathway was increased in canine thyroid carcinomas, when compared to normal canine 
thyroid gland. 
The 2 missense mutations in K-RAS identified in our study have also been 
reported in human thyroid cancer with a similar prevalence. The G12R substitution 
observed in a compact FTC has been described in 1 of 24 follicular thyroid carcinomas 
and in 3 of 108 sporadic MTCs without RET mutation in humans.
151,152
 In veterinary 
medicine, 1 of 5 dogs with pancreatic carcinoma, 1 of 126 dogs with pulmonary 
carcinoma and 1 of 19 dogs with gastric epithelial tumors were also reported to harbor 
this K-RAS mutation.
19,153,154
  
Regulation of RAS protein function occurs through intrinsic guanosine 
triphosphatase (GTPase) activity, which in the wild-type RAS switches the protein from 
an active (guanosine triphosphate[GTP]-bound) to an inactive  (guanosine diphosphate 
[GDP]-bound) state. The substitution of an amino acid without a side chain (glycine) in 
position 12 by another amino acid with a side chain (arginine), interferes with the 
geometry of the protein impeding GTP to be hydrolyzed by GTPase.
155
 Such mutations 
in RAS lead to a permanently activated protein and downstream signaling, facilitating 
uncontrolled cell division and tumor growth.
156
 
The E63K substitution observed in a MTC has also been described in 1 of 16 
MTCs without RET mutation in humans.
157
 This mutation affects an evolutionary 
conserved amino acid residue identical in all RAS proteins. Similarly to what is 
described for G12R substitution, the change of glutamic acid in position 63 by lysine 
also has been demonstrated to abolish GTPase activity, leading to constitutive 
activation of RAS and potentiating cellular transformation.
158
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In our study, no amino acid changing mutations were found in the sequenced 
regions of H-RAS, N-RAS, BRAF, PIK3CA and RET nor in the entire coding sequence 
of PTEN. These results demonstrate that the mutations most commonly involved in 
human thyroid tumorigenesis are rare and do not play a major role in the pathogenesis 
of canine thyroid cancer. 
A splice variant of K-RAS in which exon 2 was missing was observed in all 
thyroid tumors and, to the authors’ knowledge, no equivalent splice variant has been 
described in humans. Given its presence in normal thyroid gland tissue, it is unlikely 
that this splice variant is a causal factor in thyroid gland tumorigenesis. 
A BRAF splice variant, in which exons 13 and 14 were missing, was identified 
in all samples. Aberrant BRAF splicing has been described in humans.
159
 Splice 
variants that do not have the N-terminal auto-inhibitory domain lead to formation of 
truncated proteins, containing only the C-terminal kinase domain, which are 
constitutively activated.
159
 These splice variants may function as an alternative 
mechanism for oncogenic BRAF activation. However, given that this splice variant was 
also present in normal thyroid gland tissue, it seems unlikely that it plays a role in 
canine thyroid gland tumorigenesis. 
No mutations were found in the sequenced region of RET in 16 MTCs. This is 
in agreement with a case report of canine familial MTC in which no mutations were 
found after complete sequencing of genomic RET.
32
 Further research is needed to 
investigate the genetic events involved in the pathogenesis of canine MTC. 
In humans, gene amplification can lead to the activation of tumorigenesis-
related signaling pathways and plays an important role in thyroid gland 
tumorigenesis.
12
 In our study, overexpression of VEGFR-1, VEGFR-2, PDPK-1, AKT1 
and AKT2 in canine FTC, and overexpression of VEGFR-1, EGFR and PIK3CA in 
canine MTC suggests activation of PI3K/Akt pathway, particularly in FTC. PI3K/Akt 
pathway could therefore play an important role in canine thyroid tumorigenesis 
promoting cell proliferation, resistance to apoptosis and malignant transformation.
160
  
The involvement of EGFR, VEGFR-1, VEGFR-2 and PI3K/Akt pathway in 
the pathogenesis of canine thyroid carcinoma suggests these may constitute promising 
therapeutic targets. The importance of PI3K/Akt pathway activation and the value of 
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targeting this pathway have been recently demonstrated in several canine cancer cell 
lines.
25
 Furthermore, a preliminary study in dogs with solid tumors showed that 
toceranib phosphate, a multi-targeted TKI which targets VEGFR-2, was associated 
with a clinical benefit rate of 80% in 15 dogs with thyroid carcinoma.
62
 In humans with 
unresectable, radioiodine-refractory thyroid cancer, TKIs and inhibitors of PI3K/Akt 
signaling have shown encouraging results in recent clinical trials.
161
  
Despite the overexpression of many PI3K/Akt related genes suggesting 
pathway activation, the relative expression of COX-2 was not increased in canine 
thyroid tumors. Similar findings have been reported in human follicular carcinoma, 
where PI3K/Akt pathway activation is of major importance.
162
 This suggests that 
mRNA expression of COX-2 may not reflect activation of PI3K/Akt signaling in 
thyroid cancer. 
As expected, canine FTC and MTC showed distinct mRNA expression 
profiles of PI3K/Akt pathway related genes. These differences were confirmed by 
unsupervised clustering and suggest that these tumor types probably arise from 
different molecular mechanisms. The fact that the mRNA expression of CALCA did not 
overlap between FTC and MTC confirms the accuracy of tumor classification based on 
immunohistochemistry for calcitonin. 
Limitations of our mutational analysis include not sequencing normal tissue in 
patients where mutations were found, to differentiate germ line from somatic 
mutations, and only sequencing part of the coding region for most genes. Absence of 
mutations in these regions does not rule out genetic events in the remaining coding 
region or in the non-coding region of these genes.  
Our findings of increased expression of RTKs and intracellular effectors 
involved in PI3K/Akt signaling urgently ask for further research on phosphorylation of 
Akt (pAkt) and other members of this pathway to verify pathway activation. Moreover, 
future studies should also evaluate gene amplification and altered promoter activity of 
the genes found to be overexpressed in our research.  
In conclusion, 2 missense mutations in K-RAS were identified in a FTC and a 
MTC which are likely to be relevant for thyroid gland tumorigenesis. The mutations 
most frequently associated with human thyroid neoplasia are rare in canine thyroid 
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cancer. Overexpression of VEGFR-1, VEGFR-2, PDPK-1, AKT1 and AKT2 in canine 
FTC and VEGFR-1, EGFR and PIK3CA in canine MTC suggests PI3K/Akt signaling 
pathway is activated and likely involved in the pathogenesis of canine thyroid cancer, 
particularly in FTC. Further studies are needed to investigate if gene amplification or 
altered promoter activity is responsible for the increased mRNA expression of these 
genes. 
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 ABSTRACT 
Background: Prognostic markers for dogs with thyroid tumors are lacking.  
Hypothesis/Objectives: To identify clinical, pathological and 
immunohistochemical prognostic factors for dogs with thyroid tumors. 
Animals: 70 dogs with thyroid neoplasia.  
Methods: Retrospective study. Dogs with thyroid neoplasia were included 
when follow-up information and formalin-fixed paraffin-embedded tumor samples 
were available. Immunohistochemistry (IHC) was performed for thyroglobulin, 
calcitonin, Ki-67 and E-cadherin. Correlation of tumor variables (diameter, volume, 
localization, scintigraphic uptake, thyroid function, IHC) with local invasiveness and 
metastatic disease was performed on all tumor samples. Forty-four dogs treated by 
thyroidectomy were included in a survival analysis. 
Results: 50 dogs (71%) had differentiated follicular cell thyroid carcinoma 
(dFTC) and 20 (29%) had medullary thyroid carcinoma (MTC). At diagnosis, tumor 
diameter (P=0.007; P=0.038), tumor volume (P=0.020), Ki-67 (P=0.038), ectopic 
location (P=0.002) and follicular cell origin (P=0.044) were positively associated with 
local invasiveness; tumor diameter (P=0.002), tumor volume (P=0.023) and bilateral 
location (P=0.012) were positively associated with presence of distant metastases. 
Forty-four dogs (28 dFTCs, 16 MTCs; stage I-III) underwent thyroidectomy. 
Outcome was comparable between dogs with dFTC and MTC. Histologic (P=0.046) 
and macroscopic (P=0.038) vascular invasion were independent negative predictors for 
disease-free survival. Although time to presentation, histologic vascular invasion, and 
Ki-67 were negatively associated with time to metastases, and time to presentation was 
negatively associated with time to recurrence, no independent predictors were found. 
E-cadherin expression was not associated with outcome.  
Conclusions and clinical importance: Prognostic factors have been 
identified which provide relevant information for owners and clinicians. 
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 INTRODUCTION 
Thyroid cancer represents 10-15% of all head and neck neoplasms in the 
dog.
163
 Ninety percent of canine thyroid tumors detected clinically are carcinomas and 
up to 38% of dogs with carcinomas present with metastases at the time of diagnosis.
2,8
 
Thyroidectomy is the preferred treatment modality for tumors that are mobile and well 
circumscribed, while unresectable invasive tumors may be treated with external beam 
radiation or radioactive iodine-131 (
131
I) therapy.
40,42,43
 
In humans, well established prognostic factors for thyroid carcinoma include 
age, gender, tumor size, stage, histologic type and grade, vascular invasion and 
extrathyroidal tumor extension.
49,50
 Low-risk patients undergo a follow-up strategy that 
is considerably different from that of high-risk patients.
3
  
In dogs, tumor volume > 20 cm3, bilateral disease and cervical vascular 
invasion have been associated with high metastatic rates.
8,9,42
 However, these 
associations were often based on necropsy studies or studies in dogs with unresectable 
tumors and there are few published studies on prognostic predictors for dogs with 
operable thyroid tumors. Breed, sex, histologic type, and tumor size did not appear to 
affect prognosis after surgical resection, while bilateral disease and histological grade 
of malignancy were prognosticators.
8,40,41,47 
Prognostic markers are lacking for dogs 
with thyroid tumors undergoing thyroidectomy. 
Thyroid carcinoma can arise from thyroid follicular cells (follicular cell 
thyroid carcinoma - FTC), or from the parafollicular C cells (medullary thyroid 
carcinoma - MTC).
7
 According to the World Health Organization (WHO) histologic 
classification of canine thyroid tumors, FTC can be classified as well differentiated 
(dFTC) (follicular, compact, follicular-compact, papillary), poorly differentiated, 
undifferentiated or carcinosarcoma.
7
 In humans, MTC is more aggressive than dFTC.
10
 
In most veterinary studies, the prevalence of MTC is likely underestimated as these 
tumors may be difficult to distinguish from dFTC of compact type by microscopic 
observation alone; immunohistochemistry (IHC) for calcitonin or for markers of 
neuroendocrine tissue is required for their identification.
4
 In one study, MTC 
represented 36% of all canine thyroid tumors and was suggested to be more amenable 
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to complete surgical resection and have lower metastatic potential than FTC.
4
 
However, it is still not clear whether canine dFTC and MTC differ with respect to 
prognosis following thyroidectomy.  
E-cadherin is a transmembrane adhesion glycoprotein of epithelial tissues and 
plays a role in neoplastic cell behavior as a suppressor of invasion and metastasis.
55
 In 
human thyroid carcinomas, loss of E-cadherin expression is an independent prognostic 
indicator associated with a higher degree of dedifferentiation and higher metastatic 
potential.
55
 In dogs with mammary carcinoma, loss of E-cadherin expression was also 
found to be related to prognosis.
56
 The prognostic significance of E-cadherin 
expression in canine thyroid gland carcinoma has not been investigated.  
Ki-67 is a cellular proliferation marker expressed in the cell nuclei during all 
active phases of the cell cycle (G1, S, G2 and mitosis) but not in G0.
57
 In human dFTC, 
high Ki-67 labeling index is associated with higher metastatic rates at diagnosis and 
shorter disease-free survival (DFS).
58,59
 Although the use of Ki-67 as a marker for 
prognosis was shown to have limitations in certain canine tumors, its value is well 
established in mast cell tumors.
57,60
 The prognostic relevance of Ki-67 expression has 
not yet been examined in canine thyroid tumors. 
The goals of the present study were to identify clinical, pathological and 
immunohistochemical (calcitonin, Ki-67 and E-cadherin) prognostic factors for dogs 
with thyroid tumors. 
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 MATERIALS AND METHODS 
Case selection  
The medical record databases of the Companion Animal Clinics of Ghent and 
Utrecht Universities were searched for dogs diagnosed with thyroid neoplasia from 
January 1, 1986 to January 1, 2012. For inclusion in the study the diagnosis had to be 
confirmed by histopathology. Patients with no follow-up information and patients for 
which the paraffin-embedded tumor samples were not available were excluded.  
Medical records review  
The medical records of the dogs that met the inclusion criteria were reviewed. When 
the complete follow-up information was not available in the medical record, referring 
veterinarians and clients were contacted by phone. The information retrieved from 
medical records included signalment, time to presentation (from detection of cervical 
mass to diagnosis), owners impression of tumor progression rate, clinical signs, 
physical examination, tumor mobility (determined via palpation), tumor measurements, 
medical imaging results (thoracic radiographs, cervical and thoracic scintigraphy, 
cervical ultrasonography, computed tomography (CT) scan), WHO tumor stage, 
treatment, surgery report, outcome and necropsy report.
164 
Whenever possible, 
dimesnsions of the tumor were based on measurements taken immediately after 
surgical or necropsy excision and alternatively based on measurements taken during 
CT scan, cervical ultrasonography or physical examination. The volume of each 
thyroid tumor was estimated by the use of an ellipsoid formula.
165
  
Thyroid volume (mL or cm
3) = length (cm) x width (cm) x height (cm) x π/6 
When more than one thyroid lobe was affected, the sum of both lobes and/or ectopic 
tissue was used. 
Staging was performed according to the WHO staging system (Table 1), based 
on tumor measurements, thoracic radiographs, cervical and thoracic scintigraphic 
examination and, when available, cytology and histopathology of regional lymph nodes 
(LNs) (mandibular and retropharyngeal). In most cases, regional LNs were aspirated or 
excised (for patients undergoing thyroidectomy) when found to be enlarged at physical 
examination or surgical exploration; in a subset of patients, cervical ultrasonography 
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and CT-scan also aided the evaluation of regional LNs. Regional LN metastases were 
confirmed by histolopathology or by obvious macroscopic evidence of LN invasion 
during surgery.  
Thyroid function status at the time of diagnosis was determined based on basal 
circulating total thyroxine (TT4) and thyrotropin (TSH) concentrations and, when 
available, results of TSH stimulation test. 
Surgical and necropsy reports were reviewed to determine if there was 
macroscopic evidence of vascular or local invasion by the primary tumor. Macroscopic 
vascular invasion was defined as evidence of tumor emboli in the cervical blood 
vessels. Macroscopic local invasion was defined as evidence of growth of the primary 
tumor into neighboring tissues (eg, cervical muscles, esophagus and trachea). 
 
Table 1. World Health Organization’s clinical staging system for dogs with thyroid tumors. 
(Reproduced, with the permission of the publisher, from Owen LN. TMN classification of tumors 
in domestic animals. Geneva: World Health Organization, 1980)164  
Stage Primary tumor Regional LN Distant metastases 
I T1 a,b N0 M0 
II 
T0 N1 M0 
T1 a,b N1 M0 
T2 a,b N0 or N1 a M0 
III 
T3 Any N M0 
Any T N1 b or N2 b M0 
IV Any T Any N M1 
Abbreviations: T0, microscopic residual disease; T1, < 2cm; T2, 2-5cm; T3 >5cm; N0, no lymph 
node involvement; N1, ipsilateral lymph node involvement; N2, bilateral lymph node 
involvement; M0, no evidence of distant metastases; M1, evidence of distant metastases; a, freely 
movable; b, fixed. 
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Overall survival (OS), DFS, time to loco-regional recurrence (TR) and time to 
distant metastases (TM) were determined for dogs treated with thyroidectomy. Overall 
survival was defined as time from thyroidectomy to death caused by thyroid neoplasia; 
patients still alive at the last observation time and patients who died due to other causes 
were censored. If the cause of death could not be determined, it was assumed to be 
related to thyroid neoplasia. Disease-free survival was defined as TR, TM or time to 
death caused by thyroid neoplasia, whichever came first. Patients disease-free at the 
last observation time and patients who died due to other causes were censored. Time to 
loco-regional recurrence was defined as time from thyroidectomy to local recurrence or 
regional LN metastases, with dogs censored at the last follow-up whenever physical 
examination revealed no recurrence or at the time of death if necropsy revealed no 
tumor recurrence or LN metastases. For TM, distant metastasis was the event of 
interest, with dogs censored at the last observation time when thoracic radiographs 
showed no signs of metastatic disease, or at the time of death if necropsy revealed no 
distant metastases.  
Tumor specimens  
Formalin-fixed paraffin-embedded (FF-PE) tissue blocks for each patient were 
collected from the Departments of Pathology of Ghent and Utrecht Universities and, in 
some dogs, multiple blocks from one tumor site and/or blocks from multiple sites 
(local, regional lymph node, distant metastases) were available. All samples were 
obtained at surgery or necropsy. In total, 304 FF-PE blocks from 74 patients (52 from 
Utrecht University, 22 from Ghent University) were available. 
Histopathology  
Five-μm sections from each FF-PE block were stained with hematoxylin and 
eosin (HE). All HE slides were reviewed by a single board-certified pathologist (RD) 
blinded to clinical information and previous histopathology report.  
The distinction between adenoma and carcinoma was based on the histologic 
evidence of either capsular invasion, vascular invasion or metastases. The histologic 
type of primary tumors was classified according to the WHO classification as tumors of 
follicular cell origin (follicular, compact, follicular-compact, papillary, poorly 
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differentiated, undifferentiated, carcinosarcoma) or C cell (medullary) origin.
7
 
Classification of medullary thyroid tumors was also based on IHC for calcitonin. 
Follicular cell carcinomas classified as poorly differentiated, undifferentiated or 
carcinosarcoma were excluded due to their aggressive biological behavior.  
Primary thyroid tumors were characterized histologically by local invasion 
(tumor growth into neighboring tissues observed or not observed), vascular invasion 
(tumor growth into blood vessels observed or not observed), capsular invasion (not 
observed, invasion into tumor capsule, invasion beyond tumor capsule), necrosis (0, 1-
25%, 26-50%, >50%), hemorrhage (0, ≤50%, >50%), nuclear pleomorphism (0, 1-25%, 
26-50%, >50%) and mitotic index.166 Estimation of percentage necrosis and percentage 
hemorrhage was based on the observation of the entire section at 200x magnification. 
Percentage nuclear pleomorphism and mitotic index were estimated after observation 
of at least 10 random fields at 400x magnification.  
Immunohistochemistry  
Five-μm sections from FF-PE blocks from each primary tumor were prepared 
on 3-aminopropyltriethoxysilane-coated slides. After dewaxing and rehydration, 
antigen retrieval was performed by immersion in citrate (0.01 M, pH 6) buffered 
distilled water and microwaving in a pressure cooker for 15 min at 850 W and 15 min 
at 300 W. Slides were then allowed to cool for 20 min. Endogenous peroxidase was 
blocked with hydrogen peroxide 0.03% for 5 minutes followed by rinsing with 
phosphate-buffered saline (PBS pH 7.4). Sections were incubated overnight with the 
primary antibodies in a humidity chamber at 4ºC (Table 2). Preliminary evaluation of 
the optimal concentration of each primary antibody was performed with serial antibody 
dilutions using the respective positive controls (Table 2); canine normal thyroid tissue 
was used as negative control. Incubation with a polymer-based secondary antibody 
(EnVision
TM
, Dako, Glostrup, Denmark) was performed at room temperature for 30 
min. After each incubation step, sections were rinsed with PBS. 3,3’ diaminobenzidine 
(DAB, Dako) in substrate buffer solution (Dako) served as chromogen and was allowed 
to react for 5 min. The sections were then counterstained with hematoxylin, rinsed in 
tap water, dehydrated and mounted with cover slips. 
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The subset of tumors positive for calcitonin was also stained for thyroglobulin 
in an automated immunostainer (Dako, S/N S38-7410-01). 
 
Table 2. Antibodies used for immunohistochemistry 
Antibody Antibody Antibody type Dilution Positive control Negative control 
Thyroglobulin A 0251a Rabbit 
polyclonal  
1:800 Normal canine thyroid 
gland (follicular cells) 
Normal canine 
thyroid (C cells) 
Calcitonin A 0576a Rabbit 
polyclonal 
1:400 Normal canine thyroid 
gland (C cells) 
Normal canine 
thyroid gland 
(follicular cells) 
Ki-67 MIB-1a Mouse 
monoclonal 
1:200 Normal canine small 
intestine 
Normal canine 
thyroid gland 
E-cadherin  NCH-38a Mouse 
monoclonal  
1:200 Normal canine thyroid 
gland 
 
a Dako, Glostrup, Denmark 
 
 
 
 
 
 
 
 
 
Prognostic factors 
67 
Quantification of immunoreactive cells  
All slides were examined by the same observer (MC), blinded to the clinical 
information and outcome of each patient. Quantification of Ki-67 labeling index was 
performed evaluating each slide through an optical grid at 400x magnification. In the 
region of highest positivity of the section, the fields were chosen randomly with a 
minimum of 10 fields per section and counting at least 500 cells per section. Only 
neoplastic cells with nuclear staining were recorded as positive. The labeling index was 
calculated as the number of positive cells divided by the number of positive plus 
negative cells (Fig. 1).  
Quantification of E-cadherin immunolabeling was performed examining the 
entire section at 200x magnification and estimating the percentage of neoplastic cells 
with labeling of membranous E-cadherin. Tumors were classified according to 
membranous immunolabeling in 0-5%, 6-30%, 31-60%, 61-90% and >90% of positive 
cells (Fig. 2).  
Thyroid tumors positive for calcitonin were classified as medullary tumors and 
thyroid tumors negative for calcitonin were classified as follicular cell tumors.
4 
To 
ensure the accuracy of this classification, the subset of tumors positive for calcitonin 
was also stained for thyroglobulin. Calcitonin and thyroglobulin immunolabeling were 
not quantified. The tumor was considered positive when the cytoplasm of neoplastic 
cells exhibited a fine granular staining pattern with cell-to-cell variation (Fig. 3). 
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Fig. 1. Immunohistochemical 
staining of Ki-67 in a canine 
medullary thyroid carcinoma 
with a labeling index of 28.4% 
(400x). 
Fig. 2. Immunohistochemical 
staining of E-cadherin in a canine 
medullary thyroid carcinoma 
with >90% of positive cells 
(400x). 
Fig. 3. Immunohistochemical 
staining of calcitonin in a canine 
medullary thyroid carcinoma 
(400x). 
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Statistical analysis  
Correlating tumor variables with local invasiveness and metastases at time of 
diagnosis 
For binary outcomes, the statistical analysis was based on the logistic 
regression model using exact tests and an exact odds ratio calculation.
a
 The binary 
response variables corresponded to surgical/necropsy evidence of local invasion, 
histologic evidence of local invasion and evidence of distant metastases at diagnosis. 
Tumor maximum diameter, tumor volume, tumor localization, scintigraphic uptake, 
thyroid functional status, histologic type, Ki-67 labeling index and E-cadherin 
expression, were introduced in the binary regression model as covariates. Significance 
level was set at 5%. For tumor localization, the significance level was adjusted for 
multiple comparisons (Bonferroni correction). 
Comparison between follicular cell and medullary tumors with respect to the 
Ki-67 labeling index and E-cadherin expression was based on the Mann-Whitney U 
test. 
Survival analysis 
The effect of each variable on OS, DFS, TM and TR was evaluated with the 
Cox proportional hazards model.
a
 Each variable was incorporated in a univariate way, 
either as categorical or continuous. The variables analyzed included: age, time to 
presentation, weight loss, owners impression of tumor progression rate, body condition 
(determined during physical examination), tumor mobility, tumor maximum diameter 
(cm), tumor volume (cm
3
), thyroid function, tumor scintigraphic uptake, WHO tumor 
stage, surgical evidence of vascular invasion, histologic features (histologic type, 
evidence of vascular invasion, capsular invasion, local invasion, percentage necrosis, 
percentage hemorrhage, nuclear pleomorphism and mitotic index), Ki-67 labeling 
index, E-cadherin expression, and levothyroxine supplementation. Variables found to 
have an effect on outcome at the 5% significance level were incorporated in a 
multivariate analysis to rule out associated effects. 
 
 
Chapter 4 
70 
 RESULTS 
Seventy dogs were included. Relevant clinical data is summarized in Table 3. 
All hyperthyroid dogs for which clinical signs were recorded (13 of 14 dogs) 
had clinical signs compatible with hyperthyroidism. Total calcium was measured in 5 
dogs with MTC and was normal in all dogs.  
Distant metastases were most frequently located in the lungs (12 dFTCs, 2 
MTCs) and liver (2 FTCs). One dog with MTC had signs of metastasis or ectopic 
thyroid tissue in the mediastinum. 
Eighteen dogs had macroscopic and/or histologic evidence of local invasion; 7 
dogs had only macroscopic local invasion and 7 dogs had only histologic local 
invasion. 
All thyroid tumors were carcinomas; 50 (71%) tumors were classified as 
dFTCs and 20 (29%) as MTCs following calcitonin immunostaining (Fig. 3). The 
dFTCs were classified as follicular (n=13, 19%), compact (n=19, 27%), follicular-
compact (n=17, 24%) and follicular-papillary (n=1, 1%). Thyroglobulin staining was 
negative in all MTCs except in one dog considered to have a rare variant of MTC with 
mixed expression of calcitonin and thyroglobulin.
167
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Table 3. Summary of clinical data organized by histologic tumor 
type in 70 dogs with thyroid tumors. 
Histologic type dFTC MTC 
Age n=50 n=19 
   Median 10 9 
   Range 4 – 14 4 – 16 
Sex n=50 n=20 
   Male 30 (60%) 8   (40) 
   Female 20 (40%) 12 (60%) 
Weight loss n=48 n=19 
   Present 18 (38%) 4   (21%) 
   Absent 30 (62%) 15 (79%) 
Body condition n=43 n=16 
   Emaciated 10 (23%) 2   (13%) 
   Ideal 27 (63%) 13 (81%) 
   Obese 6   (14%) 1   (6%) 
Stridor n=50 n=19 
   Present 5   (10%)  
   Absent 45 (90%) 19 (100%) 
Dyspnea n=49 n=19 
   Present 5   (10%)  
   Absent 44 (90%) 19 (100%) 
Tumor localization n=50 n=19 
   Unilateral 38 (76%) 19 (100) 
   Bilateral 8   (16%)  
   Ectopic  (ventral larynx) 4   (8%)  
Tumor mobility n=38 n=19 
   Mobile 21 (55%) 11 (69%) 
   Fixed 17 (45%) 5 (31%) 
Tumor diameter (cm) n=49 n=19 
   Median 5 4 
   Range 1.8 – 120 2.5 – 8.5 
Tumor volume (cm3) n=47 n=16 
   Median 25.7 23.2 
   Range 2 – 290 4 – 117 
Thyroid function n=43 n=14 
   Hypothyroid 1   (2%) 1 (7%) 
   Euthyroid 17 (40%) 9 (64%) 
   Hyperhyroid 12 (28%)  
   Eu/hypothyroid 13 (30%) 4 (29%) 
Tumor scintigraphy n=38 n=13 
   Decreased 8   (21%) 7 (54%) 
   Normal/increased 30 (79%) 6 (46%) 
Macroscopic local invasion n=38 n=17 
   Present 9   (24%)  
   Absent 29 (76%) 17 (100%) 
Histologic local invasion n=50 n=20 
   Present 8   (20%)  
   Absent 42 (80%) 20 (100%) 
Stage n=50 n=19 
   I 1   (2%)  
   II 21 (42%) 10 (52%) 
   III 17 (34%) 6   (32%) 
   IV 11 (22%) 3   (16%) 
Abbreviations: dFTC, differentiated follicular cell thyroid 
carcinoma; MTC, medullary thyroid carcinoma 
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Correlating tumor variables with local invasiveness and metastases at time of 
diagnosis 
The analysis was performed in all 70 dogs (50 dFTCs, 20 MTCs) irrespective 
of treatment modality (Table 4). 
Tumor diameter (P=0.007), tumor volume (P=0.020), follicular cell origin 
(P=0.044) and Ki-67 (P=0.038) were positively associated with macroscopic local 
invasion. Tumor diameter (P=0.038) and ectopic location (P=0.012) were positively 
associated with histologic local invasion. Tumor diameter (P=0.002), tumor volume 
(P=0.023) and bilateral location (P=0.012) were positively associated presence of 
distant metastases at diagnosis.  
Presence of distant metastases at diagnosis was not significantly different 
between dogs with dFTC and MTC (P=0.743).  
E-cadherin expression, tumor scintigraphic uptake and thyroid functional 
status were not associated with either local invasiveness or distant metastases at 
diagnosis. 
E-cadherin expression was significantly higher (P=0.003) in MTCs (median 
immunolabeling 91-100%) compared to dFTCs (median immunolabeling 31-60%) 
(Fig. 2). Ki-67 labeling index was not significantly different between dFTCs and MTCs 
(P=0.668). 
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Table 4. Correlating tumor variables with local invasiveness and distant metastases at diagnosis in 70 
dogs with thyroid tumors. 
 Macroscopic local 
invasion 
 Histologic local 
invasion 
 Distant 
metastases 
 Odds 
Ratio 
P value  Odds 
Ratio 
P value  Odds 
Ratio 
P value 
Tumor diameter 1.29 0.007  1.13 0.038  1.29 0.002 
Tumor volume 1.02 0.020  1.01 0.139  1.01 0.023 
Tumor localization*  0.156   0.001   0.018 
      Unilateral vs. Bilateral 0.15 0.214  0.07 0.027  0.10 0.012 
      Unilateral vs. Ectopic 0.30 0.728  0.02 0.002  0.50 0.963 
      Bilateral vs. Ectopic 1.81 1.000  0.23 0.546  4.34 0.546 
Scintigraphic uptake 1.24 1.000  1.23 1.000  1.24 1.000 
Thyroid function 2.80 0.660  2.01 0.920  3.50 0.426 
Histologic type 6.89 0.044  5.03 0.095  1.59 0.743 
Ki-67 1.06 0.038  1.05 0.210  1.01 0.147 
E-cadherin 1.03 1.000  1.05 1.000  1.23 0.528 
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Survival analysis 
Forty-four dogs were treated with thyroidectomy, 3 dogs underwent 
debulking, 4 dogs were treated with thyroidectomy and 
131
I, 2 dogs were treated with 
thyroidectomy and chemotherapy, 1 dog was treated with thyroidectomy and external 
beam radiation, 6 dogs received no treatment and 10 dogs were euthanized at diagnosis.  
The 44 dogs undergoing thyroidectomy were included in the survival analysis. 
Tumor mobility was recorded in 36 dogs; 27 dogs had freely-movable tumors and 9 
had fixed tumors.  Dogs were staged as stage I (n=1), stage II (n=26) and stage III 
(n=16). In 1 dog, although there was no evidence of metastases on medical imaging, 
tumor stage (I-III) could not be determined because tumor measurements were not 
recorded. Thyroidectomy was unilateral in 42 dogs, bilateral in 1 dog and 1 dog 
underwent surgical excision of an ectopic thyroid tumor ventral to the larynx. Surgical 
reports were available for 42 dogs and no dog had macroscopic evidence of local 
invasion. Median follow-up time at the clinic was 11 m (range, 0-60 m). 
Of the 44 dogs treated with thyroidectomy, 28 dogs had dFTC (follicular 
n=12; follicular-compact n=9; compact n=7) and 16 dogs had MTC. Thirteen dogs with 
dFTC received lifelong TT4 replacement therapy after thyroidectomy. Given that 
histologic tumor type (dFTC vs. MTC), and levothyroxine therapy had no significant 
effect of on outcome, all 44 dogs were analyzed together. 
After thyroidectomy, 4 of 19 dogs with dFTC (21%) and 5 of 12 dogs with 
MTC (42%) developed distant metastases. Furthermore, 4 of 25 dogs with dFTC (16%) 
and 3 of 14 dogs with MTC (21%) developed loco-regional recurrence: locally (1 
dFTC, 1 MTC), in regional LNs (3 dFTCs, 1 MTC), locally and in regional LNs (1 
MTC). 
 Overall survival, DFS, TM and TR, were not significantly different between 
dogs with dFTC and MTC (Table 5).  
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Table 5. Comparison of outcome between 28 dogs with differentiated 
follicular cell thyroid carcinoma and 16 dogs with medullary thyroid 
carcinoma treated with thyroidectomy.  
  dFTC MTC Overall n P-value 
OS (m) 
Median 17 42 22 
44 1.00 
Range  1 – 60 0.3 – 57 0.3 – 60 
DSF (m) 
Median 17 15 17 
44 0.58 
Range  0.3 – 60 0.3 – 45 0.3 – 60 
TM (m) 
Median 60 32 42 
31 0.24 
Range 1 – 60 2 – 42 1 – 60 
TR (m) 
Median > 60 > 42 > 60 
39 0.59 
Range 0.3 – 60 0.5 – 42 0.3 – 60 
Abbreviations: dFTC, differentiated follicular cell thyroid carcinoma;  MTC, 
medullary thyroid carcinoma; OS, overall survival; DSF, disease-free 
survival; TM, time to distant metastases; TR, time to loco-regional 
recurrence; m, months 
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Results of the univariate analysis revealed that macroscopic vascular invasion 
was negatively associated with OS (P=0.011, Table 6). Macroscopic (P=0.001) and 
histologic (P=0.037) vascular invasion were negatively associated with DFS. Time to 
presentation (P=0.040), histologic vascular invasion (P=0.018) and Ki-67 labeling 
index (P=0.004) were negatively associated with TM. Each month delay in 
presentation and each 1% increase in Ki-67 labeling index increased the risk for distant 
metastases by 14% and 24%, respectively. Time to presentation was negatively 
associated with TR (P=0.038). Each month delay in presentation increased the risk for 
loco-regional recurrence by 14%. 
Given their significant effect on outcome, the above mentioned variables were 
included in a multivariate analysis (Table 6; Fig. 4). Macroscopic (P=0.007) and 
histologic (P=0.046) vascular invasion were independent negative predictors for DFS. 
No independent predictors were found for OS, TM and TR. 
Age, weight loss, tumor progression rate, body condition, stridor, dyspnea, 
tumor mobility, tumor diameter, tumor volume, stage (I-III), thyroid function, tumor 
scintigraphic uptake, histologic type, histologic local invasion, capsular invasion, 
necrosis, hemorrhage, nuclear pleomorphism, mitotic index and E-cadherin expression 
had no significant effect on OS, DSF, TM or TR.  
  
 
Table 6. Summary of univariate and multivariate survival analyses in 44 dogs with thyroid gland tumors treated by thyroidectomy. Hazard ratios, 95% 
confidence intervals and P values are given. 
 OS   DFS   TM   TR  
 HR (95% CI) P  HR (95% CI) P  HR (95% CI) P  HR (95% CI) P 
UNIVARIATE            
Time to presentation n=38 1.01 (0.94-1.09) 0.763  1.03 (0.96-1.11) 0.453  1.14 (1.01-1.30) 0.040  1.14 (1.01-1.28) 0.038 
Macroscopic vascular invasion 
4.37 (1.39-13.7) 0.011 
 
10.0 (2.62-38.5) 0.001 
 
 * 
 
0.04 (0.00-5E11) 0.837 
    Present         n=4 of 37    
Histologic vascular invasion 
1.89 (0.87-4.11) 0.109 
 
2.36 (1.05-5.31) 0.037 
 
12.7 (1.55-105) 0.018 
 
2.33 (0.51-10.8) 0.277 
   Present          n=24 of 44    
Ki-67 labeling index n=44 1.02 (0.98-1.07) 0.261  1.04 (1.00-1.07) 0.066  1.24 (1.07-1.44) 0.004  0.98 (0.86-1.13) 0.801 
MULTIVARIATE            
Macroscopic vascular invasion    47.5 (2.92-773) 0.007       
Histologic vascular invasion    2.88 (1.02-8.18) 0.046       
Abbreviations: OS, overall survival; DSF, disease-free survival; TM, time to distant metastases; TR, time to loco-regional recurrence; *Not performed because 
only 1 dog in the analysis had macroscopic evidence of vascular invasion 
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Fig. 4. Kaplan-Meier survival curves for 44 dogs with thyroid gland tumors treated 
with thyroidectomy  
 
 
 
 
 
 
 
 
 
A 
Macroscopic vascular invasion  
n=4, median DFS 2.5 m  
No vascular invasion  
n=33, median DFS 23 m 
B  
Histologic vascular invasion  
n= 24, median DFS 12 m  
No vascular invasion  
n=20, median DFS 29 m  
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  DISCUSSION 
Prognostic markers are lacking for dogs with thyroid tumors undergoing 
thyroidectomy. In our exploratory analysis, macroscopic and histologic vascular 
invasion were independent negative predictors for DFS.  
In our study, the prevalence of hyperthyroidism in dFTC (28%) was similar to 
previous reports.
52
 It can be hypothesized that functional tumors (in dogs with 
hyperthyroidism or with preserved scintigraphic uptake) are more differentiated and, 
therefore, carry a better prognosis. However, patient thyroid function and tumor 
scintigraphic uptake had no significant effect on outcome.  
Time to presentation was negatively associated with TR, which may be a 
result of delayed diagnosis and treatment. In a recent retrospective study in dogs with 
thyroid tumors, the effect of duration of clinical signs on survival approached statistical 
significance.
47
 In people, time to therapy has been shown to be independently 
associated with thyroid cancer mortality.
168
  
In agreement with an earlier study, tumor diameter was positively associated 
with  incidence of distant metastases at diagnosis.
9
 However, following thyroidectomy 
tumor diameter was not associated with outcome as previously reported.
41,47
 In humans, 
the risk of thyroid tumor recurrence and cancer-related mortality increases linearly with 
tumor size.
168
  
Macroscopic vascular invasion was negatively associated with OS and was an 
independent negative predictor for DFS. This is in agreement with earlier reports and is 
not surprising given the massive degree of neoplastic vessel infiltration necessary for 
macroscopic observation.
8
 In humans with FTC, extensive vascular invasion is rare but 
is also reported to have a poor prognosis.
169
  
Histologic vascular invasion was negatively associated with TM and was an 
independent negative predictor for DFS. Our results are in agreement with an earlier 
study showing the prognostic value of histologic grade of malignancy in dogs with 
thyroid cancer.
41
 In that study, vascular invasion was one of the most important 
histologic criteria used for the overall grade of malignancy. Although in our study 
histologic vascular invasion was negatively associated with TM and DFS, no 
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association was found with OS. This may be due to the fact that thyroid cancer 
metastases can have an indolent progression and are not always associated with rapid 
clinical deterioration. The fact that the overall median TM was approximately double 
than median OS supports this possibility. In humans with dFTC, histologic vascular 
invasion is an independent predictor of cancer-related mortality.
170
 Our study suggests 
that dogs with this histologic feature are at high risk for metastatic disease after 
thyroidectomy. Further research is necessary to determine if post-operative adjunctive 
therapy (eg, 
131
I) can improve the outcome of these patients. 
In the current study, 29% of canine thyroid tumors were MTC based on IHC 
for calcitonin. This is in accordance with previous studies where 16-36% of thyroid 
carcinomas were MTCs.
4,171
 Medullary thyroid carcinoma may be difficult to 
distinguish from dFTC of compact type by microscopic observation alone and earlier 
studies likely underestimated their prevalence.
4
 In fact, 18 of 20 MTCs in our study 
were provisorily classified as dFTC of compact type and 2 as dFTC of follicular-
compact type, prior to IHC for calcitonin. This underlines the importance of routine 
IHC for identification of MTC. 
One of the goals of our study was to investigate the prognostic relevance of 
differentiating dFTC from MTC with IHC. A previous study suggested that canine 
MTC may have a less malignant biological behavior with a higher rate of complete 
surgical excision and lower incidence of metastases at diagnosis compared to dFTC.
4
 In 
accordance with this report, we found that MTCs were significantly less likely to be 
locally invasive at presentation. However, we found no difference in the incidence of 
metastatic disease at diagnosis. More importantly, after thyroidectomy, OS, DFS, TM 
and TR were not significantly different between dogs with dFTC and MTC. This 
suggests that, although MTC is less invasive and thus more amenable to complete 
surgical resection, after thyroidectomy the outcome is comparable to dFTC.  
Ki-67 labeling index was negatively associated with TM in our study, 
although only in the univariate analysis. In humans, Ki-67 is associated with clinical 
stage and survival in both dFTC and MTC.
59,172
 It has been proposed that human 
thyroid carcinomas with Ki-67 labeling index < 5% have a more benign clinical course 
and that tumors with labeling index > 15% have a more aggressive biological 
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behavior.
173
 Interestingly, at the moment of diagnosis Ki-67 was positively associated 
with local invasiveness but not with distant metastases. 
In human thyroid cancer, loss of E-cadherin protein expression is a negative 
prognostic indicator, however we found no association between E-cadherin expression 
and outcome.
55 
Furthermore, no correlation was observed between E-cadherin 
expression and local invasiveness or distant metastases at diagnosis. This suggests that 
other factors are more important in the development of local invasion and metastatic 
disease in canine thyroid cancer. Still, it was interesting to note that E-cadherin 
expression was significantly higher in MTCs compared to dFTCs.  
The benefit of TSH-suppressive therapy with levothyroxine is well established 
in high-risk human dFTC and we recommend it routinely in the treatment of canine 
FTC.
82
 In our study, as levothyroxine was mainly administered as substitution therapy 
for dogs with low TT4 concentrations after thyroidectomy, the lack of significant effect 
on survival might be due to an insufficient TSH suppression. 
Limitations of our study include its retrospective and exploratory nature. 
Although review of IHC slides was only performed by one observer, which may 
decrease accuracy of scoring, it maximizes consistency of comparative scoring between 
slides. 
In conclusion, our study suggests that macroscopic and histologic evidence of 
vascular invasion are independent negative predictors for DFS in dogs with surgically 
excised thyroid carcinoma. Canine dFTC and MTC seem to have comparable outcome 
after thyroidectomy.  
 
 
 
 
 
 
 
 
Chapter 4 
82 
 ENDNOTES 
a
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 SPSS 20, Chicago, IL, USA. 
 ACKNOWLEDGMENTS 
The authors thank the Department of Pathobiology of Utrecht University for 
providing all paraffin embedded tumor samples of patients diagnosed and treated at 
Utrecht University. We also thank the Department of Morphology of Ghent University 
for their collaboration in sectioning the paraffin-embedded tumor samples. 
 
 
 
 
 
 
  
 
 
 
 
 83 
 
 
IMMUNOHISTOCHEMICAL EXPRESSION OF POTENTIAL 
THERAPEUTIC TARGETS IN CANINE THYROID CARCINOMA 
 
Miguel Campos
1
, Richard Ducatelle
2
, Hans S. Kooistra
3
, Gerard Rutteman
3
, Luc 
Duchateau
4
, Ingeborgh Polis
1
, Sylvie Daminet
1
 
 
 
 
 
 
 
Adapted from  
Journal of Veterinary Internal Medicine 2014; 28(2): 564-70 
 
 
 
 
 
 
1 Department of Medicine and Clinical Biology of Small Animals 
2 Department of Pathology, Bacteriology and Poultry Diseases 
4 Department of Comparative Physiology and Biometrics,  
  Faculty of Veterinary Medicine, Ghent University, Belgium 
3 Department of Clinical Sciences of Companion Animals 
  Faculty of Veterinary Medicine, Utrecht University, The Netherlands 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic targets 
85 
 ABSTRACT 
Background: Thyroid carcinoma is a common endocrine tumor in the dog. 
Local invasive growth frequently precludes surgical excision, and in up to 38% of 
dogs, the tumor has already metastasized by the time of diagnosis. Therefore, it is 
important to investigate new treatment modalities that may be useful for the large 
number of dogs with inoperable tumors or metastatic disease. 
Hypothesis/Objectives: To investigate the immunohistochemical expression 
of potential therapeutic targets in canine thyroid tumors. 
Animals: 74 dogs with thyroid neoplasia. 
Methods: Immunohistochemistry was performed for thyroglobulin, calcitonin, 
vascular endothelial growth factor (VEGF), p53, cycloxygenase-2 (Cox-2) and P-
glycoprotein (P-gp). 
Results: Fifty-four (73%) tumors were classified as follicular cell thyroid 
carcinomas (FTCs) and 20 (27%) as medullary thyroid carcinomas (MTCs). Eighty 
percent of FTCs and all MTCs had a high percentage (76-100%) of neoplastic cells 
immunopositive for VEGF. Thirteen percent of FTCs and 50% of MTCs expressed 
Cox-2. Seven percent of FTCs and 70% of MTCs expressed P-gp. No tumor was 
immunopositive for p53 expression. Expression of VEGF (P=0.034), Cox-2 (P=0.013) 
and P-gp (P<0.001) was significantly higher in MTCs compared to FTCs. 
Conclusions and clinical importance: VEGF is a potential therapeutic target 
in both FTC and MTC in dogs. Cox-2 and P-gp may be useful molecular targets in 
canine MTC. 
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INTRODUCTION 
Thyroid cancer represents 10-15% of all head and neck neoplasms in the dog, 
and 90% of thyroid tumors detected clinically are carcinomas.
2,163
 Thyroid carcinomas 
can be classified as follicular cell thyroid carcinomas (FTCs), which arise from 
follicular thyroid cells, and medullary thyroid carcinomas (MTCs), which arise from 
the parafollicular C cells and have a neuroendocrine origin. Although thyroidectomy is 
the preferred treatment modality, invasive non-resectable thyroid tumors are common 
in dogs, and in up to 38% of dogs the tumor has already metastasized by the time of 
diagnosis.
4,8
 Furthermore, almost 50% of dogs undergoing thyroidectomy experience 
recurrence or metastatic disease within 2 years of surgery.
8
 Therefore, it is important to 
investigate new treatment modalities for the large number of dogs with inoperable 
tumors or metastatic disease.  
Vascular endothelial growth factor (VEGF) is the main stimulator of 
angiogenesis in the thyroid gland, and VEGF overexpression has been found in human 
thyroid cancer.
67
 VEGF is secreted by cancer cells and binds to VEGF tyrosine kinase 
receptors on the surface of endothelial cells and thyrocytes. In people, vascular 
endothelial growth factor recptor-2 (VEGFR-2) inhibition with tyrosine kinase 
inhibitors (TKIs) is the most effective new therapeutic strategy developed to date in the 
treatment of advanced thyroid cancer.
70
 VEGF, angiogenesis and VEGF-induced 
pathway activation may play important roles in the progression of canine thyroid 
cancer and constitute important therapeutic targets. 
Tumor suppressor gene p53 encodes a nuclear phosphoprotein that mediates 
cell cycle regulation and apoptosis in response to DNA damage.
174
 Mutations that 
result in loss of normal p53 function lead to loss of cell cycle control and increased risk 
of malignancy. In normal cells, p53 protein has a short half-life and is undetectable 
with immunohistochemistry (IHC). However, some p53 gene mutations lead to 
expression of an altered p53 protein with longer half-life that is detectable by IHC.
175
 
In humans, p53 mutations have been described in 40-62% of undifferentiated thyroid 
carcinomas and in 5-10% of other thyroid carcinomas.
176
 Research in human thyroid 
cancer shows that restoration of wild-type p53 expression by gene therapy is associated 
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with inhibition of tumor cell growth and enhanced sensitivity to chemotherapy and 
radiation.
174
 Earlier investigations of the p53 gene coding region identified a somatic 
mutation in 1 of 23 canine FTCs.
27
 Thus, the p53 tumor suppressor gene may be a 
potential molecular target in canine thyroid cancer. 
Cyclooxygenases (Cox), particularly Cox-2, may play a critical role in tumor 
development and progression. In particular, epithelial neoplasms are prone to express 
large amounts of the inducible form of Cox-2. In dogs, Cox-2 over-expression has been 
described in transitional cell carcinoma (TCC) of the urinary bladder and in prostatic 
carcinoma.
177
 Several studies have shown that Cox-2 or Cox-1/Cox-2 inhibitors have 
antitumor and chemopreventive effects, presumably by induction of apoptosis, 
reduction of angiogenic growth factors and suppression of regulatory T-cells.
75,76
 Cox-2 
is an appealing therapeutic target and its expression has not yet been investigated in 
canine thyroid tumors. 
One study in 44 dogs with surgically excised thyroid carcinoma failed to 
demonstrate a clinical benefit of adjuvant chemotherapy.
47
 Moreover, the reported 
survival times for dogs with unresectable thyroid tumors treated with chemotherapy are 
disappointing.
45
 One of the major mechanisms for resistance to chemotherapy is high 
expression of ATP-binding cassette (ABC) transporter proteins such as P-glycoprotein 
(P-gp; ABCB1) and multi-drug resistance-related protein 1 (ABCC1).
77
 These ATP-
dependent membrane efflux pumps decrease the intracellular concentration of 
chemotherapeutic agents, thereby limiting cytotoxicity at their target site. Recent 
research shows that TKIs and Cox-2 inhibitors can reverse multi-drug resistance by 
decreasing the expression and function of P-gp.
78,79
 P-gp expression has been identified 
in several canine tumors and may constitute an attractive molecular target.
80
 
The goal of this study was to evaluate the immunohistochemical expression of 
VEGF, p53 protein, Cox-2 and P-gp in canine thyroid tumors and to assess their 
potential as therapeutic targets.  
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 MATERIALS AND METHODS 
Case selection  
The medical record databases of the Companion Animal Clinics of Ghent and 
Utrecht Universities were searched for dogs diagnosed with thyroid neoplasia from 
1986 to 2012. Patients for which paraffin-embedded tumor samples were no longer 
available were excluded.  
Tumor specimens  
Formalin-fixed paraffin-embedded (FF-PE) tissue blocks of each patient were 
collected. In some dogs several blocks from 1 tumor site or blocks from multiple sites 
(local, regional node, distant metastases) were available. All samples were obtained at 
surgery or necropsy. In total, 304 FF-PE blocks from 74 patients (52 from Utrecht 
University, 22 from Ghent University) were available.  
Histopathology  
Five-μm sections from each FF-PE block were stained with hematoxylin and 
eosin (HE). All HE slides were reviewed by the same board-certified pathologist (RD) 
blinded to the clinical information and previous histopathology report.  
When neoplastic thyroid tissue was identified, the section was classified as 
primary tumor, lymph node metastasis or distant metastasis. The distinction between 
adenoma and carcinoma was based on histologic evidence of either capsular invasion, 
vascular invasion or metastases. The histologic type of primary thyroid tumors was 
classified according to the World Health Organization classification as tumors of 
follicular cell origin (follicular, compact, follicular-compact, papillary, poorly 
differentiated, undifferentiated and carcinosarcoma) or C-cell (medullary) origin.
7
 
Classification of medullary thyroid tumors also was based on positive IHC for 
calcitonin, as previously described.
5
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Immunohistochemistry  
Five-μm sections from each FF-PE block were prepared on 3-
aminopropyltriethoxysilane-coated (APES) slides. After dewaxing and rehydration, 
antigen retrieval was performed by immersion in citrate-buffered (0.01 M, pH 6) 
distilled water and microwaving in a pressure cooker for 15 min at 850 W and 15 min 
at 300 W. Slides then were allowed to cool for 20 min. Endogenous peroxidase was 
blocked with 0.03% hydrogen peroxide for 5 minutes followed by rinsing with water 
and phosphate-buffered saline (PBS pH 7.4). Sections were incubated overnight with 
the primary antibodies (Table 1) in a humidity chamber at 4ºC. Validation and 
evaluation of the optimal concentration of each primary antibody were performed with 
serial antibody dilutions using the respective positive controls (Table 1); normal canine 
thyroid gland tissue was used as negative control. Incubation with a polymer-based 
secondary antibody
a
 was performed at room temperature for 30 min. After each 
incubation step, sections were rinsed with PBS. 3,3’ diaminobenzidineb, in substrate 
buffer solution served as chromogen and was allowed to react for 5 min (10 min for 
p53 antibody). The sections then were counterstained with hematoxylin, rinsed in tap 
water, dehydrated and mounted with cover slips. Immunohistochemistry for each 
antibody was performed in 2 batches given the large number of slides that had to be 
stained. 
Table 1. Antibodies used for immunohistochemistry 
aSanta Cruz Biotechnology, Inc., Dallas, TX, USA; bThermo Fischer Scientific, Loughborough, 
UK; cBD Transduction Laboratories™, San Jose, CA, USA;  dEnzo Life Sciences, Inc., 
Farmingdale, NY, USA;  eCovance, Princetron, NJ, USA; f Dako, Glostrup, Denmark;  
Antibody Antibody name Antibody type Dilution Positive control 
VEGF  SPM225
a Mouse monoclonal  1:25 Canine mammary carcinoma 
P53 Clone PAb 240
b Mouse monoclonal 1:50 Canine mammary carcinoma known 
to harbor p53 gene mutation 
Cox-2 Clone 33
c Mouse monoclonal 1:800 Normal canine kidney (macula densa) 
Pgp C494
d Mouse monoclonal 1:200 Normal canine liver 
Pgp JSB-1
e Mouse monoclonal 1:100 Normal canine liver 
Calcitonin A0576
f Rabbit polyclonal 1:400 Normal canine thyroid gland 
Thyroglobulin A0251
f Rabbit polyclonal  1:800 Normal canine thyroid gland 
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The subset of tumors positive for calcitonin also was stained for thyroglobulin 
in an automated immunostainer.
c
 
Quantification of immunoreactive cells  
All sections were examined by the same investigator (MC) who was blinded to 
the clinical information and outcome of each patient. For each marker, 
immunohistochemistry also was performed on normal canine thyroid gland to allow 
comparison with neoplastic tissue. Quantification of VEGF immunolabeling was 
performed by evaluating the entire section at 200x magnification and estimating the 
percentage of neoplastic cells positive for VEGF. Only neoplastic cells with 
cytoplasmic granular immunolabelling were considered positive.  The tumors were 
classified according to the immunolabelling as 0%, 1-25%, 26-50%, 51-75% and 76-
100% positive cells, as previously described.
178
 In each batch, endothelial cells were 
used as internal positive controls and normal thyroid gland was used as negative 
control. 
Quantification of p53 immunolabeling was performed by evaluating each 
section using an optical grid at 400x magnification.  The fields were chosen randomly 
with a minimum of 10 fields per section and counting at least 500 cells per section. 
Only neoplastic cells with nuclear staining were recorded as positive. The labeling 
index was calculated as the number of positive cells divided by the number of positive 
plus negative cells. Only sections with a labeling index ≥5% of positive neoplastic cells 
were considered positive for p53 expression, as previously described.
179
 In each batch, 
normal thyroid gland was used as negative control. 
Quantification of Cox-2 immunolabeling was performed by calculating the 
labeling index as described for p53. Only neoplastic cells with cytoplasmic granular 
staining were recorded as positive. Based on the labeling index and staining intensity 
(absent, weak, moderate or strong), an overall IHC score (0-12) was calculated as 
previously described.
180
 In each batch, normal kidney was used as positive control and 
normal thyroid gland was used as negative control. 
As recommended, 2 monoclonal antibodies recognizing 2 different epitopes of 
P-gp were used to improve the reliability of IHC (Table 1).
181
  Quantification of P-gp 
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immunolabeling was performed by evaluating the entire section at 200x magnification 
and estimating the percentage of neoplastic cells with membranous labeling of P-gp. 
The tumors were classified as 0-10%, 11-25%, 26-50%, 51-75% and 76-100% positive 
cells, as previously described.
182
 Additionally, the intensity of the staining was 
recorded as absent, weak, moderate or strong. Only sections with immunolabelling of 
≥11% of neoplastic cells with both antibodies (C494 and JSB-1) were considered truly 
positive for P-gp expression.
181,182
 In each batch, normal liver was used as a positive 
control and normal thyroid gland was used as negative control. 
Thyroid tumors positive for calcitonin were classified as MTCs and thyroid 
tumors negative for calcitonin were classified as FTCs.
5
 To ensure the accuracy of this 
classification, the subset of tumors positive for calcitonin was also stained for 
thyroglobulin. Calcitonin and thyroglobulin immunolabeling were not quantified. The 
tumor was considered positive when the cytoplasm of neoplastic cells exhibited a fine 
granular staining pattern with cell-to-cell variation. Normal thyroid gland was used as 
control in each batch. 
Statistical analysis  
Expression of VEGF, cox-2 labeling index, cox-2 IHC score and expression of 
P-gp were compared between FTCs and MTCs. For VEGF, Cox-2 labeling index and 
Cox-2 IHC score the analysis was based on the Wilcoxon rank sum test. For P-gp 
expression, the analysis was based on the Fisher exact test.
d
 Significance level was set 
at 5%. 
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 RESULTS 
Thyroid tumor tissues from 74 dogs, with a mean age of 9.3 years (range 4-16 
years) were reviewed. All thyroid tumors were classified as carcinomas. From the 74 
patients included in this study, 54 (73%) had FTC and 20 (27%) had MTC. Histologic 
subtypes of FTC included follicular (n=13, 18%), follicular-compact (n=17, 23%), 
compact (n=19, 26%), follicular-papillary (n=1, 1%), undifferentiated (n=1, 1%) and 
carcinosarcoma (n=3, 4%). 
Twelve dogs with FTC (22% of FTCs) and 3 dogs with MTC (15% of MTCs), 
or 20% of all patients, had evidence of distant metastases at the time of diagnosis. Eight 
dogs with FTC (15% of FTCs) and 4 dogs with MTC (20% of MTCs), or 16% of all 
patients, had evidence of regional lymph node metastases at the time of diagnosis.  
VEGF expression 
Immunohistochemistry for VEGF in normal canine thyroid gland indentified 
staining of endothelial cells and clusters of parafollicular cells, whereas follicular cells 
were negative with rare exceptions. In contrast, 85% of all tumors (80% FTCs, 100% 
MTCs) exhibited a high percentage of VEGF-positive tumor cells (76-100%). 
Expression of VEGF was significantly higher in MTCs than in FTCs (P=0.034; Table 
2; Fig. 1).  
P53 expression 
Immunohistochemistry for p53 in normal canine thyroid tissue did not identify 
positive nuclei. Likewise, all sections of thyroid carcinoma tissue had < 5% positive 
nuclei, and therefore no tumor was considered positive for p53 expression. Eighty-five 
percent of all thyroid tumors (87% FTCs, 80% MTCs) had < 1% positive nuclei. 
Cox-2 expression 
Immunohistochemistry for Cox-2 in normal canine thyroid gland did not 
identify positive cells. Twenty-three percent of all primary tumors (13% FTCs, 50% 
MTCs) exhibited Cox-2 expression (Table 2, Fig. 2). Cox-2 labeling index in MTCs 
(median, 0.5%; range, 0-22.4%) was significantly higher (P=0.002) than in FTCs 
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(median, 0%; range, 0-7%). Likewise, Cox-2 IHC score of MTCs (median 1; range 0-
6) was significantly higher (P=0.013) than in FTCs (median, 0; range, 0-3).  
P-gp expression 
Normal canine thyroid tissue did not have cells with membranous 
immunolabeling using monoclonal antibody JSB-1. With C494, weak membranous 
immunolabeling was observed in follicular cells (especially apical membrane), 
endothelial cells and occasionally parafollicular cells. 
Twenty-four percent of all primary thyroid tumors (7% FTCs, 70% MTCs) 
were positive for C494 and JSB-1 (Table 2, Fig. 3) and therefore were considered truly 
positive for P-gp expression. The proportion of MTCs expressing P-gp was 
significantly higher (P<0.001) than that of FTCs. The membranous staining intensity 
for C494 was considered mild in 4 (5%), moderate in 7 (9%) and strong in 7 (9%) 
primary tumors. The membranous staining intensity for JSB-1 was mild in 11 (15%), 
moderate in 4 (5%) and strong in 3 (4%) cases.  
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Table 2. Immunohistochemical expression of VEGF, cox-2 and 
P-gp (C494, JSB-1) in primary thyroid tumors of 74 dogs. 
 FTC  MTC   Total  
 count (%)  count (%)  count (%) 
VEGF      
0% 0  0  0 
1-25% 1 (2%)  0  1 (1%) 
26-50% 2 (4%)  0  2 (3%) 
51-75% 8 (14%)  0  8 (11%) 
76-100% 43 (80%)  20 (100%)  63 (85%) 
Cox-2 IHC score  
0 47 (87%)  10 (50%)  57 (77%) 
1 2 (4%)  2 (10%)  4 (5%) 
2 3 (5%)  5 (25%)  8 (11%) 
3 2 (4%)  0  2 (3%) 
6 0  3 (15%)  3 (4%) 
P-gp (C494 & JSB-1)  
negative 50 (93%)  6 (30%)  56 (76%) 
positive 4 (7%)  14 (70%)  18 (24%) 
n 54 (73%)  20 (27%)  74 (100%) 
Abbreviations: Cox-2, cyclooxygenase-2; FTC, follicular cell 
thyroid carcinoma; MTC, medullary thyroid carcinoma; P-gp, P-
glycoprotein; VEGF, vascular endothelial growth factor 
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Fig. 1. A: Immunohistochemical expression of VEGF in a FTC of compact type with  76-100% of positive 
neoploastic cells (400×).   
B: Immunohistochemical expression of VEGF in a MTC  with 76-100% of positive neoplastic cells 
(400×). 
 
 
 
Fig. 2. A: Immunohistochemical expression of Cox-2 in a FTC of follicular-compact type with labeling 
index of 6.8% (400x).  
B: Immunohistochemical expression of Cox-2 in a MTC with a labeling index of 22.4% (400×). 
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Fig. 3. A: Immunohistochemical expression of P-gp (C494) in a FTC of compact type (400×).  
B: Immunohistochemical expression of P-gp (C494) in a MTC (400×).  
C: Immunohistochemical expression of P-gp (JSB-1) in a FTC of compact type (400×).  
D: Immunohistochemical expression of P-gp (JSB-1) in a MTC (400×). 
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DISCUSSION 
Local invasive growth frequently precludes surgical excision of canine thyroid 
tumors and in up to 38% of dogs the tumor has already metastasized by the time 
diagnosis.
4,8
 Furthermore, approximately half of the patients treated with 
thyroidectomy experience local recurrence or metastatic disease within 2 years of 
surgery. Therefore, it is important to search for new treatment modalities. In this study, 
we found high expression of VEGF in both FTC and MTC, and common expression of 
Cox-2 and P-gp in canine MTC, indicating that these may represent valuable 
therapeutic targets for dogs with inoperable thyroid tumors or metastatic disease. 
In our study, 85% of all thyroid tumors (80% FTCs, 100% MTCs) expressed 
VEGF in ≥76% of tumor cells. In human thyroid carcinoma, VEGF expression also is 
up-regulated.
67
 The high expression of VEGF observed in our study suggests it may 
play an important role in the progression of canine thyroid cancer. Consequently, the 
VEGF system seems to be an attractive target for the treatment of both FTC and MTC 
in dogs. In a preliminary study in dogs with solid tumors, a multi-targeted TKI, 
targeting VEGFR-2, induced partial remission in 4 of 15 dogs and stable disease in 8 of 
the 15 dogs with thyroid carcinoma.
62
 
Loss of function mutation of p53 often leads to accumulation of p53 in the 
nucleus which becomes readily detectable by IHC staining.
183
 In our study, no section 
was considered positive for p53 protein. A low prevalence of p53 expression was 
expected because p53 mutation only was found in 1 of 23 canine FTCs in a previous 
study examining part of the coding region of the p53 gene.
27
 In humans, p53 mutations 
have been described in 40-62% of undifferentiated thyroid carcinomas and in 5-10% of 
other thyroid carcinomas.
176
 A study investigating the immunohistochemical 
expression of p53 in canine malignant tumors with and without p53 mutations 
indicated that antibody PAb240 (used in our study) had a sensitivity of 36% and a 
specificity of 94% for detection of p53 mutations on FF-PE sections.
183
 Although in 
that study another antibody (CM1) was reported to have the highest sensitivity (55%) 
for detection of p53 mutations in FF-PE tumor samples, in our laboratory it repeatedly 
stained nuclei of the negative control (normal thyroid gland) showing lack of 
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specificity. Given the reported low sensitivity of IHC with PAb240, our results may 
underestimate the true prevalence of p53 mutation in canine thyroid carcinoma. 
Nevertheless, taking our results and results from previous studies into account, the p53 
tumor suppressor gene does not seem to be a realistic therapeutic target for most cases 
of canine thyroid carcinoma.  
In this study, Cox-2 expression was observed in 50% of MTCs and in only 
13% of FTCs. The higher prevalence of Cox-2 expression in MTC is in agreement with 
reports in humans, where 26-41% of FTCs and 75-82% of MTCs have been shown to 
express Cox-2.
184
 In a study investigating Cox-2 expression in canine invasive TCC of 
the urinary bladder, the percentage of positive tumor cells at diagnosis ranged from 1 to 
22%, comparable to that found in our study.
185
 Interestingly, although in that study all 
tumors were positive for Cox-2 expression, no significant association was found 
between the level of Cox-2 immunolabeling and tumor remission with piroxicam, 
observed in 12 of 18 dogs. This suggests that clinical benefit may be observed even in 
cases of low Cox-2 expression. Our results suggest that Cox-2 is an interesting 
molecular target in canine thyroid carcinoma, particularly in MTC. 
In our study, P-gp expression with both antibodies was observed in 7% of 
FTCs and 70% of MTCs. These results suggest that expression of P-gp in canine MTC 
is common and could explain multi-drug resistance in these patients. Literature on the 
expression of P-gp in human thyroid carcinoma is scarce. In vitro studies have shown 
expression of the ABCB1 gene in tumor cells from 12 patients with MTC and in 
several MTC cell lines.
79,186
 In humans, MTC is refractory to conventional 
chemotherapy which yields partial responses in only 10 to 20% of patients.
187
 
Experimental evidence suggests that multi-drug resistance is 1 of the mechanisms for 
this highly chemoresistant phenotype and that by targeting P-gp, chemoresistance can 
be reversed.
79,186
 Our study suggests that P-gp is an interesting molecular target for the 
treatment of canine MTC. Inhibition of P-gp using specific P-gp inhibitors (eg, 
verapamil) or TKIs could increase tumor sensitivity to chemotherapy and improve 
outcome.  
Medullary thyroid carcinoma may be difficult to distinguish from compact 
FTC by light microscopy alone.
4
 The different expression of potential molecular targets 
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between these tumor types observed in our study underlines the importance of their 
adequate differentiation using routine IHC. The higher expression of Cox-2 and P-gp in 
MTC is in agreement with clinical and experimental studies in human thyroid cancer. 
In fact, there is experimental evidence of a direct causal relationship between Cox-2 
expression and P-gp regulation. Overexpression of Cox-2 leads to increased expression 
and function of P-gp in a dose-dependent manner and this effect can be blocked by 
specific Cox-2 inhibitors.
188
 Furthermore, in vitro studies in MTC cells have shown the 
ability of Cox-2 inhibitors to reverse multi-drug resistance in these cells by inhibiting 
the expression of P-gp.
79
 In an in vivo model of human colorectal cancer, Cox-2 
expression was correlated with chemoresistant phenotype, and the most tumor 
regression was achieved with a combination of cox-2 inhibitors and chemotherapy.
189
  
An estimation of the percentage of immunopositive tumor cells in each section 
was performed for VEGF and P-gp because often all tumor cells in each section were 
either positive or negative, unlike for Cox-2 or p53. We therefore considered that it 
would be more time-efficient to provide an estimation of the immunopositivity in the 
entire section, as previously described, instead of counting cellular fields with identical 
immunopositivity.
178,182
 Limitations of our study include the relative low number of 
MTCs and the fact that review of IHC was performed by only 1 observer. Although 
this may decrease the accuracy of scoring, it maximizes consistency of comparative 
scoring among sections. Additional studies are needed to confirm if protein expression, 
as identified by IHC, correlates with in vivo protein function. 
In conclusion, our study shows that the VEGF system is a potential therapeutic 
target in both FTC and MTC in dogs. Cox-2 and P-gp seem to be attractive molecular 
targets in canine MTC. p53 does not seem to be a potential molecular target for canine 
thyroid carcinoma.  
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ABSTRACT 
Hypothesis/Objectives: To investigate the effect of levothyroxine therapy on 
survival of dogs with thyroid tumors undergoing different treatment modalities. 
Design: Retrospective study. 
Animals: 42 dogs with thyroid neoplasia.  
Methods: Medical records of Ghent University were reviewed (2001-2012). 
Treatment groups included thyroidectomy with or without levothyroxine therapy 
(n=17); radioactive iodine-131 with or without levothyroxine therapy (n=11); no 
treatment or levothyroxine therapy alone (n=14). 
The effect of levothyroxine therapy, thyrotropin (TSH) suppression (TSH < 
0.1 ng/mL), tumor localization, tumor mobility, tumor maximum diameter, metastases 
at diagnosis, tumor stage and thyroid function, on survival was evaluated with the Cox 
proportional hazards model with stratification for treatment at the 5% significance 
level. 
Results: Levothyroxine therapy (P=0.716), thyrotropin suppression 
(P=0.597), tumor localization (P=0.496), tumor mobility (P=0.939) and 
hyperthyroidism (P=0.08) had no significant effect on survival. Large tumor diameter 
(P=0.003) and evidence of metastases at diagnosis (P=0.019) were negatively 
associated with survival. Dogs with stage IV disease had 4.8 times higher risk for death 
at any given time than dogs with stage II (P=0.008).  
Conclusions and clinical importance: Levothyroxine therapy does not seem 
to provide a survival benefit in dogs with thyroid tumors. Large tumor diameter and 
evidence of distant metastases at diagnosis are negatively associated with prognosis.  
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  INTRODUCTION 
Thyroid cancer represents 1.2-3.8% of all neoplasms in the dog.
44
 Ninety 
percent of thyroid tumors detected clinically are carcinomas and up to 38% of patients 
with carcinomas have evidence of metastatic disease at the time of diagnosis.
2
 
Thyroidectomy is considered the preferred treatment modality for non-invasive tumors 
while fixed invasive tumors can be treated with external beam radiation or radioiodine-
131 (
131
I).
44
 To present date, research on optimization of treatment of canine thyroid 
cancer remains scarce. The few studies investigating post-operative chemotherapy did 
not show an improvement in outcome and our group recently investigated the use of 
recombinant human thyrotropin (TSH) to optimize radioiodine uptake, which also did 
not show a clear benefit with the protocol used.
47,48,190
 Tyrosine kinase inhibitors and 
metronomic chemotherapy have been reported for palliative treatment of canine thyroid 
tumors but these treatment modalities have not yet been investigated for adjunctive 
therapy.
62
 Further research on optimization of treatment of canine thyroid cancer is 
needed. 
Thyroid carcinoma can be classified as follicular cell thyroid carcinoma 
(FTC), which arises from thyroid follicular cells, or medullary thyroid carcinoma 
(MTC), which arises from the parafollicular C cells. In humans and dogs, FTC cells 
contain TSH receptors and endogenous TSH may stimulate neoplastic cell growth and 
tumor progression.
81
 In people with differentiated FTC undergoing classical treatment, 
ie, thyroidectomy followed by 
131
I, lifelong TSH-suppressive therapy with 
levothyroxine significantly reduces recurrence rates and cancer-specific mortality.
82
 
The American and European Thyroid Associations currently recommend adapting the 
target level of TSH suppression to the patient’s risk of tumor recurrence and 
mortality.
83
 A recent study in 15 dogs with bilateral thyroid neoplasia treated by 
thyroidectomy revealed that the dogs receiving levothyroxine therapy after surgery had 
a significantly longer survival time.
48
 These results are encouraging and further studies 
are needed to corroborate these results in a larger number of dogs. Furthermore, as 
TSH suppression is the main goal of levothyroxine therapy, the effectiveness of 
suppression should also be evaluated during follow-up. 
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The aim of this study was to retrospectively evaluate the effect of 
levothyroxine therapy on survival of dogs with thyroid tumors undergoing different 
treatment modalities. Additionally, we also aimed to evaluate the effect of TSH 
suppression on survival. 
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  MATERIALS AND METHODS 
Case selection 
The medical record database of the Small Animal Clinic of Ghent University 
was searched for dogs diagnosed with thyroid neoplasia from January 1, 2001 to July 1, 
2012. For inclusion in the study the diagnosis of thyroid neoplasia had to be confirmed 
by cytology, histopathology or scintigraphic examination. Furthermore, dogs had to be 
treated with thyroidectomy, 
131
I, levothyroxine therapy or receive no treatment. Dogs 
undergoing other treatment modalities, dogs diagnosed with MTC and dogs for which 
no follow-up information was available were excluded. To study the effect of 
levothyroxine therapy on survival in each treatment group, the 52 dogs meeting the 
initial inclusion criteria were divided according to treatment: thyroidectomy with or 
without levothyroxine therapy (n=17); 
131
I with or without levothyroxine therapy 
(n=11); thyroidectomy, 
131
I and levothyroxine therapy (n=10); no treatment or 
levothyroxine therapy alone (n=14). As all dogs treated with a combination of 
thyroidectomy and 
131
I also received levothyroxine therapy this group was excluded.  
Medical record review  
The medical records of the dogs included were reviewed. When the complete 
follow-up information was not available in the medical record, referring veterinarians 
and clients were contacted by phone. The information retrieved from medical records 
included signalment, clinical signs, physical examination findings, tumor 
characteristics (maximum diameter, localization, mobility, cytology, histologic 
examination), blood hematology and routine biochemistry, medical imaging (thoracic 
radiographs, cervical and abdominal ultrasound, scintigraphic examination, CT scan), 
WHO tumor stage,
164
 treatment, follow-up TSH concentrations and date of death. 
Thyroid function at the time of diagnosis was determined based on circulating basal 
total thyroxine (TT4) and TSH concentrations. For patients receiving levothyroxine 
therapy, effective TSH suppression was defined as circulating TSH concentrations < 
0.1 ng/mL (reference < 0.5 ng/mL) during follow-up. Survival time was defined as the 
time from treatment to death of any cause; patients still alive at the last observation 
time were censored. 
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Statistical analysis 
To ascertain if levothyroxine therapy was more likely to be prescribed to high-
risk patients, which would need to be taken into account interpreting the results of this 
study, the effects of tumor localization, tumor mobility, tumor size, WHO stage and 
thyroid function, on survival were also evaluated and subsequently compared between 
dogs that received levothyroxine therapy and dogs that did not.  
The effect of each variable on survival was evaluated separately with the Cox 
proportional hazards model with stratification for treatment group (no treatment or 
levothyroxine alone; thyroidectomy with or without levothyroxine; 
131
I with or without 
levothyroxine). Each variable was incorporated in a univariate way, either as 
categorical or continuous. The variables analyzed included: tumor localization 
(unilateral or bilateral), tumor mobility (mobile or fixed), tumor maximum diameter 
(cm), evidence of distant metastases at diagnosis (absent or present), WHO tumor stage 
(I-IV), thyroid function (hyperthyroid or euthyroid/hypothyroid), levothyroxine therapy 
(yes or no) and TSH suppression (yes or no). Dogs receiving levothyroxine therapy 
with unknown follow-up TSH concentrations were excluded from the analysis of TSH 
suppression. Significance level was set at 5%. When multiple comparisons were 
performed, the significance level was adjusted (Bonferroni correction).
a
 
Dogs that received levothyroxine therapy were compared to dogs that did not 
receive this treatment with respect to tumor localization, tumor mobility, evidence of 
metastases at diagnosis and thyroid function based on a logistic regression model using 
exact tests and exact odds ratio calculation; with respect to tumor diameter and tumor 
stage based on the Mann Whitney U test.
a 
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 RESULTS 
Forty-two dogs with a mean age of 9.7 years (range 5-15 years) were included. 
There was a similar number of males (n=20) and females (n=22). Twenty-eight dogs 
(67%) had unilateral thyroid tumors, 12 (28%) had bilateral tumors and 2 dogs (5%) 
had ectopic tumors ventral to the larynx. Tumor mobility at palpation was recorded in 
25 dogs; 9 dogs (36%) had mobile tumors and 16 (64%) had fixed tumors. Tumor 
maximum diameter (range 2.6-15 cm), measured during physical examination, cervical 
ultrasound or CT, was recorded in 37 dogs.  
Thyroid function results were available in 35 dogs; 21 dogs (60%) were 
euthyroid, 6 (17%) were hyperthyroid, 6 (17%) were hypothyroid and in 2 dogs (6%) 
hypothyroidism could not be differentiated from euthyroid sick syndrome.  
Tumor cytology was performed in 30 dogs and was diagnostic for 
neuroendocrine tissue in 26 dogs (87%). In 4 dogs (13%) fine-needle aspiration 
cytology was not considered diagnostic. 
Information regarding local invasiveness was available for 28 of 33 dogs that 
underwent cervical ultrasound; in 24 dogs (86%) tumors were considered non-invasive 
and in 4 dogs (14%) there were signs of local invasion. Thoracic radiographs were 
performed in 37 dogs, revealing pulmonary metastases in 7 dogs (19%). A CT scan of 
the neck and thorax was performed in 6 dogs, showing a well circumscribed mass in 2 
dogs (33%) and local invasion in 4 dogs (67%). One dog with an infiltrative thyroid 
tumor also had evidence of pulmonary metastases at CT scan. Cervical and thoracic 
scintigraphy were performed in 28 dogs, revealing homogenous tumor uptake in 15 
dogs (53%), heterogeneous tumor uptake in 12 dogs (43%) and no uptake in the 
remaining dog (4%). Ectopic uptake foci in the thorax, consistent with ectopic thyroid 
tissue or tumor metastases, were identified in 12 dogs (46%). 
Fifteen dogs (38%) had stage II disease, 10 (26%) had stage III and 14 (36%) 
had stage IV. In 3 dogs tumor stage could not be determined because tumor 
measurements were not recorded. Distant metastases were most frequently located in 
the lungs (n=13) and liver (n=4). 
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Tumor histopathology was performed in 19 dogs (45%). One dog was 
diagnosed with an oxyphilic thyroid adenoma and 18 dogs were diagnosed with FTC. 
Treatment 
Seventeen dogs (41%) underwent thyroidectomy as main treatment modality 
(MST 29 m); 11 dogs (26%) were treated with 
131
I therapy (MST 15 m); 14 dogs (33%) 
were either treated palliatively with levothyroxine alone (n= 6, MST 7.5 m) or not 
treated (n=8, MST 3 m). 
Lifelong levothyroxine therapy was prescribed to 7 of 17 dogs undergoing 
thyroidectomy, to 8 of 11 dogs undergoing 
131
I therapy and to the 6 dogs treated 
palliatively. In one dog undergoing bilateral thyroidectomy, levothyroxine was 
prescribed as replacement therapy for hypothyroidism. In the remaining 20 dogs 
levothyroxine therapy was prescribed with the intent of suppressing endogenous TSH. 
The clinicians’ decision to prescribe levothyroxine depended mainly on the period 
during which the patient was treated. Eighteen of 21 patients receiving levothyroxine 
therapy were treated during the last 5 years of the study when TSH suppression became 
a routine component of the treatment of canine follicular cell thyroid neoplasia at our 
clinic. 
The average starting dose of levothyroxine was 11.3 ±4.7 µg/kg q12h. TSH 
suppression was recorded in 5 dogs at an average levothyroxine dosage of 15 ±7.3 
µg/kg q12h, after a median of 0.5 dose adjustments (range, 0-2). In 4 of these 5 dogs, 
follow-up TSH values were below the detection limit of the TSH assay used by the 
laboratory at the time (< 0.1 ng/mL n=2; < 0.03 ng/mL n=2). In the remaining dog, 
TSH concentration was 0.07 ng/mL at the last follow-up appointment. When TSH 
suppression was achieved, the average TT4 3 h post-pill was 38.2±12.7 nmol/L.  
Tumor mobility (P=0.423), evidence of distant metastases at diagnosis 
(P=0.514), tumor diameter (P=0.199), tumor stage (P=0.342) and thyroid function 
(P=0.817) were not significantly different between dogs that received levothyroxine 
therapy and dogs that did not. The group of dogs receiving levothyroxine therapy had a 
significantly (P=0.049) higher proportion (43%) of patients with bilateral disease than 
the group not receiving levothyroxine therapy (14%). 
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Outcome 
Levothyroxine therapy (P=0.716), TSH suppression (P=0.597), tumor 
localization (P=0.496), tumor mobility (P=0.939) and hyperthyroidism (P=0.08) had 
no significant effect on outcome (Table 1). Tumor diameter had a significant effect on 
survival (P=0.003); each cm increase in tumor diameter increased the risk for death at 
any given time by 16% (Table 1). Evidence of distant metastases at diagnosis was also 
negatively correlated with survival (P=0.019); dogs with metastatic disease had 3.4 
times higher risk for death at any given time than dogs with no evidence of metastases 
at diagnosis. Dogs with stage IV disease had 4.8 times higher risk for death at any 
given time than dogs with stage II (P=0.008). 
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Table 1. Survival analysis stratified for treatment in 42 dogs with 
thyroid tumors. P-values and Hazard Ratios (top/bottom group for 
each variable) are given.  
Variable  n P-value HR 
Levothyroxine 
Yes 21 
0.716 0.88 
No 21 
TSH suppression 
Yes 5 
0.597 0.70 
No 16 
Tumor localization 
Uni/Ect 30 
0.496 0.76 
Bilat 12 
Tumor mobility 
Mobile 9 
0.939 0.96 
Fixed 16 
Tumor diameter  
37 
0.003 1.16 
Distant metastases 
Yes 14 
0.019 3.45 
No 28 
Stage  39 0.03  
Stage IV vs II 
IV 14 
0.008 4.76 
II 15 
Stage IV vs III 
IV 14 
0.061 3.23 
III 10 
Hyperthyroidism 
Yes 6 
0.08 0.02 
No 17 
Abbreviations : HR, Hazard Ratio; Uni/Ect, Unilateral/Ectopic 
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DISCUSSION 
In humans, the benefit of TSH-suppressive therapy in the management of 
high-risk differentiated FTC is well established and for the past years the authors 
recommend it routinely in the treatment of canine FTC.
82
 However, the results of this 
study failed to demonstrate that levothyroxine therapy and TSH suppression provide a 
survival benefit in dogs with thyroid tumors. This is in disagreement with a recent 
retrospective study in 15 dogs with bilateral thyroid tumors that showed a survival 
benefit for the dogs that also received levothyroxine replacement therapy after 
thyroidectomy.
48
 The cause for the disparity of results between these studies is unclear. 
If levothyroxine therapy would have been preferentially prescribed to high-risk patients 
in our study, this could have masked its clinical benefit. However, this did not seem to 
be the case according to our statistical analysis. Although the group receiving 
levothyroxine therapy had a significantly higher proportion of dogs with bilateral 
disease, tumor localization was not a prognostic factor in our study. Furthermore, the 
aforementioned veterinary study reports a prognosis for dogs with bilateral thyroid 
neoplasia undergoing thyroidectomy comparable to what is the reported for dogs with 
unilateral disease treated similarly.
44,48
 In humans with differentiated FTC, the 
beneficial effect of TSH suppression is only proven beyond doubt in high-risk 
patients.
83
 Unfortunately, our sample size was insufficient to repeat the statistical 
analysis adequately in a subgroup of high-risk patients. 
It is possible that the lack of effect of levothyroxine therapy observed in our 
study is related to an insufficient power. In humans, retrospective studies showing the 
clinical benefit of TSH-suppressive therapy involve more than 100 patients treated 
similarly and the prospective study proving the benefit of high TSH suppression in 
high-risk patients with differentiated FTC involved nearly 3000 patients.
83
 Although 
our sample size is small, our study is the largest veterinary study investigating the 
effect of levothyroxine therapy on survival of dogs with thyroid tumors. Thyroid cancer 
is not common in dogs and studies with a much larger number of patients are difficult 
to accomplish.  
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It is also possible that the lack of clinical benefit of levothyroxine therapy 
observed in our study is due to an overall insufficient degree of TSH suppression in the 
patients receiving levothyroxine. On one hand, TSH suppression as defined in our 
study could only be confirmed during follow-up in 5 of 21 patients receiving 
levothyroxine. On the other hand, although we routinely adapt the dosage of 
levothyroxine to reach nearly immeasurably low levels of TSH during follow-up of 
these patients, the ideal target level of TSH suppression in dogs with thyroid tumors is 
not currently known. During the study period, the detection limit of the canine TSH 
assay used at our laboratory changed from 0.1 ng/mL to 0.03 ng/mL. We have 
therefore decided to evaluate 0.1 ng/mL as cut-off for TSH suppression. However, the 
high sensitivity of human TSH assays allows targeting TSH concentrations to a level 
that is far below the detection limit of the current canine TSH assays. In humans, the 
ideal level of TSH suppression in patients with DTC is a topic of much debate and, at 
present, it is recommended to adapt the target level of TSH suppression to the patients 
risk for tumor recurrence and mortality based on prognostic factors.
83
 Further research 
is warranted to investigate if TSH-suppressive therapy is beneficial in dogs with FTC 
and to determine the adequate level of TSH suppression in these patients. 
In our study, larger tumor diameter and evidence of distant metastases at 
diagnosis were negatively associated with prognosis and have already been described 
as prognosticators in canine thyroid cancer.
43,44
  
Thyroid tumors causing hyperthyroidism have preserved iodine trapping and 
hormone production, which could be associated with a higher degree of differentiation 
and a better prognosis. However, in agreement with previous reports, thyroid function 
was not associated with prognosis in our study.
43
 In humans, hyperfunctional thyroid 
carcinomas have a reported prevalence of only 1-2% and these scarce reports also 
suggest a comparable prognosis between hyperthyroid and euthyroid patients. 
Limitations of our study include its retrospective nature, the limited number of 
dogs where TSH suppression could be confirmed, and the limited number of patients in 
each treatment group. Although histopathologic examination was performed in less 
than half of the dogs, this reflects the clinical dilemma of performing incisional 
biopsies in patients with unresectable thyroid tumors. In such cases, a presumptive 
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diagnosis obtained with cytology or scintigraphy is often favored due to potential 
bleeding complications of biopsying such highly vascularized tumors. 
In conclusion, our study suggests that levothyroxine therapy does not provide 
a survival benefit in dogs with thyroid tumors and that large tumor diameter and 
evidence of distant metastases at diagnosis are negatively associated with prognosis. 
Further studies are needed to further evaluate if TSH-suppressive therapy is beneficial 
to dogs with thyroid tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levothyroxine therapy 
115 
 ENDNOTES 
 a
 IBM SPSS 20, Chicago, IL, USA 
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 ABSTRACT 
Background: In humans, administration of recombinant human TSH (rhTSH) 
allows radioactive iodine dose reduction and higher efficacy in the treatment of 
multinodular goiter and thyroid cancer. A similar effect might be expected in dogs with 
thyroid carcinoma. However, if rhTSH leads to an increase in thyroid volume it must 
be used carefully in dogs with large thyroid tumors to avoid compression of key 
anatomical structures.  
Hypothesis/Objectives:: The aim of the study was to determine the short-
term effect of rhTSH on thyroid volume and echogenicity, measured by 
ultrasonography, in healthy Beagles.   
Animals: Seven beagles Beagles. 
Methods: The dogs were divided randomly in 2 groups in a prospective 
placebo-controlled blinded cross-over study. On day 1, one group received 100 µg of 
rhTSH intravenously and the other group received placebo. After a wash-out period of 
3 weeks the groups were crossed over. Evaluation of thyroid echogenicity, 
homogeneity, shape, capsule delineation, and measurement of thyroid length, width 
and height were performed by the same observer at baseline, and at 6, 24 and 48h after 
injection of rhTSH and placebo.   
Results: There was no significant difference between the effect of rhTSH and 
placebo on thyroid volume (P=0.397), echogenicity, homogeneity or capsule 
delineation. Time had a significant effect on thyroid volume (P=0.027). No adverse 
effects after rhTSH administration were noticed.   
Conclusions and clinical importance: The effect of rhTSH on thyroid 
volume in dogs with thyroid carcinoma needs to be assessed. 
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 INTRODUCTION 
In humans with multinodular goiter and thyroid cancer, recombinant human 
thyroid stimulating hormome (rhTSH) increases radioactive iodine thyroid uptake, 
allowing 
131
I dose reduction, lower radiation-absorbed doses by extrathyroidal organs 
and tissues, and higher treatment efficacy.
121,123,140,191
 rhTSH also increases radioactive 
iodine thyroid uptake in the rhesus monkey and in hyperthyroid cats.
131,192
  
The use of rhTSH in thyroid carcinoma patients raises important safety issues. 
In humans, rhTSH increases the volume of the thyroid gland in healthy subjects and 
causes expansion of primary thyroid tumors and thyroid tumor metastases.
136-139
 
Therefore, rhTSH should be used carefully in patients with large thyroid tumors or 
central nervous system, spinal, lung or bone metastases because tumor expansion may 
compress adjacent structures, leading to complications.
140
 Tumor enlargement is 
thought to result from swelling rather than growth, and glucocorticoids are 
administered before rhTSH is given to humans.
140,193
 No information is available on the 
effect of rhTSH on thyroid gland volume in dogs. 
Sonography of the thyroid can be used to measure thyroid gland volume in 
dogs. Furthermore, gray-scale ultrasonography is a sensitive and quick test for the 
diagnosis of canine primary hypothyroidism.
194-197
  Before rhTSH is used in dogs with 
thyroid carcinoma, the influence of rhTSH on thyroid volume and echogenicity should 
be characterized. The goal of this study was to evaluate the short-term effect of rhTSH 
on thyroid volume and echogenicity, measured by ultrasonography, in healthy Beagles. 
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 MATERIALS AND METHODS 
 Seven healthy Beagles were studied; all were neutered females with mean age 
of 9.6 ± 0.79 years and mean weight of 12.3 ± 1.5 kg. All dogs were healthy and 
euthyroid based on routine clinical testing and assays for serum total thyroxin (TT4) 
and basal serum thyrotropin (TSH). TT4 was quantified using a commercially available 
solid-phase, chemiluminescent competitive immunoassay
a
, and basal serum TSH 
concentration was quantified with a commercially available solid-phase, two-site 
chemiluminescent immunometric assay
b
, both previously validated in dogs.
198
 No dog 
had received any medication for at least 8 weeks prior to the study. Environmental 
conditions were unchanged throughout the study. All dogs were fed a standard 
commercial diet once daily and water was available ad libitum. 
 The dogs were divided randomly in 2 groups in a prospective placebo-
controlled blinded cross-over study. On day 1, one group received 100 µg of rhTSH IV 
and the other group received placebo (1 mL of physiologic saline IV). After a wash-out 
period of 3 weeks, the groups were crossed over. In this manner, during the study each 
dog received rhTSH and placebo. The echogenicity, maximal length, width and height 
of both thyroid glands were measured using ultrasonography immediately prior to 
injection, and at 6, 24 and 48h after injection of rhTSH or placebo.  
Each vial of 1100 µg of rhTSH
c
 was reconstituted with 5.5 mL of sterile water 
(200 µg/mL). Individual doses of 100 µg of freshly reconstituted rhTSH in 1 mL 
plastic syringes with needle and rubber caps and were stored frozen at -20° C for a 
maximum of 12 weeks, as previously described.
17
 Before use, frozen TSH was allowed 
to defrost at room temperature minutes before administration.  
Blood samples for TT4 measurement were collected by jugular venipuncture 
immediately before injection, and at 6, 12, 24 and 48h after rhTSH administration. 
Blood was centrifuged and the serum stored at -20ºC until analysis. TT4 concentration 
was determined with the aforementioned chemiluminescent immunoassay. 
For sonography, the ventral cervical region was clipped from the larynx to the 
thoracic inlet. The dogs were in dorsal recumbency with the head in extension.  Neither 
sedation nor anesthesia were used; two helpers restrained the dogs. Ultrasound gel was 
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applied. All ultrasound examinations were performed by the same board certified 
radiologist (JHS) who was unaware of the treatment administered.  All dogs were 
scanned with the same ultrasound machine (Logiq 7, GE Medical Systems, Wisconsin, 
USA) connected to a multifrequency (7-14 MHz) linear matrix transducer with the 
frequency set at 12 MHz. Identical image presets were used for all patients. The overall 
gain was adjusted for each patient. Scanning was performed according to previously 
described method.
199
 The echogenicity of the thyroid glands was assessed by 
comparison with the surrounding muscles. The echotexture (homogeneous, 
heterogeneous), shape (rounded, ovoid, triangular) and delineation (smoothly, roughly) 
of the thyroid glands as well as the position of the esophagus (left, right) were 
recorded. The maximum height and the maximum width of each lobe, which were not 
necessarily located in the same plane, were measured on transverse images by use of 
electronic calipers. Following this, a longitudinal image of each lobe was obtained by 
starting transversally and slowly rotating the tranducer 90°. The maximum length of 
each separate lobe, excluding the cranially located external parathyroid gland if visible, 
was obtained in the longitudinal plane. The volume of each thyroid lobe was estimated 
by the use the following rotation ellipse formula:
197
  Thyroid gland lobe volume (cm
3
) 
= length (cm) x width (cm) x height (cm) x 0.479 
Based on a power analysis, the sample size was adequate to detect a 35.5% 
increase in thyroid gland volume (0.3 cm
3
 to 0.405 cm
3
) with a power of 80% for a 
two-sided test with significance level equal to 0.05.  Statistical analysis was based on a 
mixed model with dog, week and side as random effects and side, treatment, time and 
the interaction between treatment and time as categorical fixed effects, using F-tests for 
the fixed effects at the 5% significance level
d
. The change in TT4 levels over time was 
analyzed separately for the two treatment groups using a mixed model with dog as 
random effect and time as a categorical fixed effect. Each time point was compared 
with time 0 using Dunnett’s multiple comparisons method at a global significance level 
of 5%. The Pearson correlation coefficients between the TT4 concentration and the 
thyroid volume, height, length and width were calculated.  
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 RESULTS 
No significant difference was found between the effect of rhTSH vs. placebo 
on thyroid volume (P=0.397) (Table 1). Thyroid volume decreased from baseline to 6h 
then increased at 24h and then decreased at 48h (P=0.027). This volume change did not 
differ significantly between placebo and rhTSH (P=0.610).  No significant differences 
were found between the effect of rhTSH and placebo on thyroid height (P=0.497), 
width (P=0.554) or length (P=0.752). No significant changes over time were found for 
thyroid height (P=0.967), width (P=0.211) or length (P=0.066). Also no significant 
interactions between time and treatment were observed for thyroid height (P=0.841), 
width (P=0.875) or length (P=0.405). 
The relative echogenicity of the thyroid gland compared to the surrounding 
muscles was unchanged. The gland was homogeneous in all dogs except one at initial 
examination. The appearance of the heterogeneous gland remained similar during 
follow-up examinations. At initial examination, the gland was classified as ovoid 
(n=18), round (n=6) or triangular (n=4). During the follow-up studies, changes in this 
classification were observed in 20/112 examinations. The esophagus was lying on the 
left side of the trachea in 47/56 examinations and on the right side in 9/56 
examinations.  The position of the esophagus changed within the same dog between 
measurements affecting the shape of the thyroid gland. 
rhTSH caused a significant change in serum TT4 concentration over time 
(P<0.0001). TT4 concentration was significantly higher 6h after rhTSH administration 
(P<0.0001) compared with baseline (Fig. 1).  Overall no correlation was found between 
TT4 concentration and thyroid volume, length, height or width. 
No adverse effects were observed after rhTSH administration. 
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Table 1. Thyroid Gland Ultrasound Measurements in 7 Healthy Beagles after Recombinant 
Human TSH and Placebo. Mean values (standard deviation) of the estimated thyroid gland 
volume (mL), observed thyroid gland height (cm), width (cm) and length (cm) for each time 
point after placebo and rhTSH administration, the differences (95% confidence interval), 
percentage of change and P value for each comparison between placebo and rhTSH are given. 
Thyroid Volume (mL) 
Time point Placebo (StdDev) rhTSH (StdDev) Difference [95% CI] % 
change 
P-value 
Baseline 0.325 (0.070) 0.333 (0.079) -0.008 [-0.058;0.041] 2.462 0.747 
6 h 0.318 (0.077) 0.327 (0.086) -0.009 [-0.058;0.040] 2.830 0.728 
24 h 0.330 (0.079) 0.369 (0.103) -0.039 [-0.088;0.010] 11.818 0.140 
48 h 0.303 (0.074) 0.317 (0.091) -0.014 [-0.064;0.035] 4.620 0.577 
Thyroid Height (cm)   
Baseline 0.514 (0.129) 0.521 (0.089) -0.006 [-0.056;0.044] 1.167 0.802 
6 h 0.506 (0.083) 0.529 (0.103) -0.024 [-0.074;0.026] 4.743 0.359 
24 h 0.505 (0.087) 0.521 (0.115) -0.016 [-0.066;0.034] 3.168 0.540 
48 h 0.514 (0.106) 0.506 (0.108) 0.007  [-0.043;0.057] 1.362 0.780 
Thyroid Width (cm)   
Baseline 0.666 (0.100) 0.674 (0.116) -0.007 [-0.086;0.072] 1.051 0.860 
6 h 0.659 (0.073) 0.670 (0.111) -0.011 [-0.090;0.068] 1.669 0.792 
24 h 0.669 (0.086) 0.710 (0.056) -0.041 [-0.120;0.038] 6.129 0.318 
48 h 0.635 (0.109) 0.646 (0.101) -0.011 [-0.090;0.067] 1.732 0.778 
Thyroid Length (cm)   
Baseline 2.021 (0.166) 1.992 (0.157) 0.029 [-0.070;0.129] 1.390 0.565 
6 h 1.973 (0.177) 1.933 (0.158) 0.040 [-0.059;0.139] 2.027 0.432 
24 h 2.028 (0.136) 2.068 (0.157) -0.040 [-0.139;0.059] 1.972 0.432 
48 h 1.954 (0.152) 2.016 (0.146) -0.061 [-0.161;0.038] 3.122 0.229 
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Fig. 1: Mean serum TT4 concentration (nmol/L), with respective standard deviation, as a 
function of time after rhTSH administration. 
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DISCUSSION 
In this trial, no significant difference was detected between the effect of 
rhTSH and placebo on thyroid volume during the first 48h after injection. These results 
are in contrast with what has been found in humans, where rhTSH stimulation 
significantly increased thyroid gland volume.
136
 Mean thyroid volume increased by 
23.3 % 24 hours after 900 µg rhTSH stimulation, and by 35.5 % after 48 hours but 
returned to baseline values on day 4.  In another study in humans, thyroid volume 
increased by 10% 48 hours after 100 µg rhTSH injection, but this was not placebo-
controlled, and sonography was performed by multiple individuals.  
We used 100 µg of rhTSH as this is the dose that is considered most 
appropriate for TSH stimulation in dogs weighing more than 20 kg.
200
 If the effect of 
rhTSH on thyroid volume is dose dependent we may have observed a volume change at 
higher doses.  A dose effect may also explain the disparate results obtained in human 
studies noted above. 
The route of rhTSH administration could also have influenced our results. In 
humans, rhTSH is administered intramuscularly and in our study it was given 
intravenously. The intravenous route was chosen to maximize bioavailability, given the 
high cost of rhTSH. There are no data that support the intramuscular route being better 
than the intravenous route for rhTSH administration.  On the contrary, giving the same 
dose of rhTSH to healthy Beagles intravenously resulted in a significantly higher serum 
TT4 elevation compared to subcutaneous and intramuscular administration.
125
  
Intramuscular vs. intravenous administration of rhTSH was also compared in healthy 
dogs of different breeds and there was no significant effect on TT4 concentration.
201
  
In humans, the marked, fast, transient effect of rhTSH on thyroid gland 
volume was thought most likely due to intravascular and interstitial fluid accumulation, 
rather than regular growth of the thyroid tissue.
136
 Evidence of peritumoural edema or, 
less commonly, hemorrhage, and response to glucocorticoid administration also 
support this hypothesis.
138,139
  
Thyroid gland volume changed significantly over time after both rhTSH and 
placebo administration. Although this variation in thyroid volume was statistically 
rhTSH & thyroid volume in healthy Beagles  
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significant, it is too small to be clinically relevant. This is supported by the fact that 
neither thyroid height, width nor length changed significantly over time. Therefore, the 
authors consider this observation to be, most likely, a statistical aberration.  
There were no changes in the delineation, echogenicity or homogeneity of the 
thyroid gland, although changes in thyroid gland shape were observed, however 
characterization of shape is subjective. Additionally, the position of the esophagus or 
the position of the dog and pressure of the transducer could influence the shape of the 
gland on a transverse scan. 
rhTSH had a significant effect on serum TT4 concentrations and on the 
variation of serum TT4 concentrations over time. The peak serum TT4 concentration 
occurred 6 hours after rhTSH injection, as expected.
125,200
 The peak of serum TT4 
concentration coincided with the lowest thyroid gland volume. However, a decrease in 
thyroid volume was also observed in the placebo group, and there was no statistical 
association between the TT4 concentration and the observed variation in thyroid 
volume, length, height or width. 
The absence of an effect of rhTSH on thyroid volume in healthy dogs cannot 
be extrapolated to dogs with thyroid carcinoma.  Healthy thyroid tissue and neoplastic 
thyroid tissue differ histologically and functionally. Therefore, although our results 
suggest no influence of rhTSH on thyroid volume, it is not known that rhTSH will not 
cause tumor expansion in dogs with thyroid carcinoma. Therefore, rhTSH must be used 
with caution in thyroid carcinoma patients, especially patients with bulky thyroid 
masses, respiratory, central nervous system, spinal or bone metastases.  Pretreatment 
with glucocorticoids should be considered if tumor expansion would lead to 
unacceptable complications. 
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 ENDNOTES 
a IMMULITE 2000 Canine Total T4, Siemens, Los Angeles, CA, USA 
b 
IMMULITE 2000 Canine TSH, Siemens, Los Angeles, CA, USA 
c
 Thyrogen®, Genzyme Corporation, Cambridge, Maine, USA 
d
 SAS Version 9.1.3 
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 ABSTRACT 
Background: In human medicine recombinant human TSH (rhTSH) increases 
the thyroid radioactive iodine uptake (RAIU) allowing radioiodine-131 (
131
I) dose 
reduction and higher efficacy in the treatment of differentiated thyroid cancer and 
multinodular goiter.  
Hypothesis/Objectives: The goal of this study was to evaluate the effect of 
rhTSH, administered 24 h and 48 h before radioiodine-123 (
123
I), on the thyroid RAIU 
in healthy dogs.  
Animals: Seven euthyroid healthy Beagles. 
Methods: Dogs were randomly divided in three groups (two groups of two 
dogs and one group of three dogs) in a prospective, blinded, cross-over study. On week 
1, one group received 
123
I for a baseline RAIU, one group received 100 µg of rhTSH 
IV 24 h before 
123
I and one group received 100 µg of rhTSH IV 48 h before 
123
I. All 
dogs received 37 MBq of radioactive 
123
I IV and thyroid RAIU was determined 8 h, 24 
h and 48 h thereafter. The study was designed in such a manner that each dog received 
the three treatments and a wash-out period of three weeks was respected in between. 
Blood samples were taken for measurement of serum total thyroxine (TT4) and 
thyrotropin (TSH) concentration at baseline, 6 h, 12 h, 24 h and 48 h after rhTSH 
administration.  
Results: Recombinant human TSH caused no significant change on thyroid 
RAIU. The overall mean thyroid RAIU significantly decreased during the study 
independent of the treatment. Recombinant human TSH significantly increased serum 
TT4 concentration, which peaked 6 h after rhTSH administration. Compared to 
baseline, serum TSH concentration remained higher at 6 h, 12 h, 24 h and 48 h. 
However, a statistical significant difference was only reached at 6 h and 12 h after 
rhTSH administration. No adverse effects of rhTSH were observed during the study.  
Conclusions and clinical importance: Further studies are needed to 
determine the best timing and dosage of administration of rhTSH in healthy and thyroid 
carcinoma dogs. 
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 INTRODUCTION 
Thyroid tumors are uncommon in dogs, accounting for 1.2 to 3.7% of all 
neoplasms.
163
 Carcinomas are more common than adenomas, representing up to 90% of 
palpable thyroid tumors at diagnosis.
2
 Treatment modalities include surgical excision, 
external beam radiation, chemotherapy and radioiodine-131 (
131
I). Two recent 
retrospective studies have shown a high treatment efficacy and prolonged median 
survival time with 
131
I therapy both as a sole therapeutic modality and as an adjunct to 
surgery.
38,43
  
Several human studies have shown that rhTSH increases the radioactive iodine 
uptake (RAIU) by thyroid cancer tissue with relatively few side-effects.
109,202
 The same 
effect has been shown in healthy humans and in patients with multinodular goiter.
137,203
 
Recombinant human TSH allows higher efficacy, lower radiation-absorbed doses by 
extrathyroidal tissues and 
131
I dose reduction in the treatment of differentiated thyroid 
cancer and multinodular goiter.
109,113,121,123,140,191
 
Recombinant human TSH is currently used in veterinary medicine to aid in the 
diagnosis of canine hypothyroidism.
124,200,204
 Recombinant human TSH increases the 
thyroid RAIU in the rhesus monkey and a recent study has shown that it significantly 
increases the thyroid RAIU in hyperthyroid cats.
131,192
 This property of rhTSH is 
particularly interesting in dogs because high doses of 
131
I are used for the treatment of 
canine thyroid carcinoma. Radiation exposure should be kept «as low as reasonably 
achievable» (ALARA principle) and rhTSH may allow 
131
I dose reduction, higher 
treatment efficacy and reduction of radioactivity delivered to extrathyroidal tissues and 
to the environment.  
Before rhTSH starts being more intensively investigated in the treatment of 
dogs with thyroid carcinoma, it is important to evaluate its effect on thyroid RAIU. 
Currently, to the authors’ knowledge, no such studies have been performed in dogs.  
131
I decays emitting beta particles, which cause a higher localized radiation 
dose with greater potential for impaired thyroid function.
132
 
123
I decays by electron 
capture emitting gamma rays, and has been shown to be equal or superior to 
131
I as a 
scanning agent.
133
 Therefore, the goal of this study was to evaluate the effect of rhTSH, 
rhTSH & 
123
I uptake in healthy Beagles 
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administered 24 h or 48 h before radioiodine-123 (
123
I), on the thyroid RAIU in healthy 
dogs. 
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 MATERIALS AND METHODS 
Animals  
Seven healthy Beagles participated in this study. They were all spayed females 
with mean age of 9.6 ± 0.79 years and mean weight of 12.3 ± 1.5 kg at the start of the 
study. All dogs were healthy and euthyroid based on their history, thorough physical 
examination, full hematological and biochemical blood analysis, serum total thyroxin 
(TT4) concentration and basal serum thyrotropin (TSH) concentration within reference 
range. Serum TT4 concentration was determined with a commercially available solid-
phase, chemiluminescent competitive immunoassay (IMMULITE 2000 Canine Total 
T4, Siemens, Deerfield, IL, USA) previously validated in dogs, and the reference range 
used was 6.4-43.8 nmol/L.
198
 Basal serum TSH concentration was determined with a 
commercially available solid-phase, two-site chemiluminescent immunometric assay 
(IMMULITE 2000 Canine TSH, Siemens, Deerfield, IL, USA) previously validated in 
dogs, and the reference range used was <0.5 ng/mL.
198
 None of the dogs had received 
any medication for at least eight weeks prior to the study. During weeks 1, 5 and 9 of 
the study, the dogs were kept in nuclear medicine facilities for radioactivity safety 
purposes. During the washout period the dogs were kept in the kennel where they 
usually live. Environmental conditions, such as photoperiod, ventilation, temperature 
and humidity were kept unchanged throughout the study. All dogs were fed a standard 
commercial diet once daily and water was available ad libitum. Animal care was in 
accordance with European guidelines and directives (EC directive 86/609/EEC for 
animal experiments) and the study was approved by the Ethical committee of the 
faculty of veterinary medicine of Ghent University, Belgium (approval number EC 
2008/051). 
Study design  
The dogs were divided in three groups in a prospective, cross-over study. On 
week 1, one group received 
123
I for a baseline thyroid RAIU, one group received 100 
µg of rhTSH IV 24 h before 
123
I and one group received 100 µg of rhTSH IV 48 h 
before 
123
I. All dogs received 37 MBq (1 mCi) of 
123
I IV and thyroid RAIU was 
determined 8 h, 24 h and 48 h thereafter. The study was designed in such a manner that 
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each dog received the three treatments and a wash-out period of three weeks was 
respected (Table 1). 
Recombinant human TSH 
Each vial of 1100 µg of rhTSH (Thyrogen®, Genzyme Corporation, 
Cambridge, Maine, USA) was reconstituted with 5.5 mL of sterile water (200 µg/mL). 
Individual doses of 100 µg of freshly reconstituted rhTSH were prepared in 1 mL 
plastic syringes with needle and rubber caps and were stored frozen at -20º C for a 
maximum of 12 weeks.
205
 For TSH stimulation, frozen rhTSH was defrosted at room 
temperature few minutes before administration.  
 
Table 1. Cross-over design of the study. A wash-out period of three weeks was respected 
between study weeks. 
Cross-over design 
 Week 1 Week 5 Week 9 
Group I 
123
I (baseline RAIU) rhTSH 24h before 
123
I rhTSH 48h before 
123
I 
Group II rhTSH 24h before 
123
I rhTSH 48h before 
123
I 
123
I (baseline RAIU) 
Group III rhTSH 48h before 
123
I 
123
I (baseline RAIU) rhTSH 24h before 
123
I 
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 RAIU 
Each dog received 37 MBq (1 mCi) of 
123
I intravenously. The injected activity 
of 
123
I was calculated by subtracting the activity of the empty syringe from the activity 
of the full syringe both measured in a dose calibrator. To determine the thyroid RAIU, 
a static planar ventrodorsal image was obtained with a one head γ-camera (Toshiba 
GCA 901) using a low-energy high resolution collimator with the dog in sternal 
recumbency under general anesthesia. General anesthesia was induced with propofol 
and maintained with isoflurane. Data were acquired during 5 minutes for the 8h-RAIU, 
10 minutes for the 24h-RAIU and 15 minutes for the 48h-RAIU on a 128x128 matrix. 
A syringe with a known amount of radioactivity (2.5 ± 1.6 MBq) was placed next to 
the animal and served as the standard activity necessary to calculate RAIU. Regions of 
interest (ROIs) were manually drawn over the two thyroid lobes (cpmthyroid) and over 
the activity of the standard (cpmstandard).
206
  In order to correct for background activity a 
ROI was drawn over an area close to, but not overlapping, the thyroid gland 
(cpmbackground) and another ROI was placed outside the dog (cpmroom). These ROI’s 
were placed on one day and by the same person (KP) who was blinded to the dogs’ 
treatment. RAIU was calculated as a percentage of the administered dose of 
123
I 
corrected for physical decay and background activity using the following formula:  
([(cpmthyroid - cpmbackground) / (cpmstandard - cpmroom)] × (MBqstandard / MBqdose)) × 100 
 Blood sampling 
Blood samples for TT4 and TSH measurement were taken in the two weeks 
that each dog received rhTSH. Blood was collected by jugular venipuncture at baseline, 
6 h, 12 h, 24 h and 48 h after rhTSH administration. Blood was centrifuged and the 
serum was stored for 3 weeks at -20ºC to reach sufficient decay of radioactivity to be 
analyzed. To measure and follow up rhTSH serum concentrations, a commercially 
available two-site sandwich immunoassay (ADVIA Centaur TSH, Siemens, Deerfield, 
IL, USA) for human TSH determination was used.
137
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Statistical analysis 
 Data were analyzed with SAS version 9.1 (SAS, Cary, North Carolina, USA). 
The effect of rhTSH administration on RAIU was analyzed with a mixed model with 
period, treatment, time and the interaction between treatment and time as categorical 
fixed effects and dog and the period by dog interaction as random effects. Comparisons 
were based on the F-test at a global significance level of 5%, using Tukey's procedure 
for multiple comparisons. The variation of TT4 and TSH levels over time was analyzed 
using a mixed model with dog as random effect and time as a categorical fixed effect. 
Each time point was compared with time 0 using Dunnett’s multiple comparisons 
method at a global significance level of 5%. 
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RESULTS 
No significant difference was found in thyroid RAIU among the three 
protocols (no rhTSH, rhTSH 24 h before 
123
I and rhTSH 48 h before 
123
I, P=0.424). 
Thyroid RAIU increased significantly over time (P<0.0001; Fig. 1). There was no 
significant interaction between treatment and time (P=0.887).  
In all groups, the thyroid RAIU significantly decreased throughout the weeks 
of the study (P<0.0001) from 0.268 (SD=0.032) on week 1 to 0.129 (SD=0.024) on 
week 5, and 0.082 (SD=0.018) on week 9.  
Recombinant human TSH caused a significant increase in serum TT4 
concentration over time (P<0.001), reaching a peak 6 h after administration. Serum TT4 
concentration after rhTSH stimulation performed 24 h before 
123
I and 48 h before 
123
I 
did not differ significantly from each other (P=0.217; Fig. 2). 
 In both groups where rhTSH was administered, rhTSH changed significantly 
over time (P<0.0001), and was significantly higher at time 6 h (P<0.0001) and at time 
12 h, (when rhTSH was administered 24 h before 
123
I: P=0.015 and 48 h before 
123
I: 
P=0.002), compared to baseline (Table 2). 
 
Fig. 1: Thyroid RAIU in 7 Healthy Beagles. Overall mean values of thyroid RAIU (%), with 
respective standard deviation, are shown for each time point for the 3 study protocols 
(baseline RAIU, rhTSH 24 h before 123I and rhTSH 48 h before 123I). 
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Fig. 2: Serum TT4 concentrations in 7 Healthy Beagles after recombinant human TSH. Mean 
serum TT4 concentrations (nmol/L), with respective standard deviation, are given for each 
time point after rhTSH (24 h before 123I and 48 h before 123I). 
 
 
Table 2. Serum rhTSH concentration in 7 Healthy Beagles after Recombinant Human TSH 
(rhTSH) administration. Mean values (standard deviation) of serum rhTSH concentration 
(mIU/L) for each time point are given. 
Mean Serum rhTSH concentration (mIU/L) 
Time point rhTSH 24h before 
123
I rhTSH 48h before 
123
I 
Baseline 0.068 (0.038)  0.076 (0.045) 
6 h 59.543 (27.384)*  50.544 (18.257)* 
12h 19.703 (10.758)*  16.484 (6.011)* 
24 h 5.634 (2.360)  4.960 (1.636) 
48 h 1.059 (0.449)  1.77 (0.394) 
* Values significantly different from baseline (P < 0.05) 
 
 
Chapter 8 
140 
 DISCUSSION 
Canine thyroid carcinoma can be successfully treated with high doses of 
131
I.
38,43
 rhTSH is a potent stimulator of thyroid function and increases thyroid RAIU in 
humans, rhesus monkey and hyperthyroid cats.
131,140,192
 If, as in humans, rhTSH 
increases the thyroid RAIU in dogs with thyroid carcinoma it may allow 
131
I dose 
reduction and higher treatment efficacy in these patients, along with delivery of less 
radioactivity to non thyroidal tissues and to the environment. In this context, our study 
may have important clinical implications. Furthermore, this is the first study that 
investigates the effect of rhTSH on thyroid RAIU in healthy dogs.  
In our study, rhTSH administration had no influence on thyroid RAIU. These 
results contrast with studies performed in healthy humans. In a study comparable to 
ours, 25 euthyroid healthy volunteers received a baseline 24 h RAIU after 
123
I and were 
then randomly divided in three groups to receive either 100 µg of rhTSH IM 24 h 
before 
123
I (3.7 MBq or 0.1 mCi PO), 48 h before 
123
I or 72 h before 
123
I.
137
 Thyroid 
RAIU was determined in all subjects 24 h after 
123
I administration. Results revealed an 
88% increase in the thyroid RAIU when rhTSH was administered 24 h before 
123
I and a 
36% increase in the RAIU when rhTSH was administered 48 h before 
123
I. In another 
study, one week after a baseline RAIU, six healthy humans received 900 µg of rhTSH 
IM 24 h before 
123
I (11.1 MBq or 0.3 mCi) and thyroid RAIU was determined 6 h and 
24 h after 
123
I administration. Results revealed that thyroid RAIU approximately 
doubled after rhTSH administration.
207
  
Several factors may explain why rhTSH had no effect on thyroid RAIU in our 
study. It is possible that despite having a significant effect on thyroid function, rhTSH 
does not enhance the trapping and retention of iodine in dogs, and therefore does not 
increase the thyroid RAIU in this species. Although possible, this hypothesis does not 
seem likely because rhTSH has been proven to increase thyroid RAIU in other species 
such as the rhesus monkey and cats.
131,192
 
The study in hyperthyroid cats reported a 7% increase  in thyroid RAIU after 
rhTSH  administration.
131
 However, the different results obtained in this study in cats 
may be related to the hyperthyroid state of the patients or to the different dosage and 
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timing of rhTSH administration (25µg of rhTSH were administered IV 1 h before 
123
I,). 
Huysmans et al. investigated different time intervals between rhTSH injection and 
131
I 
in human patients with non-toxic multinodular goiter, and concluded that this interval 
was a determinant factor to observe changes in thyroid RAIU.
120
 In their study, a 24 h 
interval between rhTSH administration and iodine injection was significantly more 
effective than a 2 h interval. Another possibility is that biokinetics of rhTSH are 
different in dogs and humans and that the effect of rhTSH on iodine accumulation 
occurs sooner in dogs than in humans. Further studies are warranted to determine the 
optimal timing for rhTSH administration. 
rhTSH was administered 24 h and 48 h before 
123
I because studies on FRTL-5 
cells (Fischer Rat Thyroid cell Line) revealed that 12 h to 24 h are needed before TSH 
stimulates iodine
 
accumulation in thyroid cells.
90,208
 In our study, serum TSH 
concentration remained increased at 48 h, but a statistically significant increase was 
only observed at 6 h and 12 h, which might not be enough to stimulate iodine 
accumulation and increase thyroid RAIU. The results of the above-mentioned study by 
Pena et al. in healthy humans support this hypothesis.
137
 In this study, serum TSH 
concentration remained markedly elevated at 24 h (above 11 mU/L) and at 48 h (above 
4 mU/L) after rhTSH IM administration. In this context, the route of rhTSH 
administration could also have influenced our results. In our study, the intravenous 
route was chosen to maximize bioavailability, given the high cost of rhTSH. Although 
there are no reports arguing that IM route is superior to IV route, it could be that if 
rhTSH is administered intramuscularly, such as in humans, its clearance is slower 
allowing a longer stimulation of the thyroid cells with a potential increase in thyroid 
RAIU. 
It is possible that the effect of rhTSH on the thyroid RAIU is dose dependent 
and that 100 µg of rhTSH is not enough to cause a significant increase of thyroid RAIU 
in dogs. Currently, no studies have shown that the effect of rhTSH on thyroid RAIU is 
dose dependent.
120,191
 Further studies are warranted to evaluate the effect of different 
doses of rhTSH on canine thyroid RAIU. 
The progressively lower RAIU in all groups throughout the study suggests 
either a stunning effect or an alteration of the biokinetics of iodine. In human medicine 
Chapter 8 
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the topic of stunning of the thyroid gland is controversial. The phenomenon has been 
related to the diagnostic use of small amounts of 
131
I before therapy.
209,210
 It is thought 
to be related to radiotoxic effects of the radionuclide resulting in (temporary) decreased 
ability of the thyroid cells to trap and retain radioiodine.
209,211
 Stunning is considered to 
be dose dependent and seems to occur in relation with a longer interval between 
diagnostic use of 
131
I
 
and therapy.
212
 This effect is transient due to recovery of the 
thyroid cells with normalization of trapping and retaining ability after 20-25 days.
213
 
Despite the fact that the «stunning» debate in literature is predominantly about 
131
I, the 
possible occurrence of this effect has been reported in relation with the use of 
123
I (74 
MBq; 200 MBq).
213,214
 This radionuclide, exclusive for diagnostic use, decays 
primarily through emission of gamma rays and Auger electrons, thereby limiting 
radiotoxic effects to the thyroid. It was concluded that decreased uptake after 
diagnostic use of 
123
I was probably not due to the damaging effects but rather the 
consequences of differential rates of radioiodine turn-over.
214
 To avoid this stunning 
effect by the repeated injections of 
123
I we used a small amount of radioactivity (37 
MBq or 1 mCi). However, a wash-out period of 3 weeks was chosen in this study to 
allow for decay of residual 
123
I in order not to compromise the imaging results. If 
stunning would have occurred, this time interval would be borderline for recuperation 
of the thyroid cells considering the 20-25 days interval for recovery after diagnostic 
131
I. Further studies are mandatory to evaluate whether a longer wash-out period or a 
lower 
123
I dose produce similar results.  
Differential biokinetics of radioiodine due to its subsequent administration is 
another theoretical possibility. It is well known that iodine supplementation alters the 
turn-over of subsequent iodine administration. However, it has long been demonstrated 
that iodine supplementation up to 0.1 mg does not affect the uptake of 
131
I nor the 
wash-out.
215
 The specific activity of the 
123
I solution is high (1,93 x 10
6
 Ci/g) with as a 
consequence the presence of an extremely low amount of iodine (1,004 ng) in the 
solution. Therefore it is doubtful that this would have any influence on iodine turn-
over. 
Another factor capable of causing an altered turn-over of radioiodine is an 
increase in the dietary intake of iodine. However, no diet change occurred during the 
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study or previously which would explain the consecutive decrease in uptake. A change 
in the iodine content of the drinking water is also possible although it does not seem 
likely. 
As expected rhTSH had a statistical significant effect on serum TT4 
concentrations and on the variation of serum TT4 concentrations over time. The peak of 
serum TT4 concentration occurred 6 h after rhTSH injection, such as previously 
described.
125
  
Extrapolation of results from healthy dogs to patients with thyroid carcinoma 
is not possible and this is one limitation of our study. Healthy thyroid tissue and 
neoplastic thyroid tissue are functionally different. Therefore, it is possible that, despite 
our results, rhTSH has clinical use in canine patients with thyroid carcinoma. 
In conclusion, our results show that 100 µg of rhTSH administered 
intravenously 24 h and 48 h before 
123
I does not affect thyroid RAIU in healthy dogs. 
Further studies are needed to determine the best timing and dosage of administration of 
rhTSH in healthy and thyroid carcinoma bearing dogs. 
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 ABSTRACT 
Background: In humans, recombinant human thyrotropin (rhTSH) enhances 
radioactive iodine uptake (RAIU) in patients with differentiated thyroid cancer. No 
studies have been performed in veterinary medicine to optimize radioiodine treatment 
of thyroid cancer. 
Hypothesis/Objectives: To evaluate the effect of rhTSH on the uptake of 
radioiodine-123 (
123
I) in dogs with thyroid tumors. 
Animals: Nine dogs with thyroid neoplasia. 
Methods: The dogs were divided in 2 groups in this prospective cross-over 
study. In one group, 
123
I was administered for a baseline RAIU determination in week 
1. In week 4 (after a washout period of 2 weeks), these dogs received rhTSH (100 μg 
IV) 24 h before 
123
I injection. In the other group the order of the protocol was reversed. 
For each scan, the dogs received 37 MBq (1 mCi) of 
123
I intravenously (IV) and planar 
scintigraphy was performed after 8 and 24 h for tumor RAIU calculation. 
Results: Overall, rhTSH administration caused no statistically significant 
change on thyroid tumor RAIU at 8 h (P=0.89) or at 24 h (P=0.98). A significant 
positive correlation was found between the effect of rhTSH on tumor 8h-RAIU and 
rhTSH serum concentrations at 6 h (τ=0.68; P=0.03), at 12 h (τ=0.68; P=0.03) and at 
24 h (τ=0.78; P=0.02) after rhTSH injection. This study suggests that IV administration 
of 100 μg rhTSH 24 h before 123I has an inconsistent effect on thyroid tumor RAIU.  
Conclusions and clinical importance: Further studies are necessary to 
determine the best protocol of rhTSH administration to optimize thyroid tumor RAIU. 
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INTRODUCTION 
Thyroid tumors account for 10-15% of all head and neck neoplasms in 
dogs.
44,216
 Ninety percent of canine thyroid tumors are carcinomas and 16-38% of the 
patients present evidence of metastasis at the time of diagnosis.
44,217
 Surgery is the 
preferred treatment modality for mobile tumors, while large invasive tumors have a 
better prognosis with external beam radiation or radioactive iodine-131 (
131
I) therapy.
44
 
Two recent retrospective studies showed prolonged median survival times of 27 and 30 
months following 
131
I therapy.
38,43
 Furthermore, 
131
I may be the only effective therapy 
against thyroid cancer metastases. In dogs, high doses of 
131
I are required and this 
usually implies a prolonged hospitalization period and high doses of radiation 
eliminated to the environment through the excreta. Use and exposure to radiation 
should be kept ‘‘as low as reasonably achievable’’ (ALARA principle) to minimize 
risks for patient and human health.
127
 Exposure of nonthyroidal tissues to high doses of 
radiation may cause treatment complications such as fatal myelosuppression.
43,128
 
Major limitations of 
131
I therapy include its selected effectiveness in differentiated 
thyroid tumors exhibiting adequate 
131
I uptake and the potential need of multiple 
treatments for tumor control. 
In human medicine, recombinant human thyrotropin
a
 (rhTSH, Genzyme 
Corporation, Cambridge, ME, USA) is used to increase 
131
I uptake by normal and 
neoplastic thyroid tissue in the treatment and diagnostic follow-up of differentiated 
thyroid carcinoma.
108
 In addition, the use of rhTSH before 
131
I therapy is associated 
with a lower whole-body exposure to radiation, limiting treatment complications.
114
 
Thyrotropin (TSH) binds to a membrane TSH G protein-coupled receptor on 
the surface of follicular thyroid cells and triggers a cascade of intracellular reactions 
leading to synthesis and secretion of triiodothyronine (T3), thyroxine (T4) and 
thyroglobulin (Tg).
88
 Prolonged TSH stimulation (>24 h) increases the expression and 
functionality of the Na/I symporter (NIS) and, consequently, leads to an increased 
uptake and organification of iodine.
90,218
 
In veterinary medicine, rhTSH has been mainly used for the diagnosis of 
canine hypothyroidism due to the lack of specificity of the current endogenous TSH 
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assay.
200
 However, TSH receptors have already been demonstrated in canine neoplastic 
thyroid cells; both in primary tumors and metastases.
81
 The optimization of radioiodine 
treatment with rhTSH may offer important clinical advantages. On one hand, by 
increasing the uptake
 131
I by the thyroid tumor, rhTSH may improve 
131
I treatment 
efficacy and decrease the need for multiple treatments. On the other hand, rhTSH may 
allow a decrease of the therapeutic dosage of 
131
I, thereby improving radioprotection, 
limiting radiotoxicity and complying with the ALARA principle. Furthermore, 
131
I dose 
reduction could potentially reduce the required hospitalization period and costs. 
The use of 
131
I for diagnostic imaging in clinical research has several 
limitations. Its half-life (8 days) makes it impractical for repeated radioactive iodine 
uptake (RAIU) determinations within a reasonable period. Furthermore, the emission 
of beta particles during  the decay of 
131
I causes a higher localized radiation dose and 
may have a deleterious effect on the uptake of the actual 
131
I therapeutic dosage, a 
phenomenon named thyroid stunning.
132
 Unlike 
131
I, 
123
I has a much shorter half-life 
(13 h), decays by emitting gamma rays and has been shown to be equal or even 
superior to 
131
I as a scanning agent.
133
 Hence, in this study 
123
I was chosen as an 
imaging agent, despite its high cost. Recent pilot studies performed by our group have 
already investigated the use of rhTSH to optimize the uptake of radioiodine-123 (
123
I) 
in healthy dogs and hyperthyroid cats.
131,219
 The goal of this study was to evaluate the 
effect of 100 μg rhTSH, administered IV 24 h before 123I, on tumor RAIU in dogs with 
thyroid tumors. 
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 MATERIALS AND METHODS  
Sample size 
A preliminary power analysis showed that 9 patients included in a prospective 
cross-over study would suffice to detect a 28% increase in tumor RAIU with a power 
of 80% at a global significance level of 5%. 
Animals  
The inclusion criteria of our study were diagnosis of thyroid neoplasia by 
either cytology, biopsy and/or scintigraphy and tumor uptake of 
123
I at scintigraphy. 
Patients where treatment was deemed urgent due to upper airway obstruction were 
excluded. The first nine dogs referred to the Small Animal Clinic of Ghent University 
that met the inclusion criteria and for which owner consent was obtained, were 
included. Patients were recruited between December 2007 and November 2011. 
Diagnosis was based on physical examination, cervical mass cytology, cervical 
scintigraphy and, when available, histopathology from excisional biopsies. Complete 
hematological and biochemical analysis, including serum total thyroxine (TT4) and 
TSH, were performed in all patients.  
Determination of thyroid functional status was based on clinical signs, basal 
serum TT4 and TSH concentrations, cervical scintigraphy and TSH stimulation. Results 
of TSH stimulation were interpreted comparing serum TT4 concentrations at baseline 
and 6 h after rhTSH administration. Euthyroidism was confirmed when post-
stimulation TT4 was ≥ 40 nmol/L and hypothyroidism was considered likely when 
post-stimulation TT4 concentration was < 20 nmol/L.
126,200
 Dogs with post-stimulation 
TT4 between 20 and 40 nmol/L would have been classified as having undefined thyroid 
function, but such results were not observed. Dogs with baseline TT4 > 43,86 nmol/L 
and compatible clinical signs were considered hyperthyroid. 
All dogs were staged according to the WHO staging system for canine thyroid 
tumors.
164
 For this purpose, cervical palpation, tridimensional measurement of the 
tumor, radiographs or computed tomography (CT) of the thorax, cervical and thoracic 
scintigraphy were performed in all patients. Cervical ultrasound was performed in 6 
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patients. Cervical and thoracic computed tomography was performed in 4 patients. 
Abdominal ultrasound was performed in 2 patients.  
During the washout period, the dogs stayed at home. Diet and water source 
were kept unchanged during the study.  
Ethics statement 
Animal care was in accordance with European guidelines and directives (EC 
directive 86/609/EEC for animal experiments) and the study was approved by the 
Ethical committee of the Faculty of Veterinary Medicine of Ghent University and by 
the Belgian Deontological committee (approval number EC 2010/168). Furthermore, 
an owner consent form was signed by all owners. 
Study design  
The dogs were divided in 2 groups in a prospective cross-over study. In group 
A, 
123
I was administered for a baseline RAIU determination in week 1. In week 4 (after 
a washout period of 2 weeks), these dogs received rhTSH (100 μg IV) 24 h before 123I 
injection. In group B the order of the protocol was reversed (Table 1). For each scan, 
the dogs received 37 MBq (1mCi) of 
123
I IV and planar scintigraphy was subsequently 
performed at 8 h and 24 h for tumor RAIU calculation. 
Blood samples 
Blood samples were taken for serial measurements of TT4 and rhTSH serum 
concentrations in the week rhTSH was administered. Blood was collected by jugular 
venipuncture at baseline, 6, 12, 24 and 48 h after rhTSH injection. Blood was 
centrifuged and the serum was stored for at least 3 weeks at -20ºC to reach sufficient 
decay of radioactivity to be analyzed. 
The TT4 serum concentration was determined with a commercially available 
solid-phase, chemiluminescent competitive immunoassay
 
(IMMULITE 2000 Canine 
Total T4, Siemens, Deerfield, IL, USA) previously validated in dogs, and the reference 
range used was 6.45-43.86 nmol/L.
198
 Basal TSH serum concentration was determined 
with a commercially available solid-phase, two-site chemiluminescent immunometric 
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assay
 
(IMMULITE 2000 Canine TSH, Siemens, Deerfield, IL, USA) previously 
validated in dogs, and the reference range used was <0.5 ng/mL.
198
 
rhTSH serum concentrations were measured with a commercially available 
chemiluminescent microparticle immunoassay for human TSH determination in an 
immunoassay analyzer
 
(Abbott ARCHITECT i2000SR, Abbott Laboratories, Abbott 
Park, IL, USA).
220
 
Recombinant human TSH 
Each vial of 900 µg of rhTSH was reconstituted with 4.5 mL of sterile water 
(200 µg/mL). Individual doses of 100 µg of freshly reconstituted rhTSH were prepared 
in 1 mL plastic syringes with needle and rubber caps and were stored frozen at -20º C 
for a maximum of 12 weeks.
200,205
 For TSH stimulation, frozen rhTSH was thawed at 
room temperature a few minutes before administration.  
RAIU 
Each dog received 37 MBq (1 mCi) of 
123
I IV. The injected activity of 
123
I was 
calculated by subtracting the activity of the empty syringe from the activity of the full 
syringe both measured in a dose calibrator. To determine the tumor/metastases RAIU, a 
static planar ventrodorsal image was obtained with a one head γ-camera (Toshiba GCA 
901) using a low-energy high resolution collimator with the dog in sternal recumbency 
under general anesthesia. General anesthesia was induced with propofol and 
maintained with isoflurane vaporized in oxygen using a rebreathing system. Data were 
acquired during 5 minutes for the 8h-RAIU and 10 minutes for the 24h-RAIU on a 
128x128 matrix. A syringe with a known amount of radioactivity (2.5 ± 1.6 MBq) was 
placed next to the animal and served as the standard activity necessary to calculate the 
RAIU. Regions of interest (ROI) were manually drawn over the primary 
tumor/metastases and over the activity of the standard.
206
  In order to correct for 
background activity a ROI with the same dimensions as the ROI over the tumor was 
drawn over an area close to, but not overlapping, the thyroid tumor (soft tissue 
background correction) and another ROI with the same dimensions of the ROI over the 
standard was placed outside the dog (room background correction). The total number 
of counts in each ROI was recorded and transformed to counts per minute (cpm) for 
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RAIU calculation, yielding cpmtumor, cpmstandard, cpmbackground and cpmroom. These ROI’s 
were placed on one day and by the same person (EV). RAIU was calculated as a 
percentage of the administered dose of 
123
I corrected for physical decay and 
background activity using the following formula:  
([(cpmtumor - cpmbackground) / (cpmstandard - cpmroom)] × (MBqstandard / MBqinjected activity)) × 100 
Statistical analysis 
 Data were analyzed with SAS version 9.1
 
(SAS, Cary, North Carolina, USA). 
The effect of rhTSH administration on RAIU was analyzed with a mixed model with 
period, treatment, time and the interaction between treatment and time as categorical 
fixed effects and dog and the period by dog interaction as random effects. Comparisons 
were based on the F-test at a global significance level of 5%, using Tukey's procedure 
for multiple comparisons.  
 The change of TT4 serum concentration from baseline to 6 h was analyzed 
using a mixed model with dog as random effect and time as a categorical fixed effect. 
Possible associations between the effect of rhTSH on tumor RAIU (at either 
8h or 24h) and rhTSH serum concentration at all time points and results of TSH 
stimulation were evaluated with the Kendall’s τ correlation coefficient.  
The association between the effect of rhTSH on tumor RAIU (at either 8h or 
24h) and thyroid function status (euthyroid vs hyperthyroid) was evaluated on a data 
set excluding the one hypothyroid patient that was in the data set. The analysis was 
based on a mixed model with period, treatment, time, status and the interactions 
between treatment, time and status as categorical fixed effects and the dog and the 
period by dog interaction as random effects. 
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  RESULTS 
 Two mixed breed dogs, 1 medium-sized Poodle, 1 American Staffordshire 
Terrier, 1 German Longhaired Pointer, 1 Jack Russell Terrier, 1 Bearded Collie, 1 
Belgian Shepherd Malinois and 1 Beagle were included in this study. Six dogs were 
males, 3 were females, mean age was 9.5 years (range 6 – 12 years). 
Six dogs were diagnosed with unilateral thyroid tumors, 1 dog had bilateral 
thyroid tumors and 2 dogs had ectopic tumors. Three patients were diagnosed with 
thoracic metastases visible at scintigraphy (n=2) and radiographs (n=1). Histopathology 
was performed in 6 patients. The only patient for which cytology or histopathology 
were not performed was diagnosed with an ectopic thyroid tumor clearly visible at 
scintigraphy. Furthermore, the dog had clinical hyperthyroidism. 
Five dogs were euthyroid, 3 dogs were hyperthyroid and 1 dog was 
hypothyroid. All patients presented for a palpable cervical mass. Additionally, the 3 
hyperthyroid dogs presented with PU/PD and weight loss; two of these also presented 
polyphagia. The hypothyroid dog had been diagnosed several years prior to referral and 
was being treated with levothyroxine supplementation. One dog had been previously 
diagnosed and treated for hypothyroidism but was reclassified as euthyroid based on 
basal TT4 serum concentrations, cervical scintigraphy and TSH stimulation results at 
the moment of inclusion in our study. In both cases, levothyroxine supplementation 
was interrupted for at least 3 days before the study week. Four patients were diagnosed 
with stage II, 2 patients with stage III and 3 patients with stage IV thyroid cancer. 
The results of thyroid function status, tumor histopathology and tumor RAIU 
determination of each dog are summarized in Table 1. After rhTSH administration, the 
8h-RAIU increased in 5 tumors and decreased in 5; the 24h-RAIU increased in 4 
tumors and decreased in 6. Overall, rhTSH caused no statistically significant change on 
primary thyroid tumor RAIU at 8 h (P=0.89) or at 24 h (P=0.98) (Fig. 1). The RAIU of 
thoracic metastases could only be evaluated in 2 of the 3 patients with stage IV disease. 
After rhTSH administration, the 8h- and 24h-RAIU increased in 1 thoracic metastasis 
(Table 2). 
rhTSH & 
123
I uptake in dogs with thyroid tumors  
155 
Table 1. Thyroid function status, tumor histopathology, primary tumor RAIU and cross-over group in 9 
dogs with thyroid tumors. The mean and standard deviation of the 8h- and 24h-RAIU with and without 
rhTSH stimulation are given. 
Abbreviations: FTCC, follicular cell thyroid carcinoma of compact type; FTCfc, follicular cell thyroid 
carcinoma of follicular-compact type; FTCfp, follicular cell thyroid carcinoma of follicular-papillary 
type; MTC, medullary (C cell) thyroid carcinoma; NA, not available; R, right; L, left 
 
 
 
 
 
 
 
 
 
Fig. 1. Primary thyroid tumor RAIU in 9 dogs with thyroid tumors. 
The mean and standard deviation of the 8h- and 24h-RAIU with and 
without rhTSH stimulation are given. 
 
Dog Thyroid 
function 
Histology 8h RAIU 
(%) 
8h-rhTSH 
RAIU (%) 
24h RAIU 
(%) 
24h-rhTSH 
RAIU (%) 
Group 
1 Euthyroid FTCc 8,5 7,8 17,4 15,7 A 
2 Euthyroid FTCc 0,2 0,8 0,2 0,6 A 
3 Euthyroid FTCfp 3,1 3,7 4,9 8,3 A 
4 Hyperthyroid FTCc 10,6 16,2 27,2 14,8 A 
5 Hyperthyroid FTCfc 8,9 7,0 10,7 9,9 A 
6 Euthyroid NA 3,4 9,3 5,6 13,7 A 
7 Hyperthyroid NA 29,6 29,5 31,1 28,3 B 
8 Euthyroid MTC 0,7 2,0 0,9 2,8 B 
9R Hypothyroid NA 2,1 1,7 1,8 1,6 B 
9L  NA 0,8 0,4 0,7 0,5 B 
 Mean ±Std Dev 6,8 ±8,9 7,8 ±9,0 10,0 ±11,4 9,6 ±8,9  
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Table 2. Thyroid function status, metastases RAIU and cross-over group in 2 dogs with thoracic 
metastases.  
 
Table 3. rhTSH and TT4 serum concentrations in dogs with thyroid tumors before and after 
injection of 100 μg rhTSH IV. The mean values (standard deviation) of rhTSH serum 
concentrations of 6 dogs and TT4 serum concentrations of 4 euthyroid dogs with thyroid tumors 
are given for each time point. 
Time point rhTSH (mIU/L) TT4 (nmol/L) 
Baseline 0 (0) 24.2 (6.45) 
6 h 26.97 (4.47) 50.97 (7.03) 
12h 9.52 (1.45) 35.79 (10.47) 
24 h 3.30 (0.63) 25.83 (9.1) 
48 h 0.77 (0.27) 22.28 (6.94) 
TT4 and rhTSH serum concentrations were measured immediately before and 
followed up after rhTSH injection in 4 euthyroid dogs, 1 hyperthyroid dog and 1 
hypothyroid dog. The 4 euthyroid patients showed a significant increase in TT4 serum 
concentrations 6 h after rhTSH injection compared to baseline (P=0.01) (Table 3). The 
hyperthyroid dog and the hypothyroid dog did not show meaningful changes in serum 
TT4 concentrations at any time point.  
A significant positive correlation was found between the effect of rhTSH on 
tumor 8h-RAIU and rhTSH serum concentrations at 6 h (τ=0.68; P=0.03), at 12 h 
(τ=0.68; P=0.03) and at 24 h (τ=0.78; P =0.02) after rhTSH injection. When tumor 
metastases were included in the analysis, a significant positive correlation was also 
detected between the effect of rhTSH on 24h-RAIU and rhTSH serum concentrations 
at 6 h (τ=0.59; P=0.04), 24 h (τ=0.59; P=0.04) and 48 h (τ=0.67; P=0.02). No 
significant correlation was found between the change in TT4 serum concentrations from 
Dog 
Thyroid 
function 
8h RAIU 
(%) 
8h-rhTSH 
RAIU (%) 
24h RAIU 
(%) 
24h-rhTSH 
RAIU (%) 
Group 
3 – thorax Euthyroid 0.05 0.15 0.04 0.09 A 
8 – thorax Euthyroid 0.03 0.01 0.06 0.01 B 
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baseline to 6 h and the effect of rhTSH on tumor RAIU, at either 8 h (P=0.54) or 24 h 
(P=0.13). 
 Hyperthyroid dogs had significantly higher RAIU values than euthyroid dogs 
(P=0.01). Furthermore, the effect of the rhTSH on 24h-RAIU differed significantly 
between euthyroid and hyperthyroid dogs (P=0.02) but not at 8 h (P=0.98). In 
euthyroid dogs, the 24h-RAIU increased from 5.8%, at baseline, to 8.2%, after rhTSH. 
In hyperthyroid dogs, the 24h-RAIU decreased from 23%, at baseline, to 17.7%, after 
rhTSH. 
No adverse effects were observed following the administration of rhTSH. 
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 DISCUSSION 
 Thyroid cancer is the most common endocrine neoplasia in dogs and, as in 
humans, these tumors are mainly of follicular cell origin.
44
 In humans, rhTSH 
stimulates the uptake of 
131
I in patients with differentiated thyroid carcinoma and can 
be used to improve the efficacy of 
131
I therapy.
115
 Additionally, the use of rhTSH 
before 
131
I therapy is associated with a lower 
131
I effective half-life and, consequently, 
lower exposure of blood and the whole-body to radiation. This limits radiotoxicity 
without compromising the efficacy of the treatment
114
. The obvious benefits of the use 
of rhTSH to optimize the treatment of human thyroid cancer with 
131
I provide an 
interesting perspective for the optimization of 
131
I therapy of canine thyroid tumors. 
Increased 
131
I uptake by canine thyroid tumors may improve treatment efficacy and 
decrease the need for multiple treatments; reduced blood exposure to radiation may 
limit myelossupression; 
131
I dose reduction could improve radioprotection, reduce the 
hospitalization period and costs. This is the first study to evaluate the effect of rhTSH 
on radioiodine uptake in dogs with thyroid tumors. 
 Overall, no significant effect of rhTSH on tumor RAIU was observed with our 
protocol. These results are in agreement with the results of a recent pilot study 
performed by our group in healthy Beagles.
219
 In that study, rhTSH (100 μg IV, 
administered 24 h or 48 h before 
123
I) also did not cause a significant change in thyroid 
RAIU. Earlier reports have suggested the potential of exogenous TSH to increase 
thyroid RAIU in dogs.
129,130,221
 However, in these studies the effect of TSH stimulation 
on thyroid 
131
I uptake was described in a small number of healthy and 
hypophysectomized dogs and no statistical analysis was performed. In healthy humans, 
TSH stimulation with a protocol similar to the one used in this study was shown to 
approximately double thyroid RAIU.
137
 
The inconsistent effect of rhTSH on thyroid tumor RAIU observed in our 
study raises important issues regarding the dosage, the route and timing of rhTSH 
administration. The significant increase in TT4 serum concentrations 6 h after rhTSH 
injection, observed in euthyroid patients, was expected and confirmed the biological 
activity of rhTSH. The observed correlation between the effect of rhTSH on tumor 
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RAIU and rhTSH serum concentrations suggests that higher plasma concentrations of 
rhTSH may allow an increased uptake of 
123
I by thyroid tumors. The plasma 
concentration of rhTSH at different time points is mainly related to the dose 
administered. It is possible that doses higher than 100 μg may induce a more consistent 
increase of thyroid tumor RAIU. In humans, high plasma concentrations of TSH (>30 
mIU/mL) are deemed necessary to stimulate sodium-iodide symporters to concentrate 
iodine, in normal and neoplastic thyroid tissue. Hence, high doses of rhTSH (2x900μg 
IM 24 h apart) are administered 24 h before 
131
I injection for diagnostic follow-up and 
treatment of differentiated thyroid cancer. Nevertheless, the optimal magnitude of TSH 
elevation is unknown and differs among patients.
222
 It is interesting to note that, in our 
study, all patients with rhTSH serum concentrations > 30 mIU/mL 6 h after rhTSH 
injection experienced an increase in thyroid tumor RAIU after rhTSH. The 
administration of rhTSH doses similar to those given to humans with thyroid cancer is 
not realistic in the veterinary clinical setting given the high cost of rhTSH. 
Furthermore, studies in humans with multinodular goiter have demonstrated that 
rhTSH doses as low as 5 or 100 μg suffice to effectively increase thyroid RAIU.191 In 
our study, the dosage of 100 μg was chosen because this dose is considered appropriate 
for a functional stimulation of the thyroid gland in most dogs.
200
 Further studies are 
necessary to determine the effect of higher doses of rhTSH on thyroid tumor RAIU in 
dogs. 
 An important factor influencing the pharmacokinetics of rhTSH is the route of 
administration. In our study, the IV route was chosen to maximize bioavailability. 
Although there are no reports arguing that the IM route is preferable, it is possible that 
if rhTSH is administered IM, such as in humans, its clearance is slower allowing a 
longer stimulation of the thyroid cells and possibly increasing tumor RAIU more 
consistently.  
In our study, rhTSH was administered 24 h before 
123
I because studies on 
FRTL-5 cells (Fischer rat thyroid cell line) revealed that 12 to 24 h are needed before 
TSH stimulates accumulation of iodine
 
in thyroid cells and because this is considered 
the optimal timing to increase thyroid RAIU in humans.
90,120
 The optimal timing of 
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rhTSH administration to increase thyroid RAIU in dogs with thyroid tumors is 
currently unknown.  
 The inconsistent effect of rhTSH on thyroid tumor RAIU may not be related 
to the protocol of rhTSH administration but rather to intrinsic properties of the 
neoplastic thyroid tissue. A previous study has shown that the concentration and 
affinity of TSH receptors in neoplastic canine thyroid cells is variable.
81
 In that study, 8 
of 22 primary canine thyroid tumors were shown to have fewer TSH-binding sites than 
the lowest value observed in normal thyroid tissues, suggesting that TSH receptor 
concentration could be related to the functional variability of thyroid neoplasms.
81
 
Likewise, studies in humans have demonstrated that the expression of TSH-receptor 
mRNA may be decreased in thyroid carcinomas.
223
 Additionally, in vitro studies have 
revealed that TSH unresponsiveness in human thyroid carcinomas can also be related 
to defects in TSH signal transduction or errors in iodine transport.
224,225
 
 As expected, our study showed that hyperthyroid dogs had significantly higher 
RAIU values than euthyroid dogs. In hyperthyroidism, increased thyroid function 
enhances iodine trapping and organification. Hence, dogs with thyroid tumors and 
hyperthyroidism frequently present high tumoral 
131
I uptake and are often ideal 
candidates for 
131
I therapy.
52
 The significantly different effect of rhTSH on thyroid 
RAIU between euthyroid and hyperthyroid patients was an interesting finding. In a 
study of 55 dogs with thyroid tumors, dogs with evidence of autonomous hyperfunction 
of the goiter had an increased thyroidal iodine turn-over.
221
 It is possible that a positive 
effect of rhTSH on tumor RAIU occurs sooner in hyperthyroid patients and was, 
therefore, not observed with our protocol (RAIU determination 8 h and 24 h after 
123
I 
injection). On the other hand, the lack of effect of rhTSH in hyperthyroid patients may 
be caused by decreased thyroid functional reserve. This seems, however, less likely 
because in hyperthyroid cats and in humans with toxic nodular goiter (a condition 
characterized by nodular enlargement of the thyroid gland and hyperthyroidism), a 
significant increase in thyroid RAIU is observed after rhTSH administration.
121,131
 
The administration of rhTSH to patients with thyroid carcinoma raises 
important safety issues. In humans, rhTSH causes expansion of primary thyroid tumors 
and thyroid tumor metastases.
138,139
 Therefore, rhTSH should be used carefully in 
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patients with large thyroid tumors or central nervous system, spinal, lung or bone 
metastases. A pilot study performed in healthy Beagles showed no effect of rhTSH on 
thyroid gland volume.
226
 Likewise, no adverse effects of rhTSH were observed during 
our study.  
All thyroid tumors for which histopathology was available were malignant and 
5 of the 6 tumors were of follicular cell origin. This was expected as 90% of canine 
thyroid tumors are malignant and only patients with 
123
I uptake were included.
44
 In 
humans and dogs, malignant thyroid tumors are predominantly of follicular cell origin, 
but in humans only 8.1-14.8% of all thyroid nodules are malignant.
227
 Another 
important difference resides in the predominant histologic types. In dogs, thyroid 
carcinomas are predominantly mixed follicular-compact, while in humans 80% of 
thyroid malignancies are of papillary type which is rare in dogs.
10,85
 Undifferentiated 
carcinomas are relatively uncommon in both species, accounting for 2% of thyroid 
malignancies in humans and 12% in dogs.  
One dog with a C-cell carcinoma presented 
123
I uptake by the primary tumor 
and thoracic metastases. To the authors knowledge, there is only one previous report in 
veterinary medicine and very limited reports in human medicine of medullary 
carcinomas exhibiting iodine uptake.
52,228,229
 The mechanism underlying the ability of 
medullary carcinoma cells to trap iodine remains unclear. 
 In conclusion, our study shows that 100 μg rhTSH administered IV 24 h 
before 
123
I has no significant effect on thyroid tumor RAIU in dogs. The detected 
correlation between increased tumor RAIU and rhTSH serum concentrations attained 
after injection suggests that higher dosages of rhTSH may be necessary. Further studies 
are needed to determine the optimal protocol of rhTSH administration to increase 
thyroid tumor RAIU in dogs.  
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Thyroid neoplasia is a common form of endocrine cancer in dogs. Almost all 
thyroid tumors detected clinically are carcinomas and many patients present with 
pulmonary metastases at the moment of diagnosis. Approximately 2/3 of canine thyroid 
carcinomas are of follicular cell origin and 1/3 are of medullary origin. In the absence 
of metastatic disease, dogs with freely moveable tumors can be treated with 
thyroidectomy alone while dogs with invasive unresectable tumors can be treated with 
external beam radiation or 
131
I. However, 40-50% of dogs may experience local 
recurrence or metastatic disease after treatment. Research on genetic alterations, 
prognostic markers, therapeutic targets, and treatment optimization of this disease is 
lacking. The aim of this PhD research was to provide new insights into the 
pathogenesis and treatment of canine thyroid tumors. 
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1  PATHOGENESIS 
 To present date, research on the genetic events leading to canine thyroid 
cancer remains scarce. The major advances recently made in understanding the 
molecular pathogenesis of human thyroid cancer led to the discovery of new diagnostic 
tools and to the development of innovative treatments. In humans, the PI3K/Akt 
pathway is the major signaling pathway involved in follicular thyroid carcinoma and 
genetic alterations (eg, mutations, gene amplification) in the effectors of this pathway 
are frequently observed. Research on the molecular pathogenesis of canine thyroid 
cancer will help understand the process of thyroid gland tumorigenesis in dogs and  
also aid the development of new treatment strategies in the future. 
1.1  Follicular cell and medullary thyroid cancer 
In our research, the differentiation between follicular cell and medullary origin 
of thyroid cancer was based on IHC for calcitonin, in accordance with the WHO 
classification of canine thyroid tumors.
7
 Calcitonin has been shown to be the most 
sensitive marker for identification of canine MTC.
5
  
In the investigations described in chapters 3, 4 and 5, 27% of canine thyroid 
tumors were MTCs in agreement with previous studies reporting a prevalence of 16-
36%.
4,171
 In dogs, MTC may be difficult to distinguish from compact FTC by 
microscopic observation alone and earlier studies lacking IHC likely underestimated its 
prevalence.
4
 In fact, 18 of 20 MTCs in our research were provisorily classified as 
compact FTC and 2 as follicular-compact FTC prior to IHC for calcitonin. This 
underlines the importance of routine IHC for identification of canine MTC. The fact 
that in our research mRNA expression of CALCA did not overlap between FTCs and 
MTCs supports the accuracy of tumor classification based on IHC. 
The potential value of lifelong levothyroxine therapy to suppress endogenous 
TSH (TSH-suppressive therapy) in FTC is an important reason to routinely 
differentiate canine FTC from MTC with IHC. The differences observed in mRNA 
expression of PI3K/Akt related genes (chapter 3) and especially in expression of 
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potential therapeutic targets (chapter 5), further strengthen the need for differentiation 
of thyroid cancer origin in dogs. 
The definitive diagnosis of canine thyroid cancer is established by 
histopathologic examination.
230
 When excisional or incisional biopsy samples are 
available, IHC is a simple, easy and fast technique to obtain confirmation of the 
cellular origin of thyroid cancer. However, in patients with unresectable tumors, 
clinicians often favor a presumptive diagnosis obtained with cytology or scintigraphy 
due to potential bleeding complications of biopsying such highly vascularized 
tumors.
230
 In the future, immunocytochemistry may help circumvent this limitation. 
1.2  Genetic events 
In the study reported in chapter 3, we investigated known mutational hotspots 
and mRNA expression of genes commonly involved in human thyroid gland 
tumorigenesis, in 43 canine FTCs and 16 canine MTCs. Activating missense mutations 
in K-RAS were found in 1 FTC and 1 MTC. These mutations are reported in human 
thyroid cancer with similar prevalence and are likely to play a relevant role in canine 
thyroid gland tumorigenesis.
151,152,157
 The overall low prevalence of RAS mutations in 
our research is in agreement with a large veterinary study investigating mutational 
hotspots of RAS (H, N, K) in a large series of canine tumors.
17
 In that study, only 1 
mutation in H-RAS was found in a canine melanoma.  
The absence of amino acid changing mutations in the sequenced regions of H-
RAS, N-RAS, BRAF, PIK3CA, RET and in the entire coding region of PTEN, 
demonstrates that the mutations most commonly involved in human thyroid cancer are 
rare and do not play a major role in the pathogenesis of canine thyroid carcinoma. 
Further research is needed to investigate the main genetic events leading to canine 
thyroid cancer. 
The fact that we could not identify mutations frequently associated with 
canine thyroid carcinoma shows the limitations of the candidate gene approach chosen 
in our research. Sequencing mutational hotspots in candidate genes is a simple, quick 
and relatively cost-effective approach to investigate genetic alterations in target regions 
of the genome. In chapter 3, the candidate genes and target exons were selected based 
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on mutational hotspots of human thyroid cancer. An alternative approach would be to 
select candidate genes based on signaling pathways found to be activated in canine 
thyroid cancer, followed by sequencing of the entire coding region of all genes 
involved in the activated pathway(s).
14
 Additional and broader approaches to 
investigate the genetic pathogenesis of cancer include gene expression profiling, 
genome wide association studies (GWAS), next-generation sequencing and whole 
exome sequencing.
231-233
 However, these comprehensive approaches are more complex, 
take longer to analyze and involve much higher costs. 
In humans, gene amplification also plays an important role in thyroid gland 
tumorigenesis, and this is particularly the case for genes involved in the PI3K/Akt 
signaling pathway.
12
 Commonly amplified genes in human follicular thyroid carcinoma 
include EGFR, VEGFR-1, VEGFR-2, PIK3CA, PIK3CB, AKT1, AKT2 and PDPK1.
14
 
In the investigation described in chapter 3 we demonstrate increased mRNA 
expression levels of VEGFR-1, VEGFR-2, PDPK-1, AKT1 and AKT2 in canine FTC 
and increased mRNA expression levels of VEGFR-1, EGFR and PIK3CA in canine 
MTC. The distinct mRNA expression profiles of FTC and MTC suggests these tumors 
probably arise from different molecular mechanisms. Moreover, the increased mRNA 
expression of the above mentioned genes indicates the involvement of the PI3K/Akt 
pathway in the pathogenesis of canine thyroid carcinoma and suggests this pathway 
may be activated. A recent study in canine FTC had already showed mRNA and 
protein expression of VEGFR-2 and phosphorylation (activation) of EGFR and RET, 
which are known to signal through the PI3K/Akt and MAPK pathways.
71
 Further 
research is needed to investigate if gene amplification or altered promoter activity is 
responsible for the increased mRNA expression of the genes found to be overexpressed 
in our investigation. 
Despite the overexpression of many PI3K/Akt related genes, the relative 
expression of COX-2 was not increased in canine thyroid tumors. Similar findings have 
been reported in follicular thyroid carcinoma in humans, where PI3K/Akt pathway 
activation is of major importance.
162
 This suggests that mRNA expression of COX-2 
may not reflect activation of PI3K/Akt signaling in thyroid cancer. Interestingly, our 
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immunohistochemical findings in chapter 5 clearly show expression of Cox-2 in 13% 
of FTCs and 50% of MTCs. 
PI3K/Akt pathway activation has been recently demonstrated in several of 
canine cancer cell lines, including canine lymphoma, hemangiosarcoma, mammary 
carcinoma, glioma and mastocytoma.
25
 The decreased tumor cell viability observed 
with PI3K and Akt inhibitors suggests that this signaling pathway is a promising 
therapeutic target in canine cancer.
25
 
Knowledge on the pathogenesis and biological behavior of canine thyroid 
cancer can also be obtained studying the association between tumor features (clinical, 
pathological, immunohistochemical) and patient outcome. Prognostic markers help 
ascertain which tumor characteristics are associated with more aggressive phenotypes 
providing valuable information to owners and clinicians. 
1.3  Prognostic markers 
In the research detailed in chapter 4, we performed an exploratory analysis 
investigating clinical, pathological and immunohistochemical prognostic markers in 50 
dogs with dFTC and 20 dogs with MTC. A subset of 44 dogs (28 dFTCs, 16 MTCs) 
treated with thyroidectomy was included in a survival analysis. 
One of the main goals of this investigation was to ascertain if there is a 
prognostic difference between canine dFTC and MTC following thyroidectomy. A 
previous study suggested that canine MTC may have a less malignant biological 
behavior with a higher rate of complete surgical excision and lower incidence of 
metastases at diagnosis compared to FTC.
4
 In agreement with this report, we found that 
MTC was less likely to be locally invasive at diagnosis. However, we found no 
difference in the incidence of metastatic disease at diagnosis and more importantly, 
after thyroidectomy the outcome was comparable between dogs with dFTC and MTC.  
In the study reported in chapter 4, the prevalence of hyperthyroidism in dogs 
with dFTC (28%) was similar to previous reports. It can be hypothesized that 
functional tumors (in dogs with hyperthyroidism or with preserved scintigraphic 
uptake) are more differentiated and, therefore, carry a better prognosis. However, 
patient thyroid function and tumor scintigraphic uptake had no significant effect on 
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outcome. These findings are in agreement with the study described in chapter 6, where 
hyperthyroidism also did not have a significant effect on survival of 23 dogs with 
thyroid tumors undergoing different treatment modalities. In humans, hyperfunctional 
thyroid carcinomas have a prevalence of only 1-2% and these scarce reports also 
suggest a comparable prognosis between hyperthyroid and euthyroid patients.
234-236
 
Macroscopic vascular invasion was negatively associated with OS and was an 
independent negative predictor for DFS. This is in agreement with earlier reports and is 
not surprising given the massive degree of neoplastic vessel infiltration necessary for 
macroscopic observation.
8
 In humans with FTC, extensive vascular invasion is rare and 
is also reported to carry a poor prognosis.
169
  
Histologic vascular invasion was negatively associated with TM and was an 
independent negative predictor for DFS. Our results are in agreement with an earlier 
study showing the prognostic value of histologic grade of malignancy in dogs with 
thyroid carcinoma.
41
 In that study, vascular invasion was one of the most important 
histologic criteria used for the overall grade of malignancy. In humans with FTC, 
histologic vascular invasion is also an independent predictor of cancer-related 
mortality.
170
 Our findings suggest that dogs with this histologic feature are at high risk 
for metastases after thyroidectomy and are, therefore, likely to benefit from intensive 
follow-up and adjunctive therapy. Further studies are needed to determine if post-
operative adjunctive therapy (eg, 
131
I, chemotherapy, levothyroxine) can improve the 
outcome of these patients.  
In humans, Ki-67 is associated with clinical stage and survival in both FTC 
and MTC.
59,172
 In our study, Ki-67 labeling index was positively associated with local 
invasiveness at diagnosis. However, our multivariate analysis showed that it was not 
independently associated with outcome following thyroidectomy. Although in humans 
loss of E-cadherin expression is also a negative prognosticator, we found no association 
between E-cadherin expression and local invasiveness/metastatic disease at diagnosis, 
or outcome following thyroidectomy.
55
  
Human thyroid cancer is poorly responsive to chemotherapy and the few 
studies evaluating its use in dogs with thyroid tumors also showed modest results.
237,238
 
Dogs with unresectable thyroid tumors had partial responses to doxorubicin and 
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cisplatin in 44-54% of cases however adjuvant chemotherapy after thyroidectomy did 
seem to improve survival.
45-48
 Chemotherapy is most effective against rapidly dividing 
tumor cells and in agreement with previous studies the overall mitotic index observed 
in our research (chapter 4) was very low.
7,149,150
 Together with our findings on P-gp 
expression (chapter 5), this may help to explain the moderate response of canine 
thyroid cancer to chemotherapy.
  
The newly identified prognostic factors provide relevant information and may 
help to adapt treatment and follow-up to patients’ risk. However, to present date no 
treatment has been shown to be effective for adjunctive therapy. Given the need to 
investigate new ways to optimize treatment of dogs with thyroid tumors, our following 
studies focused on new therapeutic targets (chapter 5), effect of levothyroxine therapy 
on patient survival (chapter 6) and on the safety and value of rhTSH to optimize 
123
I 
uptake (chapters 7, 8, 9). 
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2  TREATMENT OPTIMIZATION 
It is important to investigate new treatment modalities for the large number of 
dogs with unresectable thyroid tumors or distant metastases. Molecular targeted 
therapy, TSH suppression and the use of rhTSH to optimize 
131
I uptake are examples of 
treatment strategies which have allowed a significant improvement of the prognosis of 
human thyroid cancer and have not yet been adequately investigated in dogs. 
Research on the expression of therapeutic targets may lead to a better 
understanding of the pathogenesis of canine thyroid cancer and also to the development 
of new therapeutic approaches. The use of VEGF inhibitors, TKIs and Cox-2 inhibitors 
in human MTC are success examples of research in this field.  
In humans, the benefit of TSH-suppressive therapy is well established for 
high-risk patients with dFTC and for the past years the authors recommend it routinely 
in the treatment of canine FTC.
82
 In a small clinical study in dogs with bilateral thyroid 
tumors undergoing thyroidectomy, levothyroxine therapy was associated with a longer 
survival time. However, larger studies are needed to confirm these results.  
rhTSH stimulates the uptake of 
131
I in humans with dFTC and can be used to 
improve the efficacy of 
131
I therapy.
115
 Additionally, the use of rhTSH is associated 
with a lower 
131
I effective half-life and, consequently, lower exposure of blood and the 
whole-body to radiation, limiting radiation dose exposure.
114
 However, the use of 
rhTSH in dogs with thyroid cancer raises important safety issues because, in people, 
rhTSH causes expansion of primary thyroid tumors and thyroid tumor metastases.
138,139
 
Before evaluating the effect of rhTSH on 
131
I uptake in dogs with thyroid tumors it is 
important to ensure its safety evaluating its influence on thyroid gland volume and 
thyroid RAIU in healthy dogs. 
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2.1  Therapeutic targets 
In the study reported in chapter 5, the immunohistochemical expression of 
VEGF, p53, Cox-2 and P-gp was investigated in 54 canine FTCs and 20 canine MTCs.  
The high expression of VEGF in 80% of FTCs and all MTCs suggests VEGF 
may play an important role in the pathogenesis of these highly vascularized tumors. 
Consequently, the VEGF system seems to be an attractive target for the treatment of 
both FTC and MTC in dogs. In human thyroid carcinoma, expression of VEGF is also 
upregulated.
66,67,239,240
 Recently, VEGF-inhibitors (eg, cetuximab, thalidomide, 
lenalidomide) and TKIs that block VEGFR (eg, vandetanib, sunitinib) have shown 
promising antitumor activity in the treatment of radioiodine-refractory FTC, advanced 
MTC, and undifferentiated thyroid carcinoma in humans.
30,161,241
 In a preliminary study 
in dogs with solid tumors, a multitargeted TKI (toceranib phosphate) targeting 
VEGFR-2, induced partial remission in 4 of 15 dogs, and stable disease in 8 of the 15 
dogs with thyroid carcinoma.
62
 It has been suggested that the clinical response of 
canine thyroid carcinomas to toceranib phosphate may result from inhibition of RTKs 
on tumor-supporting vasculature and stroma, rather than on tumor cells.
71
 Our results 
indicate that there is an overexpression of VEGF in these tumors capable of a paracrine 
stimulation of VEGF receptors on stromal endothelial cells.  
In chapter 3 we demonstrate the increased expression of VEGFR-2 mRNA in 
canine FTC. Immunohistochemical expression of this receptor had already been shown 
in canine FTC cells.
71
 Combining these findings with the observed overexpression of 
VEGF in canine FTC (chapter 5), there is enough evidence to suggest that VEGF may 
also have an autocrine action on canine FTC cells, stimulating tumor cell growth. On 
the one hand, this autocrine stimulation could be partially responsible for the 
involvement of PI3K/Akt signaling pathway in canine FTC, observed in chapter 3. On 
the other hand, PI3K/Akt pathway signaling can also induce VEGF expression.
242
  
VEGF is the most important stimulator of angiogenesis in the thyroid gland 
and tumor angiogenesis can also be targeted with continuous low-dose (metronomic) 
chemotherapy.
243
 A preliminary study on the effect of metronomic chemotherapy with 
chlorambucil in different canine tumors showed complete remission in the only dog 
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with thyroid carcinoma.
61
 This report is encouraging and larger studies are needed to 
further evaluate the value of metronomic chemotherapy in the treatment of canine 
thyroid tumors. 
In our study, no tumor expressed p53 protein. A low prevalence of p53 
expression was expected because p53 mutation only was found in 1 of 23 canine FTCs 
in a study examining part of the coding region of this gene.
27
 In humans, p53 mutations 
have been described in 40-62% of undifferentiated thyroid carcinomas but only in 5-
10% of other thyroid carcinomas.
26
 Our research suggests that p53 tumor suppressor 
gene does not play a major role in canine thyroid gland tumorigenesis and does not 
seem to be a realistic therapeutic target for most cases of canine thyroid carcinoma.  
In chapter 5 we report Cox-2 expression in 50% of MTCs and in 13% of 
FTCs. The higher prevalence of Cox-2 expression in MTC is in agreement with reports 
in humans, where 26-41% of FTCs and 75-82% of MTCs have been shown to express 
Cox-2.
184
 In a study investigating Cox-2 expression in canine invasive transitional cell 
carcinoma of the urinary bladder, the percentage of positive tumor cells in each tumor 
ranged from 1 to 22%, comparable to that found in our study.
185
 Interestingly, in that 
study no association was found between the level of Cox-2 immunolabeling and tumor 
remission with piroxicam. This suggests that clinical benefit may be observed even in 
cases of low Cox-2 expression. Our results suggest that Cox-2 is an interesting 
molecular target for the treatment of canine thyroid carcinoma, particularly MTC. 
In contrast to our immunohistochemical findings, mRNA expression levels of 
COX-2 were not increased in canine thyroid carcinoma (chapter 3). This discordance 
was an interesting finding and can have several explanations. Firstly, Cox-2 
immunolabeling was heterogeneous and while immunohistochemistry allows the 
evaluation of protein expression a large section of the tumor, mRNA expression is only 
analyzed in a small tumor fragment. Secondly, posttranscriptional factors (eg, rapid 
mRNA degradation, increased protein half-life) are also likely to play a role. In a large 
study in human lung cancer it was demonstrated that a correlation between protein and 
mRNA expression was only present in 21 of 98 genes.
244
 A similar lack of correlation 
between protein and mRNA expression has also been reported for NIS in human 
thyroid nodules.
245
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P-gp expression was observed in 7% of FTCs and 70% of MTCs which could 
explain multi-drug resistance in canine MTC. Literature on the expression of P-gp in 
human thyroid carcinoma is scarce. Human MTC is refractory to conventional 
chemotherapy yielding partial responses in only 10 to 20% of patients.
187
 Experimental 
evidence suggests that multi-drug resistance is one of the mechanisms responsible for 
this highly chemoresistant phenotype and that by targeting P-gp, chemoresistance can 
be reversed.
79,186
 Our study suggests that P-gp is an interesting molecular target for the 
treatment of canine MTC. Inhibition of P-gp with specific P-gp inhibitors (eg, 
verapamil) or TKIs could increase tumor sensitivity to chemotherapy and improve 
patient outcome. It must be kept in mind, however, that there is a multitude of other 
ABC transporters (eg, ABCC1, ABCG2) which can be expressed by cancer cells and 
that inhibition of P-gp alone, might not suffice to reverse multi-drug resistance.
246
 
The higher expression of Cox-2 and P-gp in MTC is in agreement with clinical 
and experimental studies in human thyroid cancer. In fact, there is evidence of a direct 
causal relationship between Cox-2 expression and P-gp regulation. Overexpression of 
Cox-2 leads to increased expression and function of P-gp in a dose-dependent manner 
and this effect can be blocked by specific Cox-2 inhibitors.
188
 In an in vivo model of 
human colorectal cancer, Cox-2 expression was correlated with chemoresistant 
phenotype, and the most tumor regression was achieved with a combination of Cox-2 
inhibitors and chemotherapy.
189
 Although a direct correlation between P-gp and Cox-2 
expression was not observed in our investigation, P-gp inhibition could represent an 
additional therapeutic effect of the use of Cox-2 inhibitors in dogs with MTC.  
In short, the research expounded in chapter 5 suggested that the VEGF 
system is an attractive therapeutic target for canine FTC and MTC and that Cox-2 and 
P-gp are interesting molecular targets for the treatment of canine MTC. We pursued 
our research on treatment optimization investigating the effect of levothyroxine therapy 
and TSH suppression on survival of dogs with thyroid tumors.. 
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2.2  Levothyroxine therapy 
In the investigation described in chapter 6, we investigated the effect of 
levothyroxine therapy on outcome of 42 dogs with thyroid tumors undergoing different 
treatment modalities. 
Our study failed to demonstrate that levothyroxine therapy and TSH 
suppression provide a survival benefit to dogs with thyroid tumors. This is in 
disagreement with a recent report in 15 dogs with bilateral thyroid tumors showing a 
significantly longer survival for the dogs that received levothyroxine therapy after 
thyroidectomy.
48
 The cause for the disparity of results between these studies is unclear. 
Although in our study the proportion of dogs with bilateral thyroid tumors was 
significantly higher in the group receiving levothyroxine, bilateral disease was not a 
prognostic factor. 
It is possible that the lack of effect of levothyroxine therapy observed in our 
research is related to an insufficient power. Although our sample size is small, our 
study is the largest in veterinary medicine evaluating levothyroxine therapy in dogs 
with thyroid tumors. Thyroid cancer is not common in dogs and studies with a much 
larger number of patients are difficult.  
It is also possible that the lack of clinical benefit of levothyroxine therapy in 
our research is due to an overall insufficient degree of TSH suppression in the patients 
receiving levothyroxine. On the one hand, TSH suppression as defined in our study 
could only be confirmed during follow-up in 5 of 21 patients receiving levothyroxine. 
On the other hand, the ideal target level of TSH suppression in dogs with thyroid 
tumors is not currently known. In humans, the ideal level of TSH suppression in 
patients with FTC is a topic of debate and, at present, it is recommended to adapt the 
target level of TSH suppression to the patients’ risk for tumor recurrence and mortality 
based on prognostic factors.
83
 However, the high sensitivity of human TSH assays 
allows targeting TSH concentrations to a level that is far below the detection limit of 
the current canine TSH assays. Further research is warranted to investigate if TSH-
suppressive therapy is beneficial to dogs with FTC and to determine the adequate level 
of TSH suppression in these patients. 
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Our interest in levothyroxine therapy also resulted from its wide availability, 
relative low cost and potential benefit to all dogs with FTC, independently of the 
primary treatment modality. However, we also intended to investigate new ways to 
improve the treatment of dogs with unresectable thyroid tumors specifically. Hence, in 
our final investigations (chapters 7, 8, 9) we focused on the use of rhTSH to optimize 
131
I therapy. 
2.3  Safety of rhTSH 
In the study reported in chapter 7, rhTSH (100 µg) showed no significant 
effect on thyroid gland volume in healthy Beagles for 48h after injection. These results 
contrast with what has been found in healthy humans, where thyroid gland volume 
increased by 10% 48 hours after rhTSH (100 µg) injection.
137
 In another study in 
healthy humans, a higher dose (900 µg) of rhTSH led to an increase of 23% in thyroid 
gland volume at 24 hours and 35% at 48 hours.
136
 A dose effect could explain these 
different results. In our research, we used 100 µg of rhTSH because this dose is 
considered appropriate for stimulation of thyroid function in dogs weighing more than 
20 kg.
200
 If the effect of rhTSH on thyroid gland volume is dose dependent, a volume 
change could be observed at higher doses.  
Although our results cannot be extrapolated to dogs with thyroid carcinoma, 
this preliminary data does not suggest that rhTSH induces swelling or edema of the 
canine thyroid gland at the dosage used. Still, rhTSH must be used with caution in 
thyroid carcinoma patients, especially in dogs with bulky thyroid masses, respiratory or 
central nervous system metastases.  Pretreatment with glucocorticoids should be 
considered if tumor expansion would lead to unacceptable complications.  
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2.4  Optimization of 
131
I therapy 
After completing a pilot study in healthy Beagles (chapter 8) we investigated 
the effect of rhTSH (100 μg) on the uptake of 123I in 9 dogs with thyroid tumors 
(chapter 9). 
 In these studies, rhTSH (100 μg) caused no significant change in thyroid 
RAIU. Our results contrast with earlier reports suggesting that exogenous TSH can 
increase thyroid RAIU in dogs.
53,129,130
 However, in these studies the effect of TSH 
stimulation on thyroid 
131
I uptake was described in a small number of healthy and 
hypophysectomized dogs and no statistical analysis was performed. In a recent study, 
our group demonstrated that rhTSH can cause a small but statistical significant increase 
in thyroid RAIU in hyperthyroid cats.
131
 In healthy humans, TSH stimulation with a 
protocol similar to the one used in our research was shown to approximately double 
thyroid RAIU.
137
 
The significant increase in TT4 plasma concentrations 6 h after rhTSH 
injection confirmed the biological activity of rhTSH in our investigations. Therefore, 
the inconsistent effect of rhTSH on thyroid tumor RAIU raises important questions 
regarding dosage, route and timing of rhTSH administration, which are already 
discussed in detail in chapter 9. 
The observed correlation between the effect of rhTSH on thyroid tumor RAIU 
and rhTSH plasma concentrations suggests that higher doses of rhTSH may allow a 
more consistent increase thyroid tumor RAIU and it is interesting to note that all dogs 
achieving rhTSH plasma concentrations > 30 mIU/mL 6 h post-injection had an 
increased thyroid tumor RAIU with rhTSH. In humans, high doses of rhTSH (2x900μg 
IM 24 h apart) are used to stimulate NIS in normal and neoplastic thyroid tissue. 
However, the use of these dosages in dogs may not be realistic given the high costs 
involved. Further studies are necessary to evaluate if higher doses of rhTSH allow an 
increased radioiodine uptake in dogs with FTC. 
 The significantly different effect of rhTSH on thyroid tumor RAIU between 
euthyroid and hyperthyroid patients was an interesting finding. In a study of 55 dogs 
with thyroid tumors, dogs with evidence of autonomous hyperfunction of the tumor had 
General Discussion 
179 
an increased thyroidal iodine turn-over.
53
 It is possible that a positive effect of rhTSH 
on tumor RAIU occurs sooner in hyperthyroid patients and was, therefore, not 
observed with our protocol (RAIU determination 8 h and 24 h after 
123
I). On the other 
hand, the lack of effect of rhTSH in hyperthyroid patients may be caused by decreased 
thyroid functional reserve. This seems, however, less likely because in hyperthyroid 
cats a significant increase in thyroid RAIU is observed after rhTSH administration.
131
 
Future studies should evaluate the effect of rhTSH on thyroid tumor RAIU separately 
in euthyroid and hyperthyroid dogs because the timing of radioiodine injection and 
RAIU determination may need to be adjusted in the latter group.  
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3  CONCLUSIONS 
The general aim of our research was to provide insight into the pathogenesis 
and treatment of canine thyroid tumors. For this purpose we investigated mutational 
hotspots, mRNA expression of PI3K/Akt pathway-related genes, prognostic markers, 
therapeutic targets, levothyroxine therapy and optimization 
123
I uptake with rhTSH. 
The main conclusions of our research are: 
1. K-RAS missense mutations were identified in 2% of FTCs and 6% of MTCs. The 
mutations most frequently associated with thyroid gland tumorigenesis in humans 
are rare in canine thyroid carcinoma.  
2. mRNA expression levels of VEGFR-1, VEGFR-2, PDPK-1, AKT1 and AKT2 
were increased in canine FTC and those of VEGFR-1, EGFR and PIK3CA were 
increased in canine MTC, showing the involvement of the PI3K/Akt pathway in 
the pathogenesis of canine thyroid carcinoma, particularly in FTC. 
3. The VEGF system is an attractive target for the treatment of both FTC and MTC 
in dogs; Cox-2 and P-gp seem to be interesting molecular targets for the treatment 
of canine MTC.  
4. In dogs with surgically excised thyroid carcinoma, macroscopic or histologic 
evidence of vascular invasion are independent negative predictors for DFS. dFTC 
and MTC have comparable prognosis following thyroidectomy. 
5. According to our investigation in a limited number of patients, levothyroxine 
therapy does not seem to improve survival of dogs with thyroid tumors. 
6. rhTSH (100 μg) causes no significant change in thyroid gland volume, 
echogenicity or homogeneity in healthy dogs. 
7. rhTSH (100 μg) administered IV 24 h before 123I has no significant effect on 
thyroid RAIU in dogs with thyroid tumors or in healthy dogs. The observed 
correlation between the effect of rhTSH on tumor RAIU and rhTSH plasma 
concentrations suggests that higher dosages of rhTSH may be necessary.  
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4  FUTURE DIRECTIONS 
 Our research described in chapter 3 identifies 2 K-RAS mutations likely to be 
involved in thyroid gland tumorigenesis in dogs and indicates that the PI3K/Akt 
signaling pathway is implicated in the pathogenesis of canine thyroid carcinoma, 
particularly in FTC. Further research is needed to clarify the genetic pathogenesis of 
canine thyroid cancer.  
Gene amplification could be an important genetic alteration in canine thyroid 
cancer. To investigate if this genetic event is responsible for the increased mRNA 
expression levels of several genes observed in chapter 3, future studies should evaluate 
copy number gain in these genes. This can be accomplished performing qPCR in 
genomic DNA. It would also be interesting to completely sequence the candidate genes 
selected in our research to definitively rule out point mutations in these genes. 
Furthermore, to truly investigate PI3K/Akt and MAPK pathway activation, western 
blot or immunohistochemistry should be performed on frozen tumor samples to 
evaluated phosphorylation of pathway effectors. The complete coding region of the 
genes involved in the activated pathway(s) should then be sequenced to search for point 
mutations. Other important investigations include evaluation of gene rearrangement 
with fluorescent in-situ hybridization (FISH) and more comprehensive approaches such 
as GWAS, next-generation sequencing and whole exome sequencing.  
In chapter 5 we suggest that the VEGF system is an attractive target for the 
treatment of both FTC and MTC in dogs, and that Cox-2 and P-gp are interesting 
molecular targets for the treatment of canine MTC. VEGFR-2 can be targeted with 
TKIs, Cox-2 can be targeted with Cox-2 inhibitors and P-gp can be targeted with 
specific P-gp inhibitors, Cox-2 inhibitors or TKIs. The clinical benefit of TKIs in 
canine FTC has already been shown.
62
 However, further research is needed to 
investigate the value of TKIs, Cox-2 inhibitors and specific P-gp inhibitors in the 
treatment of canine MTC.  
Although we could not demonstrate a clinical benefit of levothyroxine therapy 
in dogs with thyroid tumors (chapter 6), the value of TSH suppression is well 
established in humans with high-risk dFTC. Prospective and randomized clinical 
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studies with follow-up of TSH levels are needed to investigate if TSH suppression is 
beneficial in dogs with thyroid tumors.  
In humans, thyroid remnant ablation with 
131
I is a routine component of the 
treatment of FTC. 
131
I remnant ablation is associated with decreased recurrence and 
disease-specific mortality, and allows using Tg plasma concentrations during follow up 
as a very specific marker for tumor recurrence and metastatic disease.
3
 Although this 
was not the focus of our research, future studies should evaluate the value of adjuvant 
131
I therapy after thyroidectomy in dogs with FTC.  
In chapter 4, we show that macroscopic and histologic evidence of vascular 
invasion are independent negative predictors for DFS. Patients with these features seem 
to be at high risk for metastatic disease and death after thyroidectomy and are likely to 
benefit from intensive follow-up and additional therapy. Future studies on adjuvant 
treatment (eg, 
131
I, chemotherapy, levothyroxine therapy) should probably focus on this 
high-risk group.  
In the investigation described in chapters 9, rhTSH did not cause a significant 
increase thyroid tumor RAIU. However, the correlation observed between the effect of 
rhTSH on tumor RAIU and rhTSH plasma concentrations achieved after injection 
suggests that in future clinical studies higher dosages should be investigated. 
Additionally, repetitive stimulation with rhTSH (2x 24 h apart) could also be explored. 
Furthermore, the observed difference between the effect of rhTSH on tumor RAIU in 
euthyroid and hyperthyroid dogs suggests that future studies should probably evaluate 
these patients separately and that the timing of rhTSH administration and RAIU 
determination may need to be adjusted in the latter group due to increased thyroidal 
iodine turn-over in those patients. 
In our research, we could not evaluate the effect of diet iodine content on 
thyroid RAIU because it could interfere with the effect of rhTSH. In human medicine, 
patient preparation for 
131
I therapy includes a low-iodine diet for 2 weeks.
247
 Low-
iodine diet increases thyroid RAIU in healthy dogs and may be a cost-effective 
additional tool to the use of rhTSH to optimize 
131
I uptake in dogs with thyroid 
tumors.
248
 Clinical studies are needed to evaluate the effect of iodine-restricted diet on 
131
I uptake in dogs with thyroid tumors. 
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131
I therapy takes advantage of the unique iodide-handling machinery of 
thyroid follicular cells to trap and organify 
131
I. However, humans and dogs with 
thyroid cancer commonly present with iodine non-avid disease which is main cause of 
thyroid cancer-associated morbidity and mortality in humans.
249
 The loss of the ability 
of thyroid cancer cells to take up and concentrate 
131
I results from an impaired 
expression of iodide-handling genes and aberrant localization of NIS.
250
 Recent studies 
have shown that activation of the PI3K/Akt and MAPK signaling pathways is involved 
in the silencing of thyroid iodide-handling genes and that inhibitors of these signaling 
pathways can restore the ability of thyroid cancer cells to take up radioiodine.
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Given that canine and human FTC are remarkably similar, the dog could potentially 
serve as a model for clinical research in the capability of these drugs to restore 
131
I 
uptake in patients with FTC. 
 Our research aimed to provide information on the molecular pathogenesis of 
canine thyroid cancer and identified valuable prognostic markers that can be used to 
tailor follow-up and adjunctive therapy to patients’ risk. The newly identified 
therapeutic targets are easy to detect with immunohistochemistry and open the door to 
personalized medicine in canine thyroid cancer. Although we could not demonstrate a 
survival benefit with levothyroxine therapy or an improved tumor 
131
I uptake with 
rhTSH, our findings form a base for further research. Future challenges include 
pursuing the main genetic events leading to canine thyroid cancer, exploring clinically 
the molecular targets identified in our research, investigating adjuvant therapy (eg, 
131
I, 
chemotherapy, TSH suppression) with randomized prospective studies and continuing 
searching for ways to optimize 
131
I therapy. 
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In the past decade, major advances have been made in unveiling the molecular 
pathogenesis of human thyroid cancer. The PI3K/Akt pathway is the major signaling 
pathway involved in human follicular thyroid carcinoma which is remarkably similar in 
terms of histology and biological behavior to canine differentiated follicular cell 
thyroid carcinoma (dFTC). The discovery of the main genetic events involved in 
thyroid gland tumorigenesis in humans led to the discovery of new molecular targets 
and to the development of innovative treatments. Furthermore, stratification of patient 
risk with prognostic markers, TSH-suppressive therapy and increased 
131
I uptake with 
rhTSH, have allowed a significant improvement of the treatment of human dFTC and 
provide an interesting perspective for optimization of treatment of canine dFTC. 
The molecular pathogenesis and expression of therapeutic targets in canine 
thyroid cancer are largely unknown and, to present date, research on prognostic 
markers and treatment optimization remains scarce. Up to 38% of dogs with thyroid 
cancer have metastases at the time of diagnosis and almost half of dogs treated with 
thyroidectomy develop recurrent or metastatic disease within 2 years of surgery. Given 
the modest results of chemotherapy, it is imperative to investigate new ways to 
improve treatment. The general aim of this research was to provide new insights into 
the pathogenesis and treatment of canine thyroid cancer.  
In our 2 first studies we focused on the pathogenesis of canine thyroid cancer 
investigating genetic alterations and prognostic markers. In our first study (chapter 3) 
we try to unveil the molecular pathogenesis of canine thyroid cancer by investigating 
mutational hotspots and mRNA expression of candidate genes in 43 canine follicular 
cell thyroid carcinomas (FTCs) and 16 canine medullary thyroid carcinomas (MTCs). 
Mutation analysis of known hotspots of RAS (H, K, H), PIK3CA, BRAF, RET and of 
the entire coding region of PTEN, revealed 2 activating missense mutations in K-RAS, 
also described in human thyroid cancer. A G12R substitution was present in 1 FTC and 
an E63K substitution was present in 1 MTC. No functional mutations were found in the 
sequenced regions of H-RAS, N-RAS, PIK3CA, BRAF, RET and PTEN demonstrating 
that the mutations most frequently associated with human thyroid neoplasia are rare in 
canine thyroid cancer.  
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Quantitative RT-PCR was performed for selected receptor tyrosine kinases 
(RTKs) (VEGFR-1, VEGFR-2, EGFR) and PI3K/Akt pathway members (PIK3CA, 
PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-2) known to be commonly amplified in 
human thyroid cancer. The mRNA expression levels of VEGFR-1, VEGFR-2, PDPK1, 
AKT1, and AKT2 were increased in FTC, and those of EGFR, VEGFR-1, and PIK3CA 
were increased in MTC when compared to normal thyroid. The increased mRNA 
expression of these genes indicates the involvement of the PI3K/Akt signaling pathway 
in the pathogenesis of canine thyroid cancer, particularly in FTC. Further research is 
necessary to investigate if gene amplification is responsible for the increased mRNA 
expression of these genes. 
Given the lack of prognostic factors for dogs with operable thyroid tumors, in 
our second study (chapter 4) we investigated clinical, pathological and 
immunohistochemical prognostic factors in 50 dogs with dFTC and 20 dogs with MTC. 
In this retrospective study, IHC for calcitonin, Ki-67 and E-cadherin was performed in 
all tumor samples and tumor features (diameter, volume, localization, scintigraphic 
uptake, thyroid function, IHC) were correlated with local invasiveness and metastatic 
disease at diagnosis. Furthermore, 44 dogs (28 dFTCs, 16 MTCs; stage I-III) treated by 
thyroidectomy were included in a survival analysis. In agreement with a previous 
report, we found that MTC was significantly less likely to be locally invasive at 
diagnosis. However, we found no difference in the incidence of metastatic disease at 
the time of diagnosis and, more importantly, following thyroidectomy outcome was 
comparable between dogs with dFTC and MTC. Macroscopic and histologic vascular 
invasion were independent negative predictors for disease-free survival. In contrast 
with human reports, E-cadherin expression was not associated with outcome.  
The newly identified prognostic factors provide relevant information for 
owners and clinicians and may help to adapt follow-up and adjunctive therapy to the 
patients’ risk. However, to present date no single treatment modality has been shown to 
be effective for adjunctive therapy. Given the need to investigate new ways to improve 
treatment our following studies focused on treatment optimization, namely on new 
therapeutic targets (chapter 5), effect of levothyroxine therapy on patient survival 
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(chapter 6) and on the safety and value of rhTSH to optimize 
123
I uptake in dogs with 
thyroid tumors (chapters 7, 8, 9). 
In the study reported in chapter 5 we investigated the expression of potential 
therapeutic targets in 54 canine FTCs and 20 canine MTCs. For this purpose, we 
performed IHC for vascular endothelial growth factor (VEGF), p53, cyclooxygenase-2 
(Cox-2) and P-glycoprotein (P-gp) in all tumor samples. 80% of FTCs and all MTCs 
had a high percentage (76-100%) of neoplastic cells immunopositive for VEGF, 
suggesting it may play an important role in the pathogenesis of these highly 
vascularized tumors. Consequently, the VEGF system seems to be an attractive target 
for the treatment of both FTC and MTC in the dog. 13% of FTCs and 50% of MTCs 
expressed Cox-2, and 7% of FTCs and 70% of MTCs expressed P-gp, which suggests 
these could be interesting molecular targets for the treatment of canine MTC. No tumor 
was immunopositive for p53 expression.  
Pursuing our research on treatment optimization (chapter 6), we investigated 
the effect of levothyroxine therapy and TSH suppression (TSH < 0.1 ng/mL) on 
survival of 42 dogs with thyroid tumors undergoing different treatment modalities. In 
this retrospective study, dogs were grouped according to treatment as follows: 
thyroidectomy with or without levothyroxine therapy (n=17); radioactive iodine-131 
with or without levothyroxine therapy (n=11); no treatment or levothyroxine therapy 
alone (n=14). Although we could not demonstrate that levothyroxine therapy or TSH 
suppression improve patient survival, randomized clinical studies are needed. 
rhTSH may allow a significant optimization of 
131
I therapy in dogs with 
thyroid cancer. However, if as in humans rhTSH leads to an increase in thyroid gland 
volume it must be used carefully in dogs with large thyroid tumors or distant 
metastases to avoid compression of key anatomical structures. Therefore, we first 
evaluated the short-term effect of rhTSH on thyroid gland volume and echogenicity, 
measured by ultrasonography, in 7 healthy Beagles (chapter 7). In this prospective 
blinded cross-over study, a single observer evaluated thyroid echogenicity, 
homogeneity, shape, capsule delineation, and measurement of thyroid length, width 
and height at baseline, and at 6, 24 and 48h after injection of rhTSH (100 µg IV) or 
placebo. rhTSH had no significant effect on thyroid gland volume, echogenicity, 
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homogeneity or capsule delineation and no adverse effects were noticed. Although 
these results could not be extrapolated to dogs with thyroid tumors, this preliminary 
data did not suggest that rhTSH induced swelling or edema of the canine thyroid gland 
at the dosage used.  
After concluding a pilot study (chapter 8) on the effect of rhTSH on thyroid 
scintigraphy in healthy Beagles we investigated the effect of rhTSH on the uptake of 
123
I in 9 dogs with thyroid tumors (chapter 9). In this prospective cross-over study, 
rhTSH (100 μg) administered IV 24 h before 123I (37 MBq IV) caused no significant 
change on thyroid tumor radioactive iodine uptake (RAIU) at 8 h or at 24 h. 
Interestingly, a significant positive correlation was found between the effect of rhTSH 
on tumor 8h-RAIU and rhTSH serum concentrations 6 h, 12 h and 24 h after rhTSH 
administration, suggesting that higher dosages of rhTSH may be necessary. Further 
studies are needed to determine the best protocol of rhTSH administration to optimize 
thyroid tumor RAIU. 
Our research starts to uncover the pathogenesis of canine thyroid cancer 
identifying 2 activating mutations in K-RAS and showing the involvement of the 
PI3K/Akt pathway, particularly in FTC. The prognostic markers found in our research 
provide relevant information to owners and clinicians, and could be used to adapt 
follow-up and adjunctive therapy to each patient’s risk. The newly identified 
therapeutic targets are easily detectable with immunohistochemistry and open the 
possibility of personalized medicine. Although we could not demonstrate an improved 
survival with levothyroxine therapy or an enhanced tumor 
123
I uptake with rhTSH, 
further research is necessary. Future challenges include pursuing the main genetic 
events leading to canine thyroid cancer, performing clinical trials to further explore the 
molecular targets identified in our research, and continuing to search for ways to 
optimize 
131
I therapy and improve patient outcome. 
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De afgelopen tien jaar is er enorme vooruitgang geboekt in het ontrafelen van 
de moleculaire pathogenese van schildklierkanker bij de mens. Bij de humane 
folliculaire schildklierkanker, die op vlak van histologie en biologisch gedrag veel 
gelijkenissen vertoont met de gedifferentieerde folliculaire-cel schildklierkanker 
(dFTC) bij de hond, is de PI3K/Akt route de belangrijkste signaalweg, De ontdekking 
van de belangrijkste genetische processen in het ontstaan van humane 
schildkliertumoren ging gepaard met nieuwe moleculaire doelwitten en met de 
ontwikkeling van innovatieve behandelingen. Bovendien heeft een betere inschatting 
van het patiëntrisico met behulp van prognostische merkers, TSH-suppressieve therapie 
en toegenomen opname van 
131
I met behulp van rhTSH, gezorgd voor een duidelijke 
verbetering van de behandeling van humaan dFTC. Dit levert belangrijke nieuwe 
perspectieven ter optimalizatie van de behandeling van caniene FTC.  
De moleculaire pathogenese en expressie van therapeutische doelwitten bij caniene 
schildkliertumoren zijn nog grotendeels onbekend en, tot op heden, is onderzoek naar 
prognostische merkers en optimalisatie van de behandeling schaars. Tot 38% van de 
honden met schildklierkanker heeft uitzaaiingen op het tijdstip van diagnose en bijna 
de helft van de honden recidiveren of ontwikkelen uitzaaiingen binnen de 2 jaar na 
thyroïdectomie. Omwille van de teleurstellende resultaten met chemotherapie, is verder 
onderzoek naar nieuwe mogelijkheden om de behandeling te verbeteren noodzakelijk. 
De algemene doelstelling van dit onderzoek was het verkrijgen van inzichten in de 
pathogenese en behandeling van schildklierkanker bij de hond.  
In de eerste 2 studies werd ingegaan op de pathogenese van caniene 
schildklierkanker door het onderzoeken van genetische veranderingen en prognostische 
merkers. De moleculaire pathogenese werd bestudeerd in onze eerste studie (hoofdstuk 
3) door “hotspots” voor mutaties en mRNA expressie van kandidaat genen te 
onderzoeken bij 43 honden met FTC (73%) en 16 honden met medullaire 
schildklierkanker (MTC) (27%). Mutatie analyse in gekende hotspots van RAS (H, K, 
H), PIK3CA, BRAF, RET en in de volledige coderende regio van PTEN, toonde 2 
activerende missense mutaties in K-RAS, die ook beschreven zijn bij schildklierkanker 
bij de mens. Een G12R substitutie was aanwezig in 1  FTC, en een E63K substitutie 
was aanwezig in 1 MTC. Functionele mutaties werden niet gevonden in de regio’s van 
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H-RAS, N-RAS, PIK3CA, BRAF, RET en PTEN die gesequenced werden. Dit toont aan 
dat mutaties die frequent voorkomen bij humane schildklierkanker eerder zeldzaam 
zijn bij caniene schildklierkanker. Kwantitatieve RT-PCR werd uitgevoerd voor een 
selectie van tyrosine kinase receptoren (VEGFR-1, VEGFR-2, EGFR) en onderdelen 
van de PI3K/Akt signaalweg (PIK3CA, PIK3CB, PDPK1, PTEN, AKT1, AKT2, COX-
2), waarvan de expressie toeneemt tgv gen amplificatie (toename van het aantal genen) 
bij humane schildklierkanker. In vergelijking met de normale schildklier was er een 
verhoogde mRNA expressie van VEGFR-1, VEGFR-2, PDPK1, AKT1 en AKT2 in 
FTCs en van EGFR, VEGFR-1 en PIK3CA in MTCs. De verhoogde mRNA expressie 
van deze genen wijst op betrokkenheid van de PI3K/Akt signaalweg in de pathogenese 
van schildklierkanker bij de hond, voornamelijk bij FTCs. Verder onderzoek is 
noodzakelijk om na te gaan of gen amplificatie verantwoordelijk is voor deze 
verhoogde expressie.  
Het gebrek aan prognostische merkers voor honden met operabele 
schildkliertumoren, leidde tot een tweede studie (hoofdstuk 4) waarin zowel klinische, 
pathologische als immunohistochemische (IHC) prognostische factoren bij 50 honden 
met dFTC en 20 honden met MTC werden onderzocht. In deze retrospectieve studie 
werd IHC voor calcitonine, Ki-67 en E-cadherine toegepast op alle tumor stalen. 
Verschillende tumor variabelen (diameter, volume, locatie, opname tijdens scintigrafie, 
schildklierfunctie, IHC) werden gecorreleerd aan het lokaal invasief karakter en de 
aanwezigheid van metastasen op het moment van diagnose. Daarnaast werd de 
overleving na thyroïdectomie geanalyseerd bij 44 honden (28 dFTCs, 16 MTCs, stage 
I-III). De MTCs waren significant minder lokaal invasief op het moment van diagnose, 
wat overeenkmot met een eerder verschenen studie. Er werd geen verschil 
waargenomen tussen dFTC en MTC in het initieel voorkomen van metastasen en, nog 
belangrijker, de uitkomst na thyroïdectomie was vergelijkbaar voor beide tumoren. 
Macroscopisch en histologisch vastgestelde vasculaire invasie waren onafhankelijke 
negatieve prognostische factoren voor ziekte-vrije overleving. In tegenstelling tot 
humane studies, was er geen associatie tussen E-cadherine expressie en prognose. 
Deze nieuwe prognostische merkers verstrekken potentieel interessante 
informatie voor eigenaars en clinici omdat ze de mogelijkheid bieden om de opvolging 
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en bijkomende behandeling aan te passem aan het risico van de patiënt. En moet wel 
gezegd worden dat tot op vandaag, er van geen enkele bijkomende behandeling een 
bijkomend effect kon aangetoond worden. Gezien de nood aan nieuwe therapeutische 
opties, concentreerden onze volgende studies zich op de behandeling, met name op het 
bestuderen van nieuwe therapeutische doelwitten (hoofdstuk 5), van de invloed van 
levothyroxine toediening op de overleving van de patiënt (hoofdstuk 6) en van de 
veiligheid en waarde van rhTSH om de 
123
I opname bij honden met schildklierkanker te 
verbeteren (hoofdstukken 7, 8, 9). 
In hoofdstuk 5 werd de expressie van potentiële therapeutische doelwitten bij 
54 caniene FTCs en 20 caniene MTCs onderzocht. In deze tumor stalen werd IHC 
uitgevoerd voor “vascular endothelial growth factor” (VEGF), p53, cycloxygenase-2 
(Cox-2) en P-glycoproteïne (P-gp). 80% van de FTCs en alle MTCs toonde een zeer 
hoog percentage (76-100%) VEGF immunopositieve cellen, wat op een mogelijke rol 
voor VEGF in de pathogenese van deze sterk gevasculariseerde tumoren kan wijzen. 
Het VEGF systeem lijkt dan ook een interessant doelwit voor de behandeling van 
zowel FTCs als MTCs bij de hond. Cox-2 expressie werd waargenomen in 13% van de 
FTCs en 50% van de MTCs, en P-gp expressie in 7% van de FTCs en 70% van de 
MTCs wat suggereert dat dit aantrekkelijke moleculaire doelwitten kunnen zijn voor de 
behandeling van caniene MTCs. Geen enkele tumor was immunopositief voor p53.    
Als verdere stap om de optimalisatie van de behandeling te onderzoeken 
(hoofdstuk 6) werd het effect van levothyroxine behandeling en TSH onderdrukking 
(TSH<0.1ng/mL) op de overleving bestudeerd bij 42 honden met schildkliertumoren 
die verschillende types behandeling ondergingen. In deze retrospectieve studie werden 
honden onderverdeeld in 3 groepen naargelang hun behandeling: thyroïdectomie met of 
zonder levothyroxine supplementatie (n=17); radiojood-131 (
131
I) behandeling met of 
zonder aanvullende levothyroxine toediening (n=11); geen behandeling of enkel 
levothyroxine toediening (n=14). Een gunstig effect van levothyroxine toediening op 
de overleving kon niet worden aangetoond. Bijkomende prospectieve, gerandomiseerde 
studies zijn echter nodig om hierover definitief uitsluitsel te geven.  
In de volgende hoofdstukken werd nagegaan of het gebruik van rhTSH de 
131
I 
behandeling van honden met schildklierkanker kan optimalizeren. Indien rhTSH 
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toediening echter, net zoals bij mensen, leidt tot een toename in het schildkliervolume, 
is voorzichtigheid geboden bij honden met grote schildkliertumoren of met 
uitzaaiingen om druk op belangrijke anatomische structuren te vermijden. Daarom 
evalueerden we eerst, met behulp van echografie, het korte termijn effect van rhTSH op 
schildkliervolume en echogeniciteit bij 7 gezonde beagles (hoofdstuk 7). In deze 
prospectieve, geblindeerde, cross-over studie werden echogeniciteit, homogeniteit, 
vorm, aflijning van het kapsel, lengte, breedte en hoogte van de schildklier vóór en 6, 
24 en 48h na injecteren van rhTHS (100 µg IV) beoordeeld door één enkele 
onderzoeker. rhTSH had in de gebruikte dosis geen significant effect op volume, 
echogeniciteit, homogeniteit of aflijning van het kapsel van de schildklier. Bovendien 
werden geen bijwerkingen waargenomen. Deze resultaten kunnen echter niet zomaar 
geëxtrapoleerd worden naar honden met schildkliertumoren.  
Na het uitvoeren van een pilootstudie (hoofdstuk 8) naar het effect van rhTSH 
op scintigrafisch onderzoek van de schildklier bij 7 gezonde beagles, bestudeerden we 
het effect van rhTSH op de opname van radiojood-123 (
123
I) bij 9 honden met 
schildkliertumoren (hoofdstuk 9). Deze prospectieve cross-over studie toonde geen 
significant effect aan van IV toediening van 100 µg rhTSH 24u vóór de toediening van 
123
I (37 MBq IV) op de opname van radiojood (RAIU) in de schildkliertumor na 8 of 
24h. Er werd wel een positieve correlatie gevonden tussen het effect van rhTSH op 
tumor 8u-RAIU en rhTSH serum concentraties 6, 12 en 24h na rhTSH injectie. Dit 
suggereert dat hogere rhTSH dosissen mogelijk wel een significant effect op tumor 
RAIU zouden hebben. Verdere studies zijn noodzakelijk om het beste protocol te 
bepalen om de tumor RAIU te optimaliseren met rhTSH.  
Ons onderzoek is een belangrijke eerste stap naar het ontrafelen van de 
biologische basis van schildklierkanker bij de hond door middel van de identificatie 
van 2 activerende K-RAS mutaties en de aangetoonde betrokkenheid van de PI3K/Akt 
signaalweg, voornamelijk bij FTCs. De prognostische merkers die in onze studie 
gevonden werden, leveren belangrijke informatie aan eigenaars en clinici en kunnen 
een leiddraad zijn bij de opvolging en het instellen van bijkomende behandelingen in 
functie van het risico van de individuele patiënt. De nieuwe therapeutische doelwitten 
zijn eenvoudig aan te tonen met IHC, wat deuren opent naar “gepersonaliseerde” 
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diergeneeskunde. Hoewel een klinisch voordeel van levothyroxine behandeling en een 
invloed van rhTSH op de opname van 
123
I niet kon worden aangetoond, is verder 
onderzoek aangewezen. Toekomstige uitdagingen omvatten verder onderzoek naar de 
genetische processen die leiden tot schildklierkanker bij de hond, klinische 
onderzoeken gericht op de door ons geidetificeerde moleculaire doelwitten die ook 
mogelijks nieuwe bijkomende therapeutische mogelijkheden creeren en het 
optimalizeren van 
131
I behandeling.  
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